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Abstract 
This study aimed to investigate stem cell biology in the normal and diseased pancreas 
and liver employing robust methods for tracking stem cells and their progeny in both 
pre-clinical and human scenario. 
    Bone marrow (BM) plasticity had been demonstrated in diseased organ 
remodelling. By detection of the Y chromosome in female mice receiving a sex-
mismatch BM transplantation, BM-derived cells were present in murine pancreas with 
cerulein-induced pancreatitis. BM-derived myofibroblasts functionally contributed to 
around 8% of the total population of myofibroblasts, the cells with a key fibrogenic role. 
Fibrocytes are circulating pro-fibrogenic cells; a decrease of BM-derived fibrocytes in 
blood and detection of these cells in areas of collagen deposition indicated they 
migrated to inflamed pancreas and played a role in extracellular matrix formation. IL-10 
is an anti-inflammatory cytokine mainly secreted by BM; a lack of IL-10 increased the 
fibrosis, the inflammation and the numbers of BM-derived myofibroblasts suggesting a 
potential role of IL-10 in chronic pancreatitis.  
    Mitochondrial DNA (mtDNA) mutations permit lineage tracing within human 
tissues. Cells having identical mtDNA mutations within a cytochrome c oxidase (CCO)-
deficient area must be related having originated from a common founder cell, 
presumably a stem cell. I have demonstrated that regenerative nodules in cirrhotic liver 
are invariably clonal populations, and that these nodules often originate from progenitor 
cells from the abutting ductular reactions. An attempt to build a phylogenetic tree based 
on the accumulation of mutations in normal liver reinforced the belief that hepatic stem 
cells are located within the portal tract area and that their cell progeny migrate 
centrifugally from the portal tract region. The same techniques were applied to the 
pancreas, but many areas of CCO deficiency could be ascribed to autolysis, while the 
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discovery of identical mtDNA base changes within and outwith CCO-deficient patches 
suggested these were genetic polymorphisms, previously unreported. 
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Chapter 1: General Introduction 
Adult stem cells, a long-lived cell population of cells that have the ability to self-renew 
and give rise to multiple cell types, are essential and important for physiological adult 
tissue renewal and regeneration after injury. Frequently by dividing asymmetrically, 
they produce one daughter cell that eventually differentiates and another stem cell (self-
renew) to keep healthy tissue homeostasis and repair tissue after certain injuries 
(Weissman, 2000). For example, the haematopoietic stem cells (HSCs) in bone marrow 
(BM) give rise to a hierarchically organised set of progenitors for erythroid, myeloid, 
lymphoid, and megakaryocyte lineages and maintain the homeostasis of the 
haematopoictic system. In adult liver, although well-differentiated hepatocytes can lead 
to a regenerative response, the activation of an hepatic stem cell population after liver 
injury can be identified by using certain stem cell markers such as OV6, CK19, CD34, 
c-kit and NCAM (Strain et al., 2003), and these identified “hepatic stem cells” are 
believed to play an important role in liver injury. Because stem cells are crucial for 
maintaining both normal and diseased organ function, investigating stem cell biology by 
robust methodology is essential for understanding the mystery of life.  
    Although studying stem cell biology in adult tissue is so important, a few 
difficulties remain. First, adult tissue is actually complex. It contains many cells and cell 
types, in complex three-dimensional relationships, that make it generally difficult to 
identify stem cells clearly. Secondly, a reliable marker for adult stem cells is still 
unavailable. Many claimed stem cell markers are also expressed in other cell types and 
therefore do not represent a pure stem cell population.   
    Among many methods used for stem cell research, lineage analysis is one of the 
most powerful and reliable methods for identifying stem cells and analyzing their 
function (Petit et al., 2005). Ideally, a single ancestor cell is marked in some way that 
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the mark is heritably transmitted to all daughter cells of the initial cell, resulting in a 
labelled clone. By detecting the marker at certain times after marking and by analyzing 
the number, location and phenotype of clonally derived cells, we can draw a reasonable 
conclusion of the types of cells generated by the progenitor, their movement and their 
influence in the specific organ and disease. Furthermore, information of the stem cell 
differentiation programme can also be revealed in its clonal profile. Although 
constructing an accurate picture of a tissue’s dynamic existence from its lineage pattern 
is difficult, a thorough analysis of all the clonal types allows us to approach the 
complexity of its component cell types and their movements.  
    This thesis aims to use lineage analysis as a tool for understanding adult stem cell 
behaviour. To achieve this, two different clonal markers were chosen and tested in 
either an experimental model or in human tissues. First, the “Y chromosome” was used 
as a clonal marker for tracing BM cell lineages in a mouse experimental pancreatitis 
model. In order to further explore adult stem cell biology in human tissue, 
“mitochondrial DNA (mtDNA) mutations” were used as clonal markers for tracing 
hepatic stem cell lineages in diseased liver. Because more than one mutation could be 
found in human liver, an attempt was made to build a phylogenetic tree in normal 
human liver by studying mtDNA mutations. Finally, an effort was made to trace cell 
lineages in human normal and diseased pancreas by the same method used in human 
liver. In this chapter, I summarize the current understanding, background and 
arguements related to the thesis including adult stem cells, BM cells, methods of lineage 
tracing, mtDNA, pancreas and liver structure. 
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1.1 Adult stem cells 
1.1.1 Introduction 
Numerous efforts have been made to understand adult stem cell biology, in order to 
fulfill the purpose of curing a number of incurable diseases by adult stem cells. Since 
the first multi-lineage HSCs were discovered in splenic assays in 1961 by Till and 
McCulloch (Till and McCulloch, 1961), the potential application of adult stem cells in 
clinical practise has been tested by many researchers. Indeed, stem cells can be a 
treatment option for some diseases, and stem cell therapy is no longer a dream anymore. 
For example, using BM transplants to treat leukaemia is now routinely conducted in 
hospital every day (Gahrton and Bjorkstrand, 2000). The more we understand stem cell 
biology, the more diseases we can cure by stem cell therapy in the future.  
    Stem cells have varying potentials. The fertilized oocyte (the zygote) and the 
descendants of the first two divisions are the only cells that are totipotent, able to form 
the whole embryo and the trophoblasts of the placenta. A hollow ball of cells, the 
blastocyst and a cluster of cells called the inner cell mass are formed from these 
totipotent cells around 4 days later. The inner cell mass, where the embryonic stem (ES) 
cells are derived from, are considered to be pluripotent, able to differentiate into most 
cells that arise from the three germ layers. Unlike fertilized oocytes and ES cells, most 
adult stem cells are multipotent, capable of producing a limited range of differentiated 
cell lineages appropriate to their location. For example, the intestinal stem cell can 
produce all four indigenous lineages (Paneth, goblet, absorptive columnar and 
enteroendocrine) (Brittan and Wright, 2002), while neural stem cells have trilineage 
potential, capable of generating neurons, oligodendrocytes and astrocytes (Okano, 
2002). Furthermore, we can also recognize unipotential stem cells, cells capable of 
generating one specific cell type, e.g. hepatocytes can differentiate into daughter 
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hepatocytes after partial hepatectomy (PH) (Alison et al., 2009). These adult (somatic) 
stem cells, for example in the gut (Marshman et al., 2002) and the skin (Alonso and 
Fuchs, 2003), provide a source of differentiated functional cells that feed into the 
tissues, setting up a state of cell flux as their progeny migrate to the unit periphery, and 
maintain the adult tissues’ structure and function. 
    The basic adult stem cell generic characteristics include: (1) self-renewal; (2) slow 
cycling; (3) multipotency; (4) long-term reconstitution of functional tissue; (5) serially 
transplantability. These stem cells, residing in many adult tissues, are not only 
responsible for the normal regenerative and reparative processes, but are also believed 
to be a primary target for accumulating abnormal genetic and epigenetic changes, which 
in the end lead to many abnormal conditions including cancer. Furthermore, the adult 
stem cell population should only represent a small percentange of the entire cellularity 
within a tissue. It is logical to think that once a stem cell divides, it begins to 
differentiate and expand exponentially, thus relatively few are needed. For example, in 
the small intestine, there are no more than 10 stem cells near the bottom of the crypt out 
of a total crypt population of ~ 300 cells (Marshman et al., 2002). In skeletal muscle, 
satellite (stem) cells consist of 5% of all nuclei, while in the BM, the multipotential 
HSC is much rarer, with a frequency of perhaps 1 in 10,000 or more amongst all BM 
cells. 
1.1.2 Quiescent and active adult stem cells: a hierarchy of potential 
Mammalian adult stem cells can support rapidly regenerating tissues, e.g. producing 
billions of blood cells and intestinal cells daily, during normal physiological conditions 
(Li and Clevers, 2010). It is widely believed that stem cells are slowly cycling but 
highly clonogenic. To avoid DNA synthesis error, it seems prudent to restrict stem cell 
division. Thus, in many tissues, transit-amplifying cells (TACs) divide more frequently 
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than stem cells and provide the mature cells. In the intestinal epithelium, stem cells and 
their short-lived TACs reside in crypts (Figure 1.1). It has been suggested that the label-
retaining cells (LRCs) at the +4 position located above the Paneth cells represent stem 
cells (Potten et al., 1997). A recent study has further shown that cells expressing Bmi1 
are predominantly located at the +4 position and are able to give rise to all four 
epithelial lineages, and these Bmi1+ cells were suggested to be slowly cycling 
(Sangiorgi and Capecchi, 2008). Furthermore, some Mussashi-1+ cells located at +4 
position are not sensitive to inactivation of the cell cycle protein CDC25, suggesting 
they have quiescent features (Lee et al., 2009). On the other hand, Lgr5+ crypt base 
columnar cells (CBCCs) located at the crypt base among Paneth cells represent a long-
lived and rapidly cycling multipotent stem cell population (Barker and Clevers, 2007). 
Unlike +4 LRCs, Lgr5+ stem cells do not retain DNA labels and are sensitive to CDC25 
inactivation, supporting their proliferating behaviour. Thus, two distinct stem cell 
populations exist in the intestine: a quiescent stem cell population at the +4 position and 
a active cycling Lgr5 stem cell population among Paneth cells at the crypt base. 
However, the relationship between these cell populations is still not clear and needs to 
be determined in future studies.  
    It has been proposed that single cell population maintains tissue self-renewal 
(Figure 1.2A) and can be depicted by a hierarchical system (Figure 1.3): stem cell > 
committed progenitor > early TACs > late TACs > terminally differentiated cells, in 
order of descending replicative potential. However, an alternative “zoned” model 
(Figure 1.2B), in which both quiescent amd active stem cells coexist within the same 
tissue, may better explain these observations (Scoville et al., 2008). In the zoned stem 
cell model, the quiescent stem cell functions as a backup or reserve population, while 
the active stem cell population is responsible for most of the replenishment of the tissue. 
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The quiescent stem cell population can be activated either by a stochastic mechanism or 
by feedback upon loss of active stem cells or extensive tissue injury (McKenzie et al., 
2006). For example, in the intestine a negative feedback may be delivered to the 
quiescent stem cells from the cycling CBCCs stem cells and/or their progeny migrating 
upward and passing the +4 location. Thus, the activation of quiescent stem cells in the 
intestine may be triggered by loss of CBCCs or their progeny. Normally, we expect that 
quiescent stem cells could replace damaged active stem cells. However, under special 
circumstances, active stem cells would possibly have the capacity to replace lost or 
damaged quiescent stem cells. In the end, a robust system of a high rate of self-renewal 
and flexible damage repair mechanisms in the tissue can be guaranteed by the 
combination of these reciprocal backup systems. 
 31 
 
 
Figure 1.1. Stem cell populations and the stem cell niche in the gut. Two stem 
cells populations are suggested in the gut, the quiescent label-retaining cells 
(+4 LRCs) higher up the crypt, and the active crypt base columnar cells 
(CBCCs; Lgr5+) amongst Paneth cells. Subepithelial mesenchymal cells, 
basement membrane and submucosa layer of the crypt make up the niche. 
Signalling factors in the niches affect stem cell behaviour. Wnt signalling 
upregulates stem cell self-renewal; in turn, BMPs inhibit Wnt signalling, but 
BMP signalling is inhibited by Noggin and Gremlin. 
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Figure 1.2. Two models for self-renewal and differentiation of stem cells. (A) 
Current model of a single stem cell population located in the niche. The key 
mechanism to maintain the balance between self-renewal and differentiation is 
asymmetric division. (B) Alternative and complementary model: quiescent (pink) 
and active stem cell (red) population coexist and are located in adjacent zones 
with corresponding stimulatory and inhibitory signals. Active stem cells can be 
replaced by quiescent stem cells (heavy arrow). Active stem cells may also 
replace lost quiescent stem cells (light arrow). The prevention of quiescent stem 
cell activation may be controlled by negative feedback mechanisms from either 
active stem cells (dashed line) or their progeny (solid line). Reproduced from Li 
and Clevers, 2010. 
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Figure 1.3. A cell hierarchy in most renewing systems. A few self-renewing stem 
cells give rise to a limited number of committed progenitors, also named transit-
amplifying cells (TACs). TACs can eventually give rise to terminally 
differentiated cells. Reproduced from Alison and Islam, 2009. 
 
1.1.3 Stem cell niche 
Niches are a specialized local tissue microenvironment where stem cells reside and that 
directly support and regulate stem cells (Morrison and Spradling, 2008). The stem cell 
niche can interact with stem cells by two distinct methods: physical contact and 
diffusible factors. In these instances, the signals to stem cells in the niches may involve 
direct physical contact with resident niche cells, or extracellular matrix (ECM), or 
diffusible signals i.e. autocrine, paracrine and endocrine factors (Scadden, 2006). These 
integrated signalling systems provide the correct response and surroundings to maintain 
the self-renewal and differentiation capabilities of the stem cells.  
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    Physical contact between stem cells and their niches can influence their orientation 
of the mitotic spindles, which is a strategy that stem cells use to divide asymmetrically. 
Asymmetric stem cell division preserves stem cell numbers while generating 
differentiated cells. In the gut, for example, the alignment of mitotic spindles is 
perpendicular to the apical surface specifically in the stem cell compartment and this 
orientation correlates with the asymmetric label-retaining DNA, the immortal strand 
(Quyn et al., 2010). Because the immortal strand of DNA is always located basally, it is 
plausible that the basal stem cell daughter inherits stem cell identity (Yamashita, 2010). 
In the epidermis, stem cell asymmetric division also occurs in the basal layer, and this 
provides new cells able to mature and replace old cells that move unidirectionally 
toward the epidermal surface. The common method to control stem cell division via 
direct physical contact with a stem cell niche is to use adherens junctions/tight 
junctions, allowing for the induction of cell polarity that leads to altered cell function. 
For example, within the cerebral cortex and hippocampus of β-catenin knockout (KO) 
mice, defective adherens junctions consequentially led to a reduction in cell 
proliferation (Chae et al., 2004). Furthermore, studies in the Drosophila germarium 
have identified the signal dpp and showed that adherens junctions are important in 
preventing germarium stem cells from differentiating (Casanueva and Ferguson, 2004). 
Once stem cells evade the influence of the niche or no longer receive signals to remain 
undifferentiated, they should be able to differentiate. Cell to cell contact is one possible 
way to receive instructive signals. 
    Adjusting signalling factors such as growth factors or transcription factors is 
another way that the stem cell niche controls stem cells. For instance, the hair follicle 
bulge forms a ‘Wnt-off/bone morphogenetic protein (BMP)-on’ through the expression 
of secreted Dkk-1, sFRP, Wif, and BMP. On the other hand, the derma papilla secretes 
 35 
Wnt signals and Noggin, an antagonist of BMP signalling (Tumbar et al., 2004). 
Similarly, the Lgr5+ stem cells at the crypt base in the intestine are in a 
microenvironment with high Wnt activity (Barker et al., 2007), whereas BMP signalling 
is inhibited by Noggin and Gremlin produced by submucosal tissues and cells below the 
crypt (Fig. 1.1) (He et al., 2004; Kosinski et al., 2007). Almost all of the niche systems 
studied so far involve the use of specific signalling factors to mediate the physical 
contact between stem cells and the niche. By control of this signalling system, distant 
cell sources and/or cells within niches can influence stem cell activities without direct 
physical contact.  
 
1.1.4 Control of self-renewal vs.  progenitor proliferation  
Self-renewal of stem cells is mechanistically different from the proliferation of many 
downstream progenitor cells. For example, the multipotent neural stem cells need Bmi1 
and Hmga2 for self-renewal, but not for the proliferation of many restricted neuronal or 
glial progenitors (Molofsky et al., 2003; Nishino et al., 2008). In spite of this fact, many 
uncertainties still exist, as Bmi1 is also required for the proliferation of granule 
precursor cells in the cerebellum (Leung et al., 2004; van der Lugt et al., 1994). In the 
haematopoietic system, the trithorax protein Mll and Sox17 are required for the 
maintenance of HSCs (Jude et al., 2007; Kim et al., 2007; McMahon et al., 2007), while 
P27Kip1 is required to limit self-renewal of TACs but not stem cells (Cheng et al., 2000). 
These findings show that the mechanisms that regulate stem cell self-renewal and 
restricted progenitor proliferation seem to be different. 
    To exit the stem cell state, the p53 and Rb pathways may be required. Some types 
of progenitors can behave like stem cells again such as regaining their ability to self-
renew after mutations occur in certain members of the p53 and Rb tumour suppressor 
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genes. For example, with deletions of either p53, p16Ink4a or p19Arf, transiently self-
renewing multipotent haematopoietic progenitor cells can regain a long-term self-
renewal capability (Akala et al., 2008). Similarly, cultured astrocyte progenitors with 
the deletion of p16Ink4a and p19Arf can dedifferentiate into neural stem cells (Bachoo et 
al., 2002). Although the mechanism is still not clear, these results suggest that p53 and 
Rb pathways reinforce the ability of progenitors to exit the stem cell state. 
 
1.1.5 Asymmetric and symmetric stem cell divisions 
Asymmetric division is a method for self-renewal as well as simultaneous production of 
daughter TACs (Figure 1.4A). However, it is still possible to service all needs with 
symmetric division, providing that for every stem cell producing two daughter TACs 
there is another stem cell producing two daughter stem cells (Figure 1.4B).  
Furthermore, it is also possible that a mixture of asymmetric and symmetric stem cell 
divisions occur within a stem cell population of a given tissue (Figure 1.4C). Without 
doubt, these divisions need to be well regulated to prevent complete stem cell 
exhaustion or an increase in stem cell numbers. Impaired asymmetric division may 
change cell fates, causing a lack of response to the mechanisms that control 
proliferation.  
    Symmetric divisions of stem cells can generate the large number of stem cells 
necessary for expanding tissues and helping repair. The ability of stem cells to switch 
between symmetric and asymmetric division, depending on cell signalling cues, is 
thought to provide the precise control of this system for cell number homeostasis and 
organ regeneration.  
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1.1.5.1 Asymmetric divisions 
Two main methods control asymmetric division: intrinsic and extrinsic. The “ intrinsic” 
method involves asymmetric separation of components within a cell. This regulated 
mechanism includes cell polarity factors and segregation of cell fate determinants 
(Figure 1.4D). The “extrinsic” methods require external cell signals and/or physical 
contacts with stem cell niche.  
    The C.elegans zygote is the classical example of asymmetric division controlled by 
an intrinsic mechanism. The zygote divides into one larger daughter cell (blastomere) 
and one smaller daughter cell. The larger blastomere is fated to become ectoderm, while 
the other smaller one produces mesoderm, endoderm and germ line cells after a series of 
asymmetric divisions. Asymmetric localization of a conserved polarity complex (the Par 
complex), especially PAR-3 and PAR-6 that are regulatory subunits of atypical protein 
kinase (PAR-aPKC), are needed for the asymmetric divisions. The PAR-aPKC then 
leads to a downstream effect that determines the fate of the stem cell. Furthermore, 
these complexes also influence the asymmetric segregation of intrinsic cell fate 
determinants and the arrangement of the mitotic spindles so that their orientation is 
reproducible (Gonczy and Rose, 2005; Yamashita, 2009). The main role of the Par 
complex is to affect cell fate decision.  
    The extrinsic control is through the signalling process, produced by either direct 
physical contact and/or paracrine signalling (Chen and McKearin, 2003; Kiger et al., 
2001; Song et al., 2004; Tulina and Matunis, 2001). The stem cell niche largely 
determines the cell fate via extrinsic signals. It has been suggested that stem cells are 
anchored by specialised junctions within the niches, so that they can arrange the angle 
of the mitotic spindle plane and thus affect the direction that the daughter cell buds off 
when it divides. Specific cells can help maintain the stem cell niches. Take Drosophila 
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as an example, the ovary has Cap cells that help to initiate a pathway to stimulate 
differentiation (Ohlstein and McKearin, 1997), while Hub cells within the Drosophila 
testis can initiate the pathway that prevents differentiation (Kiger et al., 2001; Tulina 
and Matunis, 2001; Yamashita et al., 2005). Moreover, two daughter cells destined for 
different cell locations are generated from Drosophila germline stem cells divide in a 
specific orientation within a niche. They receive different external signals that lead to 
divergent cell fates, one remains in the niche and the other exits. Because the 
asymmetric division happens at the same location, so the subtle differences in daughter 
cell location can cause large changes in cell fate (Figure 1.4E).  
    The intrinsic and extrinsic signals often work simultaneously. Cells may only 
respond to external signals when intrinsic signals are primed. For instance, the intrinsic 
signals in Drosophila neuroblasts lead to the asymmetric partitioning of the cell 
determinant Numb to one of the daughter cells, subsequently changing the response of 
that cell to extrinsic signals e.g. Notch signalling activation and self-renewal (Cayouette 
and Raff, 2002; Knoblich, 2008). 
    It is difficult to characterize the type of division in adult mammalian stem cells 
because they are largely quiescent and thus hard to image (Cheshier et al., 1999; 
Morshead et al., 1994). However, some preliminary evidence shows that adult stem 
cells divide asymmetrically under normal conditions to maintain their population size. 
For example, asymmetric divisions have been found in the sub-ventricular zone of the 
adult rat forebrain in steady state normal conditions, but not exclusively as some 
symmetric divisions were also observed (Zhang et al., 2004). Furthermore, the clonal 
analysis of individual neural progenitors suggests that these undifferentiated progenitor 
cells divide asymmetrically (Morshead et al., 1998; Reid et al., 1997). It has been 
suggested that asymmetric divisions are an evolutionary conserved mechanism for stem 
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cell maintenance because many of the characteristics of asymmetric divisions are 
observed in invertebrates like Drosophila, are also found in mammals. An example of a 
conserved mechanism is the segregation of mitotic spindles, since it is also observed in 
mammaliam basal epidermal progenitors (Lechler and Fuchs, 2005), cortical zone 
progenitors (Chenn and McConnell, 1995) and also in intestinal stem cells (Quyn et al., 
2010). In fact, the PAR-aPKC complex, previously noted to occur during the 
asymmetric division of Drosophila neuroblasts (Kaltschmidt et al., 2000; Lee et al., 
2006), was also found in epidermal progenitors and their asymmetric cortical location in 
these progenitors dictates the positioning of the mitotic spindles (Lechler and Fuchs, 
2005). Therefore, the previous research on invertebrates does impact on our knowledge 
of the mammalian system, as the mammalian progenitors have some comparable 
methods for asymmetric divisions conserved from invertebrate progenitors. 
 
1.1.5.2 Symmetric divisions 
Symmetric stem cell division (Figure 1.4B) happens when more stem cells are required, 
during development or tissue regeneration. This method for producing large stem cell 
populations is predominantly controlled by extrinsic cell signalling. For example, in C. 
elegans, germline cells undergo symmetric division during development. The initial two 
germ line cells can actually expand to produce ~2000 identical daughter cells that either 
remain undifferentiated cells or become differentiating gamete cells (Kimble and 
Crittenden, 2005; Kimble and White, 1981). The authors showed that germ cells are 
developmentally equivalent by removing one of the intitial germ line cells and there was 
no effect on the generation of new stem cell pools and differentiated cells. They further 
showed that the daughter cells could replace the initial germ line stem cell if the stem 
cell niche is repositioned near the daughter cells. Furthermore if an extra niche is added, 
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it can lead to a doubling in the number of stem cells (Kimble and White, 1981). Because 
all the daughter germ line stem cells of C. elegans can be stimulated to generate their 
own progeny with the same developmental potential, so they have the same reaction to 
the extra niche as their parent stem cells (Feng et al., 1999; Kidd et al., 2005; Kipreos et 
al., 2000; Kostic et al., 2003; Lam et al., 2006).   
    In mammals, during periods of notable cell loss, symmetric divisions of stem cells 
is thought to be a strategy for restoring stem cell pools, and this has been noted in the 
nervous and haematopoietic systems (Bodine et al., 1996; Doetsch et al., 2002; 
Morrison et al., 1997; Wright et al., 2001; Zhang et al., 2004). For example, the 
subventricular zone progenitors begin to divide after an experimental stroke in the rat, 
with an increase in symmetric divisions that promotes neurogenesis (Zhang et al., 
2004). However, this is not conclusive evidence for an increase in stem cell divisions, 
and is more likely to be evidence of TAC or differentiated progenitor symmetric 
division. Thus a better marker of stem cells is needed so that individual cells can be 
clearly characterised in vivo and further help to better define the role and location of the 
mammlian stem cell niche (Kiel et al., 2005). 
    It has been suggested that in early development, mammalian stem cells may divide 
symmetrically to expand the number of stem cells, however, the evidence is not 
convincing and is based on the observation of the production of morphologically 
equivalent undifferentiated cells in the stem cell regions (Lechler and Fuchs, 2005; 
Morrison et al., 1995). Therefore, further studies are needed and any inferences made 
should still be considered provisional. 
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Figure 1.4 Mechanisms for maintaining stem cell numbers. (A) Asymmetric 
divisions. (B) An equal proportion of symmetric divisions that produce either 
TACs or stem cells. (C) A combination of symmetric and asymmetric divisions. 
(D1 and D2) Intrinsic signals that determine cell fate. (D3) External signals that 
determine cell fate. (E1 and E2) The orientation to the hub niche cells is crucial 
for stem cell self-renewal in Drosophila testis. Misorientation can cause 
additional stem cells or arrest of cell cycle. (E3) A mitotic spindle axis 
perpendicular to the basement membrane is important for maintaining stem cell 
numbers in stratified epithelia. Stem cell, pink; TACs, green. Reproduced from 
Alison and Islam, 2009. 
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1.1.6 Label-retaining cells 
A genetic marker is vital for the tagging of candidate stem cells and their progeny. 
However, there is still no perfect marker for stem cells in specific organs. Alternatively, 
the long retention of DNA labels in the cells can be considered as a substitute marker of 
“stemness” (Karpowicz et al., 2005; Kiel et al., 2007). DNA labels such as 
bromodeoxyuridine (BrdU) or tritiated thymidine can be incorporated within the 
genome during periods of DNA synthetic activity. Since a stem cell would be 
comparatively slower cycling compared to their daughter TACs that are more rapidly 
proliferating, the TACs would dilute the DNA label out much faster than a stem cell. 
Hence, more DNA label should be retained in slow cycling cells, i.e. stem cells are 
LRCs. However, because of the finding that some stem cells are not slow cycling, this 
technique is not a perfect method for detecting stem cell populations in tissues and 
indeed the hypothesis requires re-evaluation. 
    Another theory supporting the LRC method as a valuable stem cell and niche 
detection technique is the Cairns “immortal strand hypothesis”(Cairns, 1975). In this 
theory, the stem cells are thought to retain their template stand, always passing on the 
newly synthesised strand to their daughter cells. The idea is that since stem cells always 
retain the original genome copies, the mutations generated during replication are readily 
transferred (within one generation) to TACs that are soon lost from the population. This 
mechanism will produce LRCs after injection of DNA labels when stem cells are being 
formed. However, to validate the hypothesis requires the observation that LRCs go 
through further rounds of DNA synthesis, yet the daughter stem cells containing the 
immortal DNA strands are segregated from sister chromatids. This hypothesis has been 
validated in the breast (Smith, 2005), small intestine (Potten et al., 2002) as well as 
some muscle satellite cells (Shinin et al., 2006). Despite the above evidence, the “label-
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retaining” concept is somewhat incompatible with the “immortal strand hypothesis”. 
The existence of LRCs during stem cell division is based on the assumption of random 
segregation of sister chromatids into stem cell daughters; however, if the segregation of 
DNA template strands is not random and if the stem cell retains the older unlabeled 
template strand, the DNA labels will be lost within two cycles (Rando, 2007). 
Furthermore, although the theory has been proposed for over 30 years, the number of 
studies with data supporting the immortal strand hypothesis is limited and the theory has 
mainly been tested in mammalian systems in which stem cell identity remains unclear. 
Besides, not all studies fit the theory; HSCs with long-term repopulating activity have 
been shown not to retain older DNA strands during cell division (Kiel et al., 2007). 
Because of the above reasons, an alternative explanation has been proffered that 
asymmetric cell division and cell fate are co-directed by epigenetic differences between 
sister chromatids (Lansdorp, 2007). This “silent sister hypothesis” suggests that the 
daughter cell remaining as a stem cell retains chromatids with active stem cell genes, 
while the other cell with loss of stem cell properties inherits the opposite “silent” sister 
chromatids. In a sense, these two theories are not mutually exclusive, since the 
segregation of immortal strands to a stem cell group could satisfy both as a determinant 
of cell fate and as a way to promote genomic integrity. Further studies should be 
conducted in finding possible epigenetic marks, the identification of all the genes that 
are regulated by such markers and understanding the pathways involved in strand-
specific chromatid segregation.  
    Label retaining studies can only demonstrate that the cells are identified with a 
label and make no contribution/statement as to the multiple lineage potential of the 
cells, and so by itself label retention is not indicative of a stem cell. Regarding the lack 
of an ideal stem cell marker, the long-term retention of a DNA label is still considered 
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as a putative marker of “stemness”, but it must be used in the knowledge that many 
well-differentiated cells like lymphocytes or Paneth cells residing in the gut may also 
retain the DNA label. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45 
1.2 Methods for tracing stem cell lineages 
1.2.1 Direct observation 
Lineage tracing analysis is a powerful techanique for identifying stem cells. It was 
developed over 100 years ago by direct observation of the development of early living 
embryos of annelids, ascidians and molluscs. By direct observation, the entire course of 
embryonic development of C. elegans has been fate mapped (Sulston et al., 1983). 
During the embryonic development of C. elegans, it was observed that many cells 
divide for a period in a stem cell-like manner (Chalfie et al., 1981). Although direct 
observation is a non-invasive method, the major shortage, which limits its application, is 
that it can be only applicable to small groups of cells that are present in an optically 
clear tissue. 
 
1.2.2 Marker addition 
Many different reagents including vital dyes, radioactive molecules and intracellular 
tracers have been directly used for marking cells for lineage tracing. The lipid soluble 
vital dyes, DiI and DiO, can be incorporated into cell membranes and give a high 
intensity of fluorescence (Axelrod, 1979). By radioactive labelling involving soaking 
the cells or tissue in tritiated thymidine and then grafting them back into the host tissue, 
cell lineage can be traced. The common intracellular tracers are horseradish peroxidase 
and fluorophores conjugated to dextran. They are introduced into cells by injection, 
ballistic techniques or electroporation (Lawson et al., 1986). Although the marker 
addition can allow us to trace cell lineages prospectively, however, all direct labelling 
methods have the disadvantage that the label is diluted by cell division and is of little 
use for long-term lineage analysis. 
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1.2.3 Retroviral infection 
Cells are infected by replication-defective retroviruses carrying marker genes (most 
commonly LacZ, alkaline phosphatase, green fluorescent protein (GFP) or luciferase) 
and therefore the viral genome is integrated into the host genome. This technique, firstly 
used to trace cells of the murine retina, allows the infected cells and all their progeny to 
be followed over time (Price et al., 1987). It is safe since the virus is defective, that is 
unable to form new viruses and therefore secondary infection is impossible and the 
labelling is strictly cell autonomous. Furthermore, infected cells can be selected for 
growth in culture because the retrovirus contains a drug resistance cassette.  
    This method has been largely used in tracing cell lineages, especially the CNS 
system in the chick and mouse. However several limitations of this method have been 
found. First, the intra-uterine injection of the virus can damage the embryo. Second, the 
expression of the virus depends on its site of integration into the host genome. 
Furthermore, the virus gene can be silenced by a variety of epigenetic repression 
mechanisms. Moreover, the clonal boundaries are often hard to define as infection of 
adjacent cells can occur. Efforts have also been made to reduce this limitation by 
utilizing retroviral libraries (Golden et al., 1995) and using lentiviruses (Naldini et al., 
1996). 
 
1.2.4 Genetic alteration 
There are several ways causing alteration of genes including genetic mosaics, 
transplantation and recombination. The huge advantage of this method is that the 
marker is inherited by all daughter cells. 
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1.2.4.1 Genetic mosaics 
Genetic mosaics mean the presence of two populations of cells with different genotypes 
in one individual who has developed from a single fertilized egg. Genetic mosaics are 
useful in the study of biological systems, and can be created intentionally in many 
model organisms in a variety of ways. They allows not only for the study of genes that 
are important for very early events in development, but also for the lineage tracing 
analysis. They have been used in a wide range of species, such as Drosophila, C.elegans 
and rodents. For example, in female mice hemizygous for a β-galactosidase transgene 
on the X-chromosome have been used to study the behaviour of limbal stem cell clones 
(Collinson et al., 2002). However, the disadvantage of this technique is that many cells 
are initially marked and the results can be hard to interpret. Natural genetic mosaics can 
occur in human tumours. The clonality of human tumours has been studied by following 
cells marked by chromosomal translocations, retroviral integration sites and the 
expression of X-linked markers (Garcia et al., 2000). Nevertheless, this technique has 
not been widely used in order to study the existence of cancer stem cells. 
 
1.2.4.2 Transplantation 
Genetic mosaics can also be created by transplantation of cells. This technique has been 
widely used in the study of BM/HSCs in adult mice. After a lethal dose of irradiation to 
eradicate the BM/HSCs cells in a recipient mouse, BM/HSCs from a donor mouse are 
transplanted into the circulatory system of a recipient mouse. Following a period of 
time, BM/HSCs are able to repopulate the BM and the haematopoietic system. 
Therefore, the choice of tracing BM/HSCs cell lineage has been transplantation.   
    The Y chromosome has been widely used as a natural marker for tracing BM/HSC 
cell lineages in mice and even in humans. Basically, after the female recipient receives 
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male donor BM cells, the cell lineage of BM can be traced by detection of the Y 
chromosome, which can be only found in male donor BM cells and their progeny. By in 
situ hybridisation (ISH) for the Y chromosome, the bone marrow-derived cells 
(BMDCs) can be analyzed in various organs. In our lab, this technique has been widely 
used in order to study the BMDCs, (especially BM-derived myofibroblasts) in liver, 
intestine and cancer (Brittan et al., 2002; Direkze et al., 2004; Forbes et al., 2004; Russo 
et al., 2006). At the beginning of my PhD, the role of BMDCs in the pancreas had not 
been fully revealed. This technique was chosen as a reliable method for studying the 
identity of BMDCs in an experimental pancreatitis mouse model. 
 
1.2.4.3 Recombination 
Genetic recombination can produce marked cell clones in the natural tissue 
environment. The development of site-specific recombination systems is a major 
advance (Golic, 1991; Lakso et al., 1992), which allows us to target specific genes. In 
mice, the principal method for clonal analysis to date is to use hormone-dependent 
recombinase expression. Generally speaking, a cell-type-specific promotor is connected 
to Cre recombinase (Metzger et al., 1995; Orban et al., 1992). In order to temporally 
control the activity of recombinase, Cre is fused to a hormone receptor, like the estrogen 
receptor (ER) (Webster et al., 1988). Such fusion proteins need tamoxifen, the ER 
ligand, to activate recombinase function (Forde et al., 2002). In this scheme, mice with 
Cre-ER genes are crossed to mice with a reporter gene such as Rosa 26R, which express 
a LacZ gene interrupted by an intervening LoxP site-flanked stop codon. Administering 
low-dose tamoxifen to these bigenic mice leads to removal of the intervening LoxP stop 
sequence in a fraction of the cells expressing Cre-ER, allowing transcription of LacZ 
gene and expression of β-galactosidase activity in these cells and their descendants 
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(Figure 1.5). This method is very useful in tracing cell lineages in mouse experimental 
models and has been used in recent studies of stem cell populations within skin 
(Clayton et al., 2007), testis (Nakagawa et al., 2007) and intestine (Barker et al., 2007). 
 
 
Figure 1.5 Cre-ER and LacZ genetic recombination for a cell lineage marking 
approach. A specific promotor connected to Cre-ER drives the expression of 
Cre-ER. Addition of Tamoxifen permits activation of Cre recombinase. As a 
consequence, an intervening stop sequence in the Rosa-LacZ reporter 
construct is removed by Cre recombinase. The transcription of the LacZ gene 
expresses β-galactosidase activity in these cells and their descendants. 
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1.2.5 A novel marker for humans: mitochondrial DNA mutations 
An adequate method for lineage studies in humans is required in order to understand 
adult stem cell behaviour and to locate their niche in specific tissues. Although great 
improvements have been made in experimental models because of advances in genetic 
techniques, a lack of a proper marker blocks the advance of lineage study in humans.  
To explore stem cell progeny in adult human tissues, the use of mtDNA mutations as a 
novel marker for clonal lineage analysis has been developed (Fellous et al., 2009b). This 
method allows us to explore the expansion of a single cell’s progeny that contain a 
clonal mtDNA mutation. Because the mtDNA encoded enzyme cytochrome c oxidase 
(CCO) is affected by mtDNA mutations, we can detect the presumed clonal patches by 
dual-colour enzyme histochemistry and further confirm the clonal mutation by 
analyzing the entire mtDNA genome from each single cell microdissected from a 
particular patch. Such phenotypically distinct (enzyme-deficient) cell areas need a time 
period of up to 40 years to become established, and because stem cells are believed to 
be long-lived cells in adult tissues and hence have enough time to acquire a sufficient 
level of mutation, these clonal patches are highly suggestive of an origin from stem 
cells. This technique has been applied to human stomach (McDonald et al., 2008), 
intestines (Greaves et al., 2006; Gutierrez-Gonzalez et al., 2009), liver (Fellous et al., 
2009a), pancreas and skin (Fellous et al., 2009b), and helps us to locate the stem cell 
niches. My thesis is to use lineage analysis as a tool to explore stem cell behaviour in 
both animals and humans, and this technique allows me to conduct lineage studies in 
human tissues in health and disease (cirrhotic liver, normal liver, normal pancreas and 
chronic pancreatitis). 
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1.3 Mitochondrial DNA 
1.3.1 Mitochondrial DNA mutations in stem cells 
Mitochondria are intracellular organelles required for oxidative phosphorylation. 
Mitochondria contain their own genome, mtDNA, which is a small (16.5kb), self-
replicating DNA genome present in multiple copies in the mitochondrial matrix.  
MtDNA mutations can be inherited or can occur sporadically. These mutations can 
eventually affect all copies of the mitochondrial genome within a cell (homoplasmy) or 
there may be a mixture of wild-type and mutated genomes in the same cell 
(heteroplasmy) (Lightowlers et al., 1997). Because mitochondria contain multiple 
mtDNA copies and cells may contain hundreds or thousands of mitochondria, in the 
presence of heteroplasmy high levels of mutated mtDNA must be present within an 
individual cell before a defect in oxidative phosphorylation becomes phenotypically 
apparent (Sciacco et al., 1994).  
    The idea that mtDNA mutations can be accumulated in a human stem cell 
population was first proposed in 2003 (Taylor et al., 2003). To investigate the existence 
of mtDNA mutations in stem cells and whether the stem cell can accumulate high 
enough levels sufficient to result in a biological defect, Taylor et. al. decided to study 
colonic crypt stem cells. Although they were unable to isolate single stem cells from the 
intestine, colonic crypt stem cells have some properties that can be exploited to test the 
basic assumptions described above. Firstly, colonic crypt stem cells are located at the 
crypt base. Second, the turn-over rate of cells within a crypt is rapid, however, only 
stem cells are long-lived cells and thus the only cells with enough time to accumulate 
the requisite mutation burden. Thirdly, it was shown in a mouse model that the majority 
of cells within an individual crypt are the progeny of a single stem cell (Schmidt et al., 
1988). By enzymatic staining and further mtDNA sequencing, Taylor and colleagues 
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elegantly showed that mtDNA mutations can accumulate in human colonic stem cells 
located at the crypt base. Furthermore, the stem cell progeny can be observed by the 
resulting biochemical defects. This lead to the observation of crypts with mixed or a 
single phenotype. Regarding the latter, the mutations were identical throughout the 
whole crypt and in some cases in the neighbouring crypts, which proves that crypts can 
proliferate through crypt fission (McDonald et al., 2006).  
    To date, as previously mentioned, this approach helps us to locate the stem cell 
niche in varies organs including liver, stomach, intestine, pancreas and skin (Fellous et 
al., 2009b). Furthermore, it allows us to explore the expansion of stem cell progeny, 
creating a cell fate map, in adult healthy and diseased organs. 
 
1.3.2 Mitochondrial structure and function 
Mitochondria are essential intracellular organelles occupying a substantial portion of the 
cytoplasmic volume of cells and functioning like the power centres of the cells, 
providing the majority of energy for cellular processes. The number of mitochondria 
varies from one to over 1000 within different cell types, but can be correlated to the 
metabolic energy requirement and also most commonly located at the sites of energy 
consumption within the cell. Normally, cells with elevated metabolic activity and 
consequently a high ATP demand contain more mitochondria. For example, in the rat 
liver, each hepatocyte contains 1000-2000 mitochondria, which in total occupy about 
one-fifth of the cell volume. Mitochondria are usually pictured as stiff, elongated oval 
cylinders; forming spheres 0.5-2 µm in diameters or cylinders of up to 5 µm in length. 
However, they are actually highly dynamic structures exhibiting budding, fusion and 
fission. Each mitochondrion is enclosed by two highly specialized membranes, outer 
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and inner membranes, with highly different functions. They segregate mitochondria into 
two distinct parts: the inner matrix and a narrow intermembrane space (Figure 1.6).  
    The relatively smooth outer membrane contains wide aqueous channels (pores) 
formed by porin, allowing the passage of molecules 5000 Daltons or less between the 
cytosol and the intermembrane space. Thus, with respect to the small molecules, the 
inner membrane space is chemically equivalent to the cytosol. The other proteins that 
form the outer membrane include import receptors, enzymes for mitochondrial lipid 
synthesis, enzymes that convert lipid substrates, and enzymes for division and fusion of 
the organelle. 
    The inner membrane (cristae) is a highly convoluted structure with a series of 
infoldings that project into the matrix. The proteins within the inner membrane have 
three main functions: (1) to carry out the oxidation reactions of the electron-transport 
chain, (2) to synthesize ATP, (3) to transport proteins. The membrane is impermeable to 
ions and most small charged molecules because an electrochemical gradient of H+ is 
formed across this membrane in order to drive the synthesis of ATP.  
    The matrix is a large internal space that contains several identical copies of the 
mtDNA genome, special ribosomes, tRNAs and a highly concentrated mixture of 
hundreds of enzymes. These enzymes are required for the oxidation of pyruvate and 
fatty acids, expression of the mitochondrial genes, and for the citric acid cycle (Ernster 
and Schatz, 1981).  
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Figure 1.6 The structure of a mitochondrion.  
 
1.3.3 Electron-transport chain 
The generation of ATP is through the electron-transport chain, termed oxidative 
phosphorylation. Basically, the electron-transport chain is made up of 4 multi-subunit 
complexes, attached to the inner membrane (Figure 1.7). Through passing a high-energy 
electron by this chain, some of the energy released drives the three respiratory enzyme 
complexes that pump H+ out of the matrix, resulting in an electrochemical proton 
gradient. This gradient drives H+ back through ATP synthase to produce ATP. The 
details of the electron-transport chain are described below: 
    (1) Complex I (NADH dehydrogenase) receives two electrons from NADH 
produced by the citric acid cycle and transfers them to a lipid-soluble carier ubiquinone 
(Coenzyme Q). Additional redox reactions at complex I cause reduction of ubiquinone, 
which delivers two electrons to a Fe-S centre. A second Fe-S centre reduces a second 
ubiquinone that can diffuse laterally in the inner membrane, shuttling electrons to 
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complex III. A total 4 H+ are pumped into the intermembrane by complex I in order to 
produce an electrochemical proton gradient across the inner membrane.  
    (2) Complex II (succinate dehydrogenase; SDH) also sequesters two electrons from 
an artefact of the citric acid cycle, oxidising succinate to fumarate. Two electrons are 
also released and transferred to complex III by reducing the same membrane bound 
ubiquinone as complex I. Complex II is unique. It does not cross the inner membrane, 
does not transport protons across the inner membrane and is encoded only by nuclear 
DNA.  
    (3) Complex III (cytochrome c reductase) receives electrons from the reduced 
ubiquinone by way of complex I or II, and further releasing two protons into the 
intermembrane space. The electrons are transported to cytochrome c, releasing a further 
two protons. Cytochrome c transports one electron at a time from complex III to IV.  
    (4) Complex IV (CCO) is the last juncture in the electron-transport chain. It 
accepts electrons and reduces O2 to produce water. This process induces a further two 
more protons to be pumped to the intermembrane space. The negative free energy of 
electron transfer along the chain is to siphon out protons and set up the electrochemical 
proton gradient.  
    The ATP is generated in complex V (ATP synthase). The oxidative 
phosphorylation of ADP to ATP is driven by the electrochemical proton gradient 
previously set up.  
 56 
 
Figure 1.7 A representative drawing of the electron-transport chain. Electrons 
are transferred through the complexes in the electro-transport chain, generating 
energy to pump protons from the matrix into intermembrance space. This 
process produces an electrochemical proton gradient across the inner 
membrane that drives ATP synthase to generate ATP from ADP and inorganic 
phosphate. CoQ, coenzyme Q; Cyt c, cytochrome c. Reproduced from Duchen, 
2004.  
 
1.3.4 Mitochondrial DNA genome 
Most proteins in mitochondria are encoded in the nucleus. However, mitochondria 
contain their own genome, which constitutes ~ 1% of cellular DNA. It was suggested by 
Dr. Lynn Margulis in 1970 (Margulis, 1970) that mitochondria resulted from an 
endosymbiotic relationship involving aerobic bacteria and a primitive anaerobic 
eukaryocyte. The respiration in aerobic bacteria depends on glycolysis and fermentation 
for energy, providing an evolutionary advantage to the host cell. 
    Human mtDNA resides in the matrix and contains 16,569 base pairs (Anderson et 
al., 1981). The base pairs organise into a closed looped double stranded duplex, relating 
to its bacterial origin. There are about 1500 genes encoding for mitochondrial proteins. 
 57 
While most of the genes are encoded in nuclear DNA, 37 genes are in mtDNA. These 
genes include 22 tRNA genes and 2rRNA genes for protein synthesis, and respiratory 
chain subunits (Table 1.1). Human cells contain different numbers of mitochondria, 
from 1 to over thousands, depending on the energy needs (Gray, 1989). Each 
mitochondrion contains ~ 2 - 10 copies of mtDNA, and can contain a mixture of 
mutated and wild type (WT) mtDNA (heteroplasmy). Cell phenotype is only altered 
when threshold levels of mutation are exceeded. Theoretically, if the number of copies 
of mutated mtDNA is not over the threshold, it is possible for a cell to function 
normally with mtDNA mutation inside. It is also possible that mtDNA mutations exist 
in a homoplasmic state where every mtDNA has an identical mutation. Although debate 
on the mechanism employed by heteroplasmic cells to switch to a homoplasmic state 
continues (Nekhaeva et al., 2002a), it has been suggested that because cellular 
mitochondria are dispersed randomly during cytokinesis, a homoplasmic state could 
arise without selection.  
 
Table 1.1 Components of the electron-transport chain complexes encoded by 
the nuclear amd mitochondrial genomes. 
 
Complex Subunits Nuclear Encoded 
Subunits 
Mitochondrial Encoded 
Subunits 
I NADH dehydrogenase 46 39 7 (ND1, ND2, ND3, ND4, 
ND4L, ND5, ND6) 
II Succinate dehydrogenase 
(SDH) 
4 4 0 
III Cytochrome c reductase 11 10 1 (Cytochrome b) 
IV Cytochrome c oxidase 
(CCO) 
13 10 3 (CCO I, CCO II, CCO III) 
V ATP synthase 14 12 2 (ATPase 6, ATPase8) 
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1.3.5 Mitochondrial DNA mutation rate threshold 
Mitochondria are subjected to interactions with a high level of oxidants as they are host 
sites for oxidative phosphorylation, thus increasing their chances of damage by 
oxidative species. In fact, these oxidative species have been shown to enhance mtDNA 
mutation rates compared to nuclear DNA (Richter et al., 1988). It has been shown that 
the rate of point mutation in mtDNA control regions is age dependent (Pak et al., 2005), 
although this may be as a result of oxidative stress driving tissue aging via intrinsic 
apoptosis (Sastre et al., 2003; Shigenaga et al., 1994). During the commencement of 
replication, mtDNA is temporarily located at or close to the inner membrane where 
oxidative phosphorylation occurs (Albring et al., 1977). Because of this spatial location, 
mtDNA are forced into an environment ripe with highly reactive oxygen species (ROS), 
making it vulnerable to oxidative attack. It was estimated that around 5% of the oxygen 
utilised is converted into some form of ROS during ATP production (Aitken et al., 
1992; Beckman and Ames, 1997). Besides being in close proximity to an elevated 
concentration of ROS, mtDNA is also lacking in protective mechanisms (Bogenhagen, 
1999). They also lack histones and a chromatin structure that would provide some 
physical protection from free radical ROS damage (Wallace, 1992). Furthermore, any 
apparatus for proof reading and excision repair mechanisms protecting nuclear DNA are 
not available for mtDNA (Beckman and Ames, 1997; Croteau and Bohr, 1997). It has 
been suggested that the rate of mutation in mtDNA is nearly 10 times higher than 
nuclear DNA (Neckelmann et al., 1987). Due to it compact size compared with nuclear 
DNA, mtDNA has less non-coding regions, with overlapping of adjacent genes and 
absence of introns. This indicates that many polymorphisms accumulate in coding 
regions with an increased risk of a significant harmful effect, including diminished 
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oxidative phosphorylation capacity, reduced ATP production, cell degeneration and 
apoptosis. 
    Abnormal mitochondrial metabolism caused by previous mtDNA mutation may 
actually accelerate the mtDNA mutation rate (Lightowlers et al., 1997), thus these cells 
may be predisposed to generate subsequent mutations. Subsquently mitochondria have 
developed a high mtDNA mutation threshold. Taking muscle and neuronal tissue for 
example, the threshold is thought to be as high or higher than 90% of mtDNA mutated 
before any biological abnormalities appears (Moraes et al., 1993). The proportion of 
mutated mtDNA within a cell determines the level of effect on phenotypic expression, 
and this level varies between individuals, organs and tissues (Johns, 1995). The impact 
of mtDNA mutations on cells depends on the energy requirements and the type of 
mutations, with a threshold effect being shown in a variety of cell lines (Attardi et al., 
1995; Hayashi et al., 1991). While the threshold for deleted mtDNA is claimed to be in 
the region of 50 - 60% (Hayashi et al., 1991; Mita et al., 1990; Moraes et al., 1992; 
Shoubridge, 1994), point mutations normally need to reach a higher threshold level 
before a biochemical defect is shown. It has been suggested that the threshold level for 
some tRNA point mutations needs to be up to 90% (Boulet et al., 1992; Chomyn et al., 
1992).  
    Post-mitotic cells, such as cardiac myocytes and neurons, tend to show clear-cut 
age dependent mtDNA alterations compared to highly proliferative tissues that often 
have few or undetectable alterations. Highly proliferative cells such as BM and epithelia 
should accumulate more mutations, resulting from the higher levels of replication and 
thus a higher probability of malfunction. However, it is now believed that such 
mutations tend to be transient because constant cell turnover prohibits the build-up of 
damage through straight-forward dilution and therefore enhances the loss of mutant 
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cells. A few studies have described the accumulation of mtDNA mutations in 
proliferating cells (Michikawa et al., 1999; Nekhaeva et al., 2002b). The paradigm 
linking slowly renewal tissues e.g. heart or CNS to a lack of regenerative capacity is 
suggested to be misguided, since the evidence showed the cell renewal comes from stem 
cell populations within these tissues (Anversa and Kajstura, 1998; Horwitz, 2003; Zitnik 
and Martin, 2002). The general opinion is that slowly renewing or post-mitotic cells 
suffer from most mtDNA damage and may be influenced proportionally by age 
compared to mitotic cells. Post-mitotic cells alter considerably over the course of time 
because of their long life span and their slow turnover rate, which allows the 
accumulation of mtDNA mutations by way of prolonged exposure to ROS. The 
evidence has been forthcoming in muscle (myoclonic encephalopathy with red ragged 
fibres) that ageing tissue has more oxidative damage, mtDNA deletions, point mutations 
and irregular forms of mtDNA (Ames et al., 1993; de la Asuncion et al., 1996). Another 
point supporting this idea is that post-mitotic tissue has a higher requirement for energy 
and therefore has a higher level of mitochondrial activity to satisfy this demand.  
    Mutations that arise in mtDNA sometimes cause defects, mainly associated with 
the electron-transport chain or mitochondrial biogenesis, resulting in a variety of clinical 
phenotypes. However, it is also possible for nuclear mutations to give rise to 
mitochondrial defects, as a number of mitochondrial proteins are nuclear encoded. 
Several mutations can occur in the mitochondrial genome including deletions, 
duplications, point mutations or maternally inherited rearrangements (DiMauro et al., 
1998). The types of disease states that arise from mtDNA mutations are heterogeneous 
due to the appearent nature of mitochondria and their core involvement in metabolic 
homeostasis. To date, more than 50 different human mitochondrial diseases have been 
identified (Pieczenik and Neustadt, 2007), even including some frequently observed 
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disorders such us heart failure, neurodegeneration and diabetes mellitus (DM) (Luft and 
Landau, 1995).  
    Those tissue types labelled as post-mitotic or slow turnover populations like 
neurons, cardiac and skeletal muscle, kidney, liver and pancreas have demands for high 
energy, and are therefore highly sensitive to mtDNA mutation perhaps due to increased 
ROS damage. In contrast, more rapid dividing cells like BM cells are relatively less 
affected, possibly because of loss of mutation via clonal selection or dilution (Singhal et 
al., 2000). This may be important in order to maintain stem cell purity. 
    It has been suggested that the long lasting detrimental effects of mtDNA mutations 
are heritable. This implies that the spread of mutation can result from pre-existing 
mutated cell replication or the presence of a mutated stem cell population feeding into 
the post-mitotic tissue with defective copies of mtDNA. 
 
1.3.6 Mitochondrial DNA lineage tracing 
The mitochondrial genome has a substantial rate of sequence divergence and multiple 
polymorphic variations, providing a perfect tool for researching in human evolution. 
Thus it appears to be logical to utilize the same technique to track the evolution of 
individual cells within tissue. 
    Individuals can have various mtDNA mutations, which can be either inherited or 
have arisen sporadically. Although the mechanism of how mutations accumulate to 
pathogenic levels is as yet undefined, clonal expansion through random genetic shift is 
one theory (Elson et al., 2001). As mentioned before, Taylor et al. aimed to establish 
whether mtDNA mutations occur in stem cells, and if so, whether the mutations can 
reach levels symptomatic of a biochemical defect. To answer these questions they 
studied human colonic crypt stem cells (Taylor et al., 2003). It has been suggested that 
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the colonic stem cells are located at the crypt base and replenish the cells above 
(Spradling et al., 2001). Studying colonic crypts enables direct observation of a stem 
cell’s progeny. 
    Because of the strict upward migration of cells from the crypt base to the apex, 
common mtDNA mutations within crypt cells can be used as a marker of what is 
happening in the actual stem cells. To monitor mtDNA mutations within crypt cells, 
they used a dual histochemical enzyme assay that stained for two enzymes within the 
electron-transport chain, CCO (brown colour) and SDH (blue colour). A proportion of 
the genes encoding the protein subunits for CCO are encoded within the mitochondrial 
genome, whereas the genes for subunits for SDH are exclusively encoded in nuclear 
DNA and therefore unaffected by mtDNA mutation. When both enzymes are normal 
only the brown of the CCO stain is visible. However, if CCO loses its function then the 
blue of the SDH stain is revealed. This allows us to visualise the cells that have 
exceeded the threshold level of mutated mtDNA and therefore helps us to identify cells 
with possible mtDNA mutations. The results showed three types of crypts (Figure 1.8). 
While the majority of crypts were all-brown WT colonic crypts (Figure 1.8A), it is also 
possible to have a homogeneous CCO-deficient crypt (Figure 1.8B), which could be 
regarded as resulting from a solitary stem cell with a mtDNA mutation repopulating a 
whole crypt. A third type of crypt was recognised that had a mixed phenotype of both 
CCO-deficient and CCO-positive columnar cells extending from the crypt base (Figure 
1.8C). In such a case it can be supposed that at least two stem cells - one WT and the 
other CCO-deficient are instrumental in crypt formation in these mixed phenotype 
crypts. Sequence analysis can further identify the mtDNA mutations in a cell within the 
CCO-deficient crypts, which is absent in the CCO-positive control crypts. The clonality 
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of the orginal cell (i.e. stem cells) can be revealed and confirmed by an identical 
mutation being present in all CCO-deficient cells within a blue crypt.  
    Further studies have shown that clusters of CCO-deficient crypts can occur 
(Greaves et al., 2006). MtDNA sequencing of single cells from each crypt in a particular 
cluster revealed they all had the identical mutations, which were not present in the 
surrounding CCO-positive crypts. Therefore all cells must have been derived from an 
original mutated cell in a single crypt, that through niche succession resulted in its 
progeny occupying the whole crypt, after which the crypt must have divided by crypt 
fission to produce identical daughter crypts (McDonald et al., 2006). 
    Since this technique has successfully characterized the relationship between 
colonic crypt formation and stem cells, it also has paved the way to allow the 
application of mtDNA mutations to study cell lineage in other human tissues. In fact, 
this technique has been applied to many human normal tissues such as liver, stomach, 
small intestine, pancreas and skin and it has also been seen as a method to find the 
location of the stem cell niche in specific tissues (Fellous et al., 2009b).  
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Figure 1.8 Two-colour histochemistry for CCO and SDH shows three types of 
crypts, with (A) normal, (B) deficient, and (C) mixed pattern of mitochondrial 
function. It reflects the phenotype in the stem cells that form each type of crypt. 
Reproduced from Schon, 2003.   
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1.4 Bone marrow 
1.4.1 Introduction 
Most basic definitions of adult mammalian stem cells were based on BM/HSC research 
(Weissman, 2000). In the present day, the ability of transplanted BM/HSCs to rebuild 
the damaged HSC niche in the context of disease is well established and used as a 
therapy for haematological malignancy, practised in hospitals around the world. The 
BM is composed of both HSCs and mesenchymal stem cells (MSCs); MSCs are non-
HSCs that have ability to differentiate into both mesenchymal and non-mesenchymal 
cells including bone, cartilage, fat, myoblasts, neurons and astrocytes (Beyer Nardi and 
da Silva Meirelles, 2006; Bianco et al., 2001; Deans and Moseley, 2000; Jori et al., 
2005; Pittenger et al., 1999; Zhang et al., 2003). Many clinical trials with MSCs for the 
treatment of diseases such as acute myocardial infarction, end-stage ischaemic heart 
disease, osteogenesis imperfecta, and amyotrophic lateral sclerosis have been conducted 
(Chen et al., 2004; Horwitz et al., 2001; Mazzini et al., 2003; Perin et al., 2003; Strauer 
et al., 2002; Wollert et al., 2004). Likewise, HSCs have been claimed to be more plastic 
than previously thought, with numerous reports of their ability to generate a variety of 
organ parenchymal cells (Alison et al., 2006b; Grove et al., 2004; Wagers and 
Weissman, 2004). However, the role of BM in the maintenance of haematopoietic 
lineages plus a possible contribution to non-haematopoietic organ regeneration is not 
the whole story. There is increasing evidence that BMDCs directly contribute to fibrosis 
in a variety of situations from wound healing to end-stage fibrotic disease and even 
tumour desmoplasia. We now know that BM cells can differentiate along the 
myofibroblast and fibroblast lineages, synthesising and secreting components of the 
ECM. This observation is of considerable clinical relevance, possibly opening up new 
strategies of anti-fibrotic therapy.  
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1.4.2 Bone marrow plasticity 
Marrow-located BM cells, apart from being probably the only source of haematopoietic 
cells in the adult, have been credited with the ability (pluripotency) to generate a range 
of cell types extending way beyond the classic haematopoietic differentiation repertoire 
(Alison et al., 2003; Anjos-Afonso et al., 2004; Grove et al., 2004; Jiang et al., 2002; 
Korbling and Estrov, 2003; Neuringer and Randell, 2004; Wagers et al., 2002). One 
method used to track BMDCs is to transplant marked BM into marker-negative 
recipients and then detect engraftment in a non-haematopoietic organ by virtue of the 
persistent donor marker (Figure 1.9). However, not everyone is convinced of the 
versatility of BM stem cells, either because fusion of BMDCs with indigenous host cells 
occurs (Alison et al., 2004; Alison et al., 2003) or because many of the claims for 
BMDC plasticity have simply not been produced by others, for example, BM to heart: 
yes (Orlic et al., 2001), no (Balsam et al., 2004); BM to oocytes: yes (Johnson et al., 
2005), no (Eggan et al., 2006). Notably, there are instances where, without cell fusion, 
BMDCs make a modest contribution to parenchymal cell replacement (Harris et al., 
2004; Ianus et al., 2003; Okamoto et al., 2002).  
    Whether we call it BM plasticity or a normal lineage fate of BMDCs, there is now 
a growing body of evidence to indicate that cells from BM can differentiate into 
myofibroblasts and fibroblasts (Brittan et al., 2005; Brittan et al., 2002; Direkze et al., 
2003; Direkze et al., 2004; Epperly et al., 2003; Forbes et al., 2004; Ishii et al., 2003), 
cells which have a pivotal role in tissue fibrosis.  
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Figure 1.9. Experimental strategy used to the track the fate of transplanted BM 
cells. Labelled BM cells are transplanted into a lethally irradiated label-negative 
recipient. Examples of labels used include male, Green fluorescent protein 
(GFP)-positive or β-galactosidase-positive cells. These cells are identified in the 
recipient by either in situ hybridization (ISH) for Y chromosome detection (brown 
dots), GFP immunohistochemistry (brown cells) or X-gal histochemistry (blue 
structures), respectively. These markers of donor origin are combined with a 
marker of phenotypic differentiation – such as immunohistochemistry for a 
stromal cell antigen (for example, α-smooth muscle actin (α-SMA)) to define a 
myofibroblast phenotype.  
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1.4.3 Contribution of bone marrow-derived cells in organ fibrosis 
1.4.3.1 Lung 
There have been numerous studies focused on the relationship between stem cells and 
pulmonary fibrotic diseases such as interstitial pneumonia and asthma in recent years. 
However, the role of BMDCs in lung injury, repair and remodelling remains unclear 
and controversial.  
    In humans, analysis of allografted lungs in patients suffering from bronchiolitis 
obliterans has demonstrated the involvement of myofibroblasts, some of BM origin, in 
the pathogenesis of bronchiolitis obliterans (Brocker et al., 2006). Likewise, chimerism 
of both epithelial and endothelial cells has been found in human lung biopsies taken 
from BM transplant recipients (Mattsson et al., 2004; Suratt et al., 2003). 
    Animal models of lung injury and fibrosis have provided very good evidence that 
adult BMDCs participate in the generation of fibrosis (Table 1.2a) (Brocker et al., 2006; 
Epperly et al., 2003; Hashimoto et al., 2004; Ishii et al., 2005; Phillips et al., 2004). 
Circulating monocyte: macrophage/fibrocyte lineages also contribute to the marked 
fibroproliferative changes found in pulmonary vessels in chronic pulmonary hypoxic 
hypertension (Frid et al., 2006). The mechanisms of trafficking of BM cells to the lung 
are beginning to emerge; defects in Smad3, a critical component of transforming growth 
factor β signalling, lead to reduced BMDC trafficking to the lung and reduced fibrosis 
after administration of bleomycin (Epperly et al., 2006). On the other hand, some 
observations suggest that maybe adult marrow-derived cells, particularly MSCs, have a 
beneficial effect with respect to lung repair and regeneration (Table 1.2b) (Ortiz et al., 
2003; Rojas et al., 2005). The protective effect of MSCs in bleomycin-induced fibrosis 
appears to be through the production of an interleukin 1(IL-1) receptor antagonist, 
blocking the action of the proinflammatory cytokines tumor necrosis factor α (TNFα) 
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and IL-1 (Ortiz et al., 2007). It is important to distinguish studies that make animals 
chimaeric (adoptive transfer) before application of an injurious insult, so that the fate of 
BM can be monitored – these tend to show that BMDCs contribute to fibrosis, from 
studies that administer BM cells systemically after the injury, often achieving a 
reduction of fibrosis. 
 
Table 1.2a. Bone marrow involvement in pulmonary fibrosis  
Author Species Method Injury Evidence  Comments 
Epperly et al. 
2003  
Mouse GFP+ BMTx; 
also Tx of 
clonal 
marrow 
stromal line 
Irradiation 22-47% of 
cells in 
fibrotic areas 
were GFP+ 
Dividing GFP+ 
cells were 
vimentin+. 
Hashimoto et 
al. 2004  
Mouse GFP+ BMTx BLM 27% of lung 
cells were 
GFP+ Col I+. 
> 80% of Col 
I+ cells were 
GFP+ 
GFP+ cells did 
not express 
SMA. 
Phillips et al. 
2004  
SCID mouse h.fibrocyte 
i.v. injection 
4 days after 
BLM 
BLM CD45+ COL 
I+ CXCR4+ 
fibrocytes 
accumulate 
in lung 
Migration due 
to CXCL12 
chemotactic 
gradient 
Ishii et al. 
2005  
Mouse GFP+ BMTx 
to SCID mice 
BLM GFP+ 
fibroblasts 
found in 
normal & 
injured lungs 
at same 
frequency (7-
9%) 
GFP+ 
fibroblasts 
were Col I+ 
Brocker et al. 
2006  
Human Lung 
allografts and 
sex-
mismatch 
BMTx 
Bronchiolitis 
obliterans 
All allografts 
had 
recipient-
derived 
fibroblasts 
(av.32%).  
ISH results 
confirmed by 
STR-PCR 
genotyping 
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Table 1.2b. Bone marrow in alleviation of pulmonary fibrosis 
Author Species  Method Injury Evidence Comments 
Ortiz et al. 
2003  
Mouse MSCTx after 
BLM 
BLM Reduced 
collagen 
expression 
Some MSCs 
differentiated to 
Type II 
pneumocytes 
Rojas et al. 
2005  
Mouse GFP+ 
MSCTx after 
BLM 
BLM GFP+ cells 
differentiate 
to 
pneumocytes, 
fibroblasts & 
endothelia. 
Myelosuppressio
n increases 
susceptibility to 
BLM. 
Abbreviations: BLM, bleomycin; BMTx. Bone marrow transplantation to wild-
type mouse unless otherwise specified; Col I, collagen I; GFP, green 
fluorescent protein; ISH, in situ hybridization; MSC, mesenchymal stromal/stem 
cell; SCID, severe combined immunodeficient; SMA, smooth muscle actin; 
STR-PCR, short tandem repeat – polymerase chain reaction.  
 
1.4.3.2 Liver 
Traditionally, activated fibroblasts in the liver are considered to derive from activation 
and proliferation of resident stellate cells and periportal fibroblasts (Friedman, 2000; 
Rippe and Brenner, 2004). However, traditional boundaries between the various 
fibrogenic cell populations are becoming blurred. In the liver, it is thought that there is 
more than one population of collagen-producing cells, disparate in derivation, 
phenotype and response to liver injury (Magness et al., 2004). For example, in the CCl4-
injured mouse liver, direct lineage tracing has indicated that many fibroblasts are 
derived from hepatocytes through epithelial-mesenchymal transition (EMT) (Zeisberg et 
al., 2007). Like other organs, fibrogenic cells in the liver can also originate from the 
BM. Chronic liver disease is usually accompanied by progressive fibrosis. In the 
progression to chronic liver injury/inflammation, hepatic stellate cells (HpSCs) become 
activated, proliferate and synthesize collagen. HpSCs express α-smooth muscle actin 
(α-SMA), the histological hallmark of myofibroblasts, and are thought to be the pivotal 
in the pathogenesis of liver fibrosis. A growing body of evidence indicates that the 
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myofibroblast population, at least in part, derives from BMDCs (Table 1.3a) (Baba et 
al., 2004; Forbes et al., 2004; Kisseleva et al., 2006; Russo et al., 2006). For example, 
female mice, having had a male BM transplant, were chronically poisoned with CCl4 
and up to 70% of HpSCs and myofibroblasts associated with septal scars were BM 
derived (Russo et al., 2006). Analysis of individual sex chromosome complements in 
BM-derived myofibroblasts did not find cell fusion to be a significant mechanism for 
generating these cells. 
    A BMDC contribution to hepatic fibrogenesis has also been shown in the bile duct-
ligated mouse, a model of cholestatic liver disease (Kisseleva et al., 2006). Interestingly, 
these BMDCs were not typical myofibroblasts, since they lacked expression of α-SMA. 
One possible origin of these cells could be fibrocytes, the circulating population of 
CD45+ cells known to deposit collagen at sites of injury. The exact origin of BM-
derived liver myofibroblasts also remains uncertain, while one study definitely 
implicates MSCs (Russo et al., 2006), the other study suggests HSCs (Miyata et al., 
2008). 
    Moreover, intravenously transplanted human MSCs will more readily differentiate 
into myofibroblasts rather than hepatocytes in the chronically damaged livers of non-
obese diabetic/severe combined immunodeficient mice (di Bonzo et al., 2008). 
    As in the lung, surprisingly, the intravenous injection of BM cells, particularly 
MSCs, appears to be therapeutically useful to animals with ongoing hepatic damage 
(Table 1.3b) (Fang et al., 2004; Higashiyama et al., 2007; Oyagi et al., 2006; Sakaida et 
al., 2004; Zhao et al., 2005), and phase I trials involving the injection of autologous BM 
cells to cirrhotic patients have reported modest improvements in clinical scores (Gordon 
et al., 2006; Kallis et al., 2007; Terai et al., 2006; Terai et al., 2005). The mechanism 
that underlies this improvement is not clear; one animal study (Sakaida et al., 2004) 
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claims that BM cells differentiate to hepatocytes and secrete matrix metalloproteinases 
(MMPs), but many others find no hepatocyte differentiation of BM cells, even when the 
damaged liver is pretreated with retrorsine to prevent indigenous hepatocytes from 
regenerating (Popp et al., 2007; Vig et al., 2006). Of course, the beneficial effects of 
BM cells, particularly MSCs, may have more to do with an anti-inflammatory effect, or 
the secretion of paracrine-acting growth factors (Prockop, 2007). 
 
Table 1.3a. Bone marrow involvement in hepatic fibrosis  
Author Species Method Injury Evidence  Comments 
Forbes et al. 
2004  
Human Sex-
mismatch 
liver 
allografts, 
one female 
had male 
BMTx 
Cirrhosis 6-22% of 
SMA+ cells in 
female donor 
liver were Y+. 
12.4% of 
SMA+ cells 
were Y+ in 
female 
recipient of 
male BMTx - 
bone marrow 
origin. 
Baba et al. 
2004  
Mouse GFP+ BMTx CCl4 GFP+ cells in 
liver express 
GFAP & 
desmin, after 
injury express 
SMA 
 
Kisseleva et 
al. 2006  
Mouse Col I+ GFP+ 
BMTx 
BDL 2 weeks 
after 
adoptive 
transfer 
GFP+ cells 
were SMA-ve 
but expressed 
CD45 & Col 
a1 (I) 
Injury 
recruits BM-
derived 
fibrocytes.  
Russo et al. 
2006  
Mouse Male BMTx 
to female 
CCl4 70% of SMA+ 
myofibroblasts 
were BM-
derived  
No cell 
fusion, Y+ 
cells express 
mRNA for 
procollagen 
a1 (I) 
Abbreviations: BDL, bile duct ligation; CCL4, carbon tetrachloride; see Table 1.2 
for other abbreviations. 
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Table 1.3b. Bone marrow and alleviation of hepatic fibrosis  
Author Species Method Injury Evidence  Comments 
Fang et al. 
2004  
Mouse Flk1+ MSCTx 
immediately 
after 1st CCl4 
injection 
DMN or CCl4 Reduced 
fibrosis, 
limited 
differentiation 
to albumin+ 
epithelial 
cells 
MSCTx after 1 
week of CCl4 
has no effect 
Zhao et al. 
2005  
Rat MSCTx 
during liver 
injury regime 
CCl4 Reduced 
fibrosis 
Animal 
survival rates 
improved 
Sakaida et 
al. 2004 & 
Terai et al. 
2005  
Mouse GFP+ BMTx 
midway 
through 8 
week CCl4 
regime 
CCl4 Reduced 
fibrosis 
linked to 
MMP-9 
expression 
Engrafted 
cells claimed 
to be 
hepatocytes 
Oyagi et al. 
2006  
Rat MSCTx at 
start of CCl4 
treatment 
CCl4 Reduced 
fibrosis. 
Restoration 
of normal 
albumin 
levels 
If MSCs not 
exposed to 
HGF before 
Tx, then no 
effect 
Higashiyama 
et al. 2007  
Mouse EGFP+ BMTx CCl4 MMP-9 & 13 
expressed by 
GFP+ and 
GFP- cells  
G-CSF 
enhanced 
engraftment 
and 
accelerated 
fibrosis 
regression 
Abbreviations: DMN, dimethylnitrosamine; G-CSF, granulocyte-colony 
stimulating factor; HGF, hepatocyte growth factor; MMP, matrix 
metalloproteinase; see Table 1.2 for other abbreviations. 
 
1.4.3.3 Kidney 
There is also evidence that some BMDCs are progenitors for renal 
fibroblasts/myofibroblasts (Table 1.4) (Broekema et al., 2007; Cornacchia et al., 2001; 
Grimm et al., 2001; Imasawa et al., 2001; Li et al., 2007b; Roufosse et al., 2006). For 
example, BMDCs can contribute in a small way to the pool of fibroblast-specific 
protein1-positive cells infiltrating the interstitium of mouse kidneys suffering from 
unilateral ureteric obstruction, with many other interstitial cells being derived from 
tubular epithelial cells undergoing EMT during fibrogenesis (Iwano et al., 2002). In 
human renal allografts undergoing rejection, approximately one third of mesenchymal 
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cells in vessels and the interstitium were of recipient origin, implicating them in renal 
fibrosis (Grimm et al., 2001). It is important to establish the functional capabilities of 
BM-derived myofibroblasts, but in another unilateral ureteric obstruction model, the 
synthesis of interstitial collagen by BMDCs could not be demonstrated (Roufosse et al., 
2006). In the glomerulus, mesangial cells are the main source of ECM, and a number of 
studies point to the BM origin of some of them (Cornacchia et al., 2001; Imasawa and 
Utsunomiya, 2002). 
 
Table 1.4. Bone marrow involvement in renal fibrosis  
Author Species Method Injury Evidence  Comments 
Cornacchia 
et al. 2001  
Mouse Os/+ BMTx 
to congenic 
ROP+/+ 
mice 
Os/+ mice have 
diffuse 
glomerulosclerosis 
Glomerular 
hypertrophy 
and increase 
ECM 
Sclerotic 
phenotype 
transferred to 
normal mice 
by BM-
derived 
progenitors of 
mesangial 
cells 
Imasawa et 
al. 2001   
 
 
 
Mouse GFP+ BMTx 8Gy irradiation 
associated with 
BMTx 
Cells isolated 
24 weeks 
after BMTx. 
60% of 
desmin+ cells 
were GFP+ 
Cells 
contracted in 
response to 
angiotensin – 
mesangial 
phenotype 
Grimm et 
al. 2001  
Human 6 male 
recipients 
of renal 
allografts 
from 
females 
Chronic rejection 34-38% of 
aSMA+ cells in 
vessel walls 
were Y+. 30% 
of aSMA+ 
cells in 
interstitium 
were Y+  
Up to one-
third of 
mesenchymal 
cells remain 
of donor 
origin 
Roufosse 
et al. 2006  
Mouse Male 
Procollagen 
(a2) I -
luciferase 
BMTx 
UUO 8.6% of 
aSMA+ cells 
were Y+ 
No luciferase 
expression, 
so appear 
non- 
functional 
Broekema 
et al. 2007  
Rat R26-human 
Alk Phos 
transgenic 
BMTx  
Unilateral IRI (45 
mins) 
32% of SMA+ 
myofibroblasts 
co-expressed 
R26 Alk Phos 
R26 Alk 
Phos+ cells 
were 
procollagen I+ 
Li et al. 
2007  
Mouse EGFP+ 
BMTx 
Adriamycin 30% of SMA+ 
myofibroblasts 
are BM 
derived 
 
Blockade of 
TGFb 
attenuates 
fibrosis 
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Abbreviations: Alk Phos, alkaline phosphatase; IRI, ischaemia reperfusion 
injury, UUO, unilateral ureteral obstruction; see Table 1.2 for other 
abbreviations. 
 
1.4.3.4 Intestine 
BMDCs can also contribute to intestinal subepithelial myofibroblasts (ISEMFs) in the 
gut. Analysing the colons and small intestines of female mice that had received a BM 
cell transplant from male donors, and additionally studying gastrointestinal biopsies 
from female patients with graft-versus-host disease after BM cell transplantation from 
male donors, Brittan et al. noted that BM cells contributed up to 50% of the ISEMFs 
(Brittan et al., 2002). This contribution was increased to almost 70% when the recipient 
mice had a colitis induced by an intracolonic injection of trinitrobenzene sulfonate 
(Brittan et al., 2005). Likewise, BMDCs make a substantial contribution (45%) to 
colonic ISEMFs in the severely inflamed mucosa of IL-10–/– female mice (Bamba et 
al., 2006). 
 
1.4.3.5 Tumours 
Tumour-associated myofibroblasts and fibroblasts have a very active role in 
tumourigenesis producing the likes of growth factors and chemokines (Kalluri and 
Zeisberg, 2006; Li et al., 2007a) and even bestowing on cancer cells a more invasive 
and metastatic phenotype (Karnoub et al., 2007). Thus, BM-derived myofibroblasts are 
not just resident bystanders in their new location (Anderson et al., 2001) and, indeed, 
BM-derived myofibroblasts do produce ECM (Direkze et al., 2006; Ishii et al., 2005). 
    Various groups have demonstrated a contribution of BMDCs to the tumour 
desmoplastic reaction (Table 1.5) (Direkze et al., 2004; Direkze et al., 2006; Ishii et al., 
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2003; LaRue et al., 2006; Sangai et al., 2005). For example, they were found 
surrounding xenografted pancreatic tumours in sub-lethally irradiated SCID mice 
transplanted with BM cells from β-galactosidase transgenic and recombination-
activating gene 1-deficient double-mutant mice (Ishii et al., 2003). Direkze et al. also 
demonstrated that BMDCs have the ability to transdifferentiate to myofibroblasts and 
fibroblasts in the tumour stroma in a mouse model of pancreatic insulinoma (Direkze et 
al., 2004). Rat insulin promoter large T antigen (RIPTag) mice develop β cell tumours 
of the pancreas, and here female RIPTag mice were transplanted with male BM cells. 
Donor-derived myofibroblasts were found to comprise almost 25% of the total 
myofibroblast population. A further study explored the effect of different cancer cell 
lines on the presence of BM-derived myofibroblasts and vascular endothelial cells 
(Sangai et al., 2005). Xenografted tumours were created from 10 different human 
tumour cell lines and each tumour type had a different percentage of BM-derived 
myofibroblasts and vascular endothelial cells. 
    The contribution of BM cells to tumour stroma provides a potentially new portal 
for the application of anticancer therapies: in effect, using stem cells as Trojan horses. 
For example, with regard to tumour fibroblasts, Studeny and colleagues (Nakamizo et 
al., 2005; Studeny et al., 2002; Studeny et al., 2004) have used BM-derived MSCs as 
vehicles for interferon delivery into tumours. They found that MSCs with forced 
expression of interferon-β inhibited the growth of a variety of xenografted tumours 
including malignant melanoma, breast cancer and intracranial gliomas. 
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Table 1.5. Bone marrow involvement in tumour desmoplasia  
Author Species/Tumour Method Evidence  Comments 
Ishii et al. 
2003  
Mouse/human 
pancreatic cancer 
cell line 
(Capan-1) 
b-gal/RAG1 
deficient 
BMTx to 
SCID mice 
Almost 40% of 
myofibroblasts 
were of BM 
origin after 28 
days 
 
Direkze et al. 
2004 and 
2006  
Mouse/Insulinoma 
generated by Large 
T Ag linked to insulin 
promoter 
Male GFP+ 
BMTx to 
female 
25% of aSMA+ 
cells were BM 
derived 
Donor aSMA+ 
cells expressed 
procollagen a1 
(I) mRNA 
Sangai  et 
al. 2006  
Mouse/ten different 
human cancer cell 
lines 
b-gal/RAG1 
deficient 
BMTx to 
SCID mice 
Donor derived 
myofibroblasts 
varied from 0-
30% 
Variation in 
donor derived 
myofibroblasts 
also depended 
on site  
La Rue et al. 
2006  
Mouse/Melanoma or 
Lewis Lung 
carcinoma 
GFP+ BMTx 
of population 
clonally 
derived from 
an HSC 
HSC derived 
myofibroblasts 
(GFP+/pro a1 
(I)) varied from 
0-29%. 
No cell fusion 
Abbreviations: RAG, recombination activating gene; see Table 1.2 for other 
abbreviations. 
 
1.4.4 Bone marrow-derived cells in pancreatic fibrosis 
In the pancreas, many studies of BMDCs have focused on the possible contribution of 
BMDCs to islet cells, but have yielded inconsistent results (Choi et al., 2003; Hess et 
al., 2003; Ianus et al., 2003). Recently, Marrache et al. have shown that BMDCs do 
engraft in the pancreas in a mouse model of severe pancreatic fibrosis (Marrache et al., 
2008). They used desmin as a marker of pancreatic stellate cells (PaSCs) (Novelli et al., 
2003) and showed that BMDCs contributed to 5.12% +/- 1.12 of the PaSC population in 
pancreatic fibrosis. These BM-derived stellate cells were activated as demonstrated by 
α-SMA expression, suggesting a role in tissue repair. Based on dolichos biflorus 
agglutinin and cytokeratin 19 (CK19) staining, BMDCs could also contribute at a very 
low level (0.62%+/-0.11) to the ductal epithelium of the chronically inflamed pancreas. 
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However, despite the results from these pilot studies, questions on the role of BMDCs 
in pancreatic fibrosis still remain. Thus, I will be further exploring the role of BMDCs 
in murine models of acute and chronic pancreatitis. 
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1.5 Pancreas 
1.5.1 Pancreatic development, histology and function 
1.5.1.1 Pancreatic development 
The vertebrate pancreas emerges from the endoderm as dorsal and ventral buds, which 
eventually fuses into a single anlage during development (Slack, 1995). In the 
beginning, the pancreatic anlage is surrounded by mesenchymal tissue and is located in 
close proximity with the gut tube. The ventral pancreas emerges from endothelial cells 
near the liver, and the dorsal pancreas emerges from below the notochord region. The 
arrangement of the dorsal pancreas is controlled by cell signalling molecules released 
from the notochord and endothelial cells, while signals released from the cardiac 
mesoderm affect ventral pancreatic development. The primitive ductal systems, which 
classically are thought to give rise to islets and acinar glands, are formed by the 
epithelium within this anlage undergoing branching morphogenesis. It has been 
suggested that mesenchymal signals to the epithelial tissue control this process (Gittes et 
al., 1996; Kumar et al., 2003; Li et al., 2004), while a small contingent claim that the 
duct, acinar and islet cell lineages come from different progenitors, segregating in the 
pancreas before the process of morphogenesis (Gu et al., 2003). Many signalling 
pathways have been highlighted for their role in pancreatic development, including 
Notch, Hedgehog, EGF, FGF, and TGF-β pathyway. All these pathways activate 
transcription factors being affiliated to four major families; Pax, Nkx, bHLH and 
homeobox gene families (Habener et al., 2005). It has been suggested that these 
transcription factors have a central role in both development and maintenance of the 
pancreas. For instances, Nkx2.2 and Nkx6.1 are required for terminal differentiation of 
the beta cell, while Pax4 and Pax6 are necessary for delta and alpha cell fate 
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specification respectively. Another homeobox gene, HlxB9, is essential for dorsal 
pancreas development. The core transcription factors that control both exocrine and 
endocrine pancreatic development include Pdx1, p48 and Neurogenin 3 (Ngn3). The 
pancreas does not form in Pdx1 mutant mice; only the endocrine cells are specified in 
p48 mutant mice; and only the exocrine cells develops properly in Ngn3 mutant mice 
(Herrera et al., 2002).  
 
1.5.1.2 Pancreatic histology 
The pancreas has both endocrine and exocrine functions and cells differentiate from the 
ductal epithelium during development. Interlobular connective tissue septae separate the 
pancreas into lobules. The main function of the exocrine acinar cells is to produce 
digestive enzymes that feed into a ductal network. The endocrine cells migrate from the 
ductal skeleton, aggregating around capillaries to form isolated clusters of cells called 
the islets of Langerhans (Figure 1.10). These islets are scattered throughout the exocrine 
glandular tissue that consists of closely packed secretory acini. It is estimated that there 
are approximately 1 million islets within a human pancreas. Each islet is composed of 
roughly 3000 cells of which 75% are insulin-producing β-cells (Fellous et al., 2007). 
The rest of the islet consists of α-cells that produce glucagon (~ 5%), δ-cells that 
produce somatostatin (~ 20%) and PP-cells that produce pancreatic polypeptide (~ 1%) 
cells. Islets are richly vascularised and also contain several other cell types. 
 
1.5.1.3 Pancreatic function 
The exocrine system consists of acinar cells, the pyramidal-shaped secretory glandular 
cells that provide digestive enzymes via a network of ducts; intercalated ducts, 
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intralobular ducts and interlobular ducts that finally empty into the ampulla of Vater, 
situated in the duodenum. The function of the acinar cells is to produce digestive 
enzymes including lipase, chymotrypsin and carboxypolypeptidase for digesting 
proteins, pancreatic amylase for digesting carbohydrates and pancreatic lipases, 
cholesterolesterase and phospholipase, for digesting fat (Guyton, 2005). 
    The endocrine component is mainly composed of four different endocrine cells; β-
cells, α-cells, δ-cells and PP cells and constitutes approximately 1% of the mass of the 
pancreas. It regulates glucose usage and storage through secretion of insulin produced in 
the β-cells, glucagon secreted from the α-cells, somatostatin made in the δ-cells (inhibits 
the endocrine pancreas) and pancreatic polypeptide produced in the PP-cells (which 
inhibits the exocrine pancreas). 
 
Figure 1.10 Haematoxylin and eosin (H&E) of normal human pancreas showing 
its exocrine (1) and endocrine (2) cell types. Pancreatic lobules are segregated 
by interlobular connective tissue septae (4). The acinar tissue (1) produces 
digestive enzymes that are transported via the intralobular ducts (3). The 
endocrine component, islets of Langerhans (2) are embedded within the 
pancreatic exocrine tissue.  
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1.5.2 Acute pancreatitis, chronic pancreatitis and pancreatic fibrosis 
1.5.2.1 Acute pancreatitis 
Acute pancreatitis is defined as an acute inflammation in the pancreas. Althouth the 
injury is mild in 80% of patients who can recover without complication, however, the 
other 20% of patients will suffer from substantial morbidity and mortality (Lund et al., 
2006; Williams and Simms, 1999). Furthermore, recurrent attacks of acute pancreatitis 
can eventually cause serial complications including pancreatic fibrosis, diabetes and 
cancer. Acute pancreatitis is a disease caused by different aetiologies. Despite the fact 
that about 15 - 25% of pancreatitis episodes are of unknown cause, the most common 
triggering factors are biliary stones and alcohol abuse.  
    Many investigators believe that acute pancreatitis is induced by the unregulated 
activation of trypsin within acinar cells, although controversy still remains. The 
activation of this enzyme within the pancreas causes the autodigestion of the gland and 
local inflammation. The main triggering factors for this acute inflammation include 
pancreatic hyperstimulation (mainly seen in experimental models), gallstones, and 
alcohol abuse. Acute pancreatitis occurs when protective mechanisms are overwhelmed. 
These protective mechanisms include autolysis of activated trypsin, the synthesis of 
trypsin as an inactive form (trypsinogen), enzyme compartmentalisation, synthesis of 
specific trypsin inhibitors such as serine protease inhibitor Kazal type 1, and a low 
intracellular ionised Ca2+ concentration. The activation of trypsinogen into trypsin 
within acinar cells will further activate the complement and kinin pathyways, and 
several enzymes such as elastase and phospholipase A2 (Frossard and Hadengue, 2001). 
Additionally, local production of mediators such as TNFα, IL-1, interleukin 6 (IL-6) 
and interleukin 8 (IL-8) from neutrophils, macrophages and lymphocytes further initiate 
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inflammation. Anti-inflammatory cytokines, such as interleukin 10 (IL-10), decrease the 
severity of experimental pancreatitis (Gloor et al., 1998). 
    Besides these events, endothelial cells are activated, and this enables the 
transendothelial migration of leukocytes (Frossard et al., 1999). Furthermore, decreased 
oxygen delivery and generation of oxygen-derived free radicals also contribute to injury 
(Poch et al., 1999). Thus, the severity of pancreatic damage is decided by injury to the 
acinar cells and to activation of inflammatory and endothelial cells, regardless of the 
initial factors that trigger the disease. 
  
1.5.2.2 Chronic pancreatitis and pancreatic fibrosis 
Chronic pancreatitis is defined as the permanent destruction of the gland and a failure of 
the organ resulting from repeated pancreatic inflammation. The key pathological feature 
of this disease is pancreatic fibrosis (Behrman and Fowler, 2007). Clinically, most 
patients suffer from chronic abdominal pain, weight loss, steatorrhea, and diabetes. 
Furthermore, it is associated with an increased risk for the development of pancreatic 
carcinoma (Lowenfels et al., 1993; Malka et al., 2002). The causes of this disease vary. 
In India, the most common cause is tropical pancreatitis, while in Western countries the 
majority of patients with this disease are alcoholic. Genetic abnormalities can also lead 
to chronic pancreatitis. Although the causes of chronic pancreatitis may differ, the major 
histological features are similar: pancreatic fibrosis.    
    It is now believed that pancreatic fibrosis begins as an acute process that 
progresses to chronic irreversible damage as a result of repeated acute attacks (Figure 
1.11) (Witt et al., 2007). This necrosis-fibrosis concept is supported not only by clinical 
(Ammann and Muellhaupt, 1994; Mullhaupt et al., 2005) data, but also by experimental 
models. Animal models of pancreatic fibrosis have now been developed by inducing 
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repeated episodes of acute necroinflammation in the pancreas using an inhibitor of 
superoxide dismutase (Matsumura et al., 2001) or by administration of supraphysiologic 
doses of cerulein (Kunzli et al., 2008; Marrache et al., 2008). Recently, it has been 
demonstrated that repeated pancreatic necroinflammation induced by endotoxin 
administration in alcohol-fed mice also leads to pancreatic fibrosis (Vonlaufen et al., 
2007).  
    The molecular mechanisms responsible for pancreatic fibrosis after 
necroinflammatory episodes are now better understood, largely due to the 
characterization of the cells that play a critical role in the fibrogenic process, namely, 
the PaSCs (Omary et al., 2007). In normal pancreas, the inactive PaSCs are located in 
peri-acinar regions and are identified by intracellular fat droplets, vitamin A 
autofluorescence and molecular markers such as vimentin, desmin, glial fibrillary acidic 
protein (GFAP) and nestin (Apte et al., 1998; Bachem et al., 1998). When primary 
PaSCs are cultured, and also in the pancreas as a consequence of pancreatic injury, the 
PaSCs are activated, behaving like myofibroblasts and are associated with several 
morphological changes (Apte et al., 1998; Bachem et al., 1998), including nuclear 
enlargement and enhanced prominence of the endoplasmic reticulum network. 
Furthermore, the activated PaSCs express α-SMA and collagen type I, indicating these 
cells are a source of fibrosis in chronic pancreatitis and pancreatic adenocarcinoma 
(Apte et al., 2004; Casini et al., 2000; Haber et al., 1999). 
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Figure 1.11. Necrosis-fibrosis concept of progressive pancreatic injury. 
Repeated attacks of acute pancreatic necroinflammation result in increasing 
residual damage to the pancreas, eventually resulting in irreversible damage to 
the gland, characterized by acinar atrophy and fibrosis. Reproduced from Witt et 
al., 2007. 
 
1.5.3 Pancreatic stem cells 
1.5.3.1 Proposed adult stem cells for β-cell regeneration 
Diabetes is an attractive target for cellular replacement therapy since a successful 
clinical trial demonstrated that grafting healthy human islets to diabetic patients and 
using a non-steroidal immunosuppression regime could result in insulin-independence 
(Shapiro et al., 2000). However, the islet transplantation protocol in this study is not 
ideal because of the need for mutiple donors. The therapy requires pancreatic tissues 
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from two or more donors, and as a consequence the shortage of pancreatic tissue has 
become a major limitation. Nevertheless this finding encouraged research in the field of 
pancreatic stem cells, especially looking for cells that can regenerate new β-cells. To 
explain the mechanisms of β-cell regeneration, it has been proposed that renewal occurs 
via adult stem cells existing in the BM (Ianus et al., 2003), spleen (Kodama et al., 
2003), pancreatic duct (Bonner-Weir and Weir, 2005; Inada et al., 2008; Ramiya et al., 
2000), acinar cells (Lipsett and Finegood, 2002) and islets (Guz et al., 2001; Seaberg et 
al., 2004; Suzuki et al., 2004; Zulewski et al., 2001). However, most evidence 
supporting the existence of adult stem cells relies on indirect evidence like transient 
Pdx1 or insulin expression outside the β-cell population. The most convincing 
experiment would be a robust lineage analysis demonstrating that cells come from one 
of the above described locations can give rise to insulin+Pdx+ cells in vivo has not yet 
been performed. 
 
1.5.3.2 Pancreatic stem cell niches 
Very little information about the possible location of the pancreatic stem cell niche has 
been presented, and it is probabily because of the lack of direct evidence of the 
existence of adult pancreatic stem cells. Until recently, the work done by Fellous et al. 
(Fellous et al., 2009b) suggested that an active stem cell niche exists in the standard 
state human pancreas, either within the duct or close to it, which provides both ductal 
and acinar cell lineages. By using mtDNA mutations as a clonal marker, it has been 
shown that the same mutation was present in both the pancreatic ductal cells and 
associated acinar cells, suggestive of a common origin. This evidence supported the 
notion that a common bipotential-progenitor cell exists within the adult human 
pancreas. However, based on this technique, it is very difficult to identify whether it 
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was the ductal cells generating the acinar patch or vice versa, or even that an entirely 
separate cell type i.e. a dedicated pancreatic progenitor cell was producing both cell 
types.  
 
1.5.3.3 Pancreatic stem cell markers 
Researchers have looked for potential markers involved in the maintainence of 
“stemness”, such as retention of BrdU (slow proliferation), Oct4 (pluripotency) or ATP-
binding cassette (ABC) transporter expression (cytoprotection). Despites the efforts 
made, it has been difficult to establish the existence of an adult pancreatic multipotent 
stem cell, because of a lack of definitive markers.  
    Transcription factors expressed during pancreatic development are the main 
candidates for stem cell markers in adult pancreas, because they highlight a possible 
recapitulation of elements of embryonic development in adult pancreatic regeneration. 
This idea is supported by the expression of Pdx1, a transcription factor associated with 
pancreatic development in ducts, after partial pancreatectomy in rats (Liu et al., 2007). 
In fact, all pancreatic cells lineages originate from the pancreatic anlage expressing the 
homeobox transcription factor Pdx1, so it is reasonable to think this pathway is 
recapitulated during adult pancreatic regeneration (Gannon et al., 2000; Gu et al., 2002; 
Kim and MacDonald, 2002).  
    Ngn3, a transcription factor required during the foetal development of endocrine 
cells, has also been proposed as a marker of islet cell precursors (Gannon et al., 2000). 
More recently, it was demonstrated that following pancreatic duct ligation, some 
pancreatic cells begin to express Ngn3 (Xu et al., 2008). These Ngn3+ cells were 
thought to be pancreatic facultative stem cells because they can be isolated from the 
injured mouse pancreas by flow cytometry and generate functional islet cells in vitro. 
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However, the mechanism of facultative stem cell activation and the pancreatic cell type 
that initiates Ngn3 expression has not been identified. It is not clear what contribution 
these facultative stem cells have to normal pancreatic growth and repair, and whether 
these facultative stem cells persist in patients with diabetes. 
    The hepatocyte growth factor (HGF) receptor, c-Met, was proposed as a pancreatic 
stem cell marker. It has been demonstrated that cells isolated from neonatal and adult 
mouse pancreata express c-Met (Suzuki et al., 2004), which also have an active role in 
pancreatic development (Beattie et al., 1996; Otonkoski et al., 1996). Ductular cells 
with c-Met expression showed a high capacity of multiple lineage differentiation, and 
HGF expression also enhanced the budding of islet-like structures (Ramiya et al., 2000). 
However, low levels of donor-derived pancreatic endocrine cells were generated from 
the transplantation of β-cells derived in vitro from c-Met positive cells. 
    In an experimental cerulein-induced pancreatitis mouse model, regeneration was 
seen in acinar cells with expression of many pancreatic progenitor cell genes, including 
Pdx-1, E-cadherin, β-catenin and Notch components (Jensen et al., 2005). The Notch 
target gene Hes1 was also expressed showing that Notch signalling is reactivated in 
dedifferentiated pancreatic cells. It would suggest that acinar cells in the adult pancreas 
have the ability to dedifferentiate and initiate a genetic program similar to that 
expressed by embryonic pancreatic precursors. 
    Besides searching for pancreatic specific stem cell markers, pluripotent markers 
are also used to identify the origins of new β-cells (Zhao et al., 2007). Markers 
including Oct4, Sox2, CD133, CD34, CK19, insulin and nestin were sought on normal 
human pancreas sections. The results showed that Oct4 and Sox2 were mainly 
expressed in the ductular structures. This suggests that a ductular origin of islet 
neogenesis compatible with the observation of endocrine cells budding from the ducts 
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during development. These Oct4+Sox2+ cells did not express CK19, CD34, CD133, 
insulin or nestin, and appeared to describe a distinct cell population that may represent 
stem cells in the adult pancreatic ducts. However for definitive proof, it would still need 
to be shown that these cells have multilineage potential. 
    ABC transporters are thought to provide a protective function for stem cells and 
have been proposed as potential stem cell markers (Alison et al., 2006a). ABC 
transporters (notably ABCG2) generate the so-called side populations, have been 
isolated from human foetal islets that have a high proliferative and clonogenic potential. 
These side populations have been induced in vitro to form lineages that produce insulin 
or glucagon, Pdx1 and Glut2. However, the phenotype of these cells would need to be 
correlated to the characteristics of stem/progenitor cells (Lechner et al., 2002; Poliakova 
et al., 2004). 
    Despite their contribution in advancing research, this overcrowded non-distinct 
group of stem cell markers often generate ambiguity. Alternative methods should be 
explored for the purpose of identifying pancreatic stem cells and tracking their progeny. 
 
1.5.4 Pancreatic self-replication and neogenesis 
1.5.4.1 Self-replication 
It has been suggested that there is no stem cell in the adult pancreas, and that all 
regeneration is via replication of pre-existing pancreatic cell populations. This theory is 
most notably supported by Dor et al. (Dor et al., 2004) whose genetic lineage tracing 
studies demonstrated that β-cells are maintained by proliferation of pre-existing insulin 
expressing cells not only in the normal pancreas, but also during a period of pancreatic 
regeneration induced by a 70% pancreatectomy. However, this study does not rule out 
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the presence of a pancreatic stem cell population, because the stem cells themselves 
may also express insulin. The expression of the insulin promoter in cells outside the 
islets, for example in the ducts, may also invalidate the core assumption that insulin is 
exclusively present in well-differentiated β-cells (Bonner-Weir et al., 2008; Bonner-
Weir et al., 2004; Butler et al., 2004; Dutton et al., 2007). Thus, this study cannot 
exclude the possibility that ductal cells might contribute to the islets. 
    Further evidence for supporting self-replication driving pancreatic regeneration 
came from the sequential administration of two DNA analogue-based labels for 
detecting multiple rounds of cell division in vivo (Teta et al., 2007). It was applied to 
insulin-secreting regenerating β-cells of murine pancreatic islets, showing that double-
labelled cells were very rare, even after enormous pancreatic injury. It was shown that 
β-cells are formed equally from all beta cells, concluding that there was no pancreatic 
cell hierarchy. Similarly, a study monitoring the dilution of a fluorescent plasma 
membrane marker accompanying cell division in the entire β-cell pool showed equal 
levels of fluorescence dilution across the β-cell population, and speculated that β-cells 
are replenished equally by replication of all differentiated cells (Brennand et al., 2007). 
    These studies provide clear evidence that proliferation of pre-existing cells 
contribute to the majority of tissue restoration (Desai et al., 2007; Jensen et al., 2005). 
However, the replicative potential of adult pancreatic cells may work in collaboration 
with pancreatic progenitors, residing in the ducts, that can transdifferentiate to new islet 
/acinar cells (Bonner-Weir and Weir, 2005). 
 
1.5.4.2 Islet neogenesis 
The theory of ductal neogenesis has arisen from the observations that during 
development and regeneration, parenchymal cells can be seen budding from the ducts 
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and that relevant endocrine progenitor markers are expressed in the ductal epithelium 
(Bonner-Weir et al., 2000; Bonner-Weir et al., 2004; Gao et al., 2003). Additionally, a 
hypothesis termed the “streaming pancreas” was proposed by Zajicek et al. (Zajicek et 
al., 1990). This is a controversial theory based on the tracking of proliferative cells 
labelled using [3H]-TdR in male rat pancreata. They measured the distance labelled cells 
travelled from intercalated ducts at various time points (1 hour, and 14, 28, 42, 56, 90 
and 120 days) after injection. The labelled cells were observed to be gradually moving 
away from the ducts at a daily rate of 0.52 µm. It was also observed that the labelling 
index steadily decreased with time in acinar cells, whereas islet cells displayed a peak in 
the labelling index on day 42, then declined. They explained the results on the 
assumption that acinar cells can migrate to islets and that they are actually “islet cell 
precursors”, hence increasing the label intensity of islets by cell infiltration. To 
summarize this theory, adult pancreatic stem cells migrate out from ductular epithelium 
to differentiate into acinar cells capable of replication that continuously stream at a low 
kinetic rate until they reach a quiescent state followed by cell death. If an acinar cell 
reaches an islet it is then stimulated to differentiate to an islet cell. 
    The potential for ductal-derived cells to differentiate into an endocrine phenotype 
has also been shown in several in vitro studies. The ductal cells isolated from pre-
diabetic non-obese diabetic mice can form functional islets when they are implanted 
into the mice, restoring glucose homeostasis (Ramiya et al., 2000). Studies in the rat and 
non-human primates have also shown the possibility of islet neogenesis from ductal 
cells (Bonner-Weir et al., 2000; Bonner-Weir and Weir, 2005), as well as in vitro 
differentiation of mouse ductal cells into endocrine-like cells (Seaberg et al., 2004).  
    Support for the theory of ductal neogensis has been provided from in vivo models 
of regeneration induced by damage. For example, in the rat pancreatectomy model, new 
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islets were seen in the area of the proliferating ducts at 3 days after surgery, and 2 days 
after the initiation of replication in the pancreatic remnant (Bonner-Weir et al., 1983). 
These focal regions had expanded to form entirely new pancreatic lobes comprised of 
entirely differentiated exocrine and endocrine cells within 7 days. According to these 
data it was suggested that regeneration is mediated by a combination of ductal 
neogenesis and replication of adult acinar and β-cells (Bonner-Weir et al., 1983). 
    To further investigate the differentiation potential of cells with a ductal phenotype, 
CK19+ non-endocrine pancreatic epithelial cells were isolated from a human pancreas 
(Hao et al., 2006). When co-transplanted with foetal pancreas into the kidney capsule of 
immunodeficient mice, these CK19+ cells were able to differentiate into both exocrine 
and endocrine cells. It was believed that the foetal pancreas releases inductive factors 
that promote these CK19+ epithelial cells to differentiate into insulin expressing cells. 
However, it was not clear what these inductive signals were and therefore they could 
not be compared with those factors released during adult regeneration.   
    The hypothesis that pancreatic progenitors arise from differentiated ductal cells 
that have regressed to an immature pluripotent cell phenotype was supported by lineage 
tracing techniques (Inada et al., 2008). A duct-cell-specific promoter, human carbonic 
anhydrase II (CAII), was connected to the Cre gene to drive Cre-recombinase 
expression, and the Cre-LoxP system was used as a lineage tracing method to track islet 
neogenesis. The results showed that CAII-positive cells i.e. ductal cells behave like 
progenitors, giving rise to acinar cells and islets when neogenesis was stimulated by 
either injury (ductal ligation model) or during the neonatal period. 
    Further supportive evidence came from the comparison of the gene expression 
profile of newly formed islets with those from pre-existing islets and pancreatic ducts 
(Bonner-Weir et al., 2004). A significant number of candidate marker genes were 
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expressed in both new islets and ducts, but not in mature islets; this supports the 
hypothesis that endocrine cells generated during neogenesis have a ductal origin. 
 
1.5.5 Pancreatic epithelial-mesenchymal-epithelial transition 
Generally, cell differentiation is thought to be a one-way process (unidirectional) and 
irreversible. However, there is evidence showing plasticity amongst differentiated adult 
cells via a process named cellular or lineage reprogramming (Hochedlinger and 
Jaenisch, 2006; Orkin and Zon, 2008). In the literature, this process is also called 
transdifferentiation, dedifferentiation or transdetermination (Slack, 2007). For example, 
cellular reprogramming is used in amphibian limb regeneration (Brockes and Kumar, 
2002) and is thought to be important in certain types of metaplasia. In vitro, skin cells 
can be reprogrammed by the artificial introduction of transcription factor combinations 
to become induced pluripotent stem cells (Meissner et al., 2007; Park et al., 2008; 
Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007; Yu et al., 
2007).  
    Apart from ductal cells, acinar cells are also thought to be another possible source 
of new pancreatic beta cells. Pancreatic acinar cells have been demonstrated to have the 
potential ability to transdifferentiate into endocrine cells via a ductal state (Lardon and 
Bouwens, 2005; Lipsett et al., 2007; Means et al., 2005). The hypothesis being that 
acinar-to-duct transdifferentiation (acinoductal metaplasia) can then be followed by 
duct-to-endocrine re-differentiation. This theory has been supported by an in vitro 
experiment whereby under specific growth conditions, acinar cells were stimulated to 
transdifferentiate into duct-like structures, which were then triggered to produce low 
levels of insulin (Lipsett et al., 2007). The acinar transdifferentiation has also been 
suggested as a possible explanation for the association of metaplastic ductal lesions with 
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pancreatitis, which could cause an increased risk of pancreatic cancer. To investigate the 
acinar-to-duct transdifferentiation theory, a Cre-loxP-based genetic lineage tracing 
experiment was employed (Strobel et al., 2007). The results showed that acinar 
transdifferentiation was not found to play a role in normal tissue regeneration. All acinar 
cells were seen to originate from pre-existing acinar cells and the majority of 
metaplastic lesions were not of acinar origin, but acinar-to-ductal transdifferentiation 
was only observed in a minority of mucinous metaplastic lesions. 
    A more effective process would be the direct transforming of one cell type into 
another, bypassing the requirement to revert to an undifferentiated state. It has been 
shown in an embryonic study that pancreatic cells can be converted to liver cells in one 
step (Shen et al., 2000). Mature lymphocytes have also been shown to have the 
capability to be reprogrammed to form macrophages (Xie et al., 2004). This and iPS 
studies spotlighted that a combination of factors may be required in artificially 
reprogramme adult cells. For example, by using a strategy of re-expressing key 
developmental regulators in vivo, mature exocrine cells in mouse pancreas were targeted 
for reprogramming by delivery of several transcription factors expressed during 
pancreatic development including Ngn3, Pdx1 and Mafa, and a slight increase in extra-
islet insulin positive cells was revealed among these transformed cells (Zhou et al., 
2008). Despite the need for reprogramming by transcription factor delivery, the fact that 
acinar cells can be transdifferentiated directly to β-cell supports the theory that acinar 
cells are islet cell precursors as hypothesised by Zajicek et al. 1990 (Zajicek et al., 
1990). 
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1.6 Liver 
1.6.1 Liver development, histology and function 
1.6.1.1 Liver development 
Liver arises from the endodermal germ layer during gastrulation (Wells and Melton, 
1999). More specifically, cells of the ventral foregut endoderm adopt a hepatic fate at 3-
4 weeks into human gestation. Then the hepatic epithelium invades the surrounding 
mesenchyme to form the liver bud. Fibroblasts and stellate cells come from the 
mesenchyme, while the liver bud, containing hepatoblasts, differentiates to form the 
mature liver. As the liver grows, epithelial/mesenchymal interaction promotes further 
cell proliferation and morphogenesis. The hepatoblasts are bi-potential progenitors. 
Those residing next to the portal vein become biliary epithelial cells, while the majority 
of hepatoblasts in the parenchyma form hepatocytes (Lemaigre, 2003; Shiojiri, 1984).  
 
1.6.1.2 Liver histology 
A protective capsule of connective tissue (Glisson’s Capsule) surrounds the human liver 
that extends to form complex septae throughout the liver. The interlobular septae divide 
the liver into anatomical units called lobules that have a hexagonal shape approximately 
2 mm in length and 700 µm in diameter (Figure 1.12A). At the periphery of each lobule 
are 3 - 6 portal triads (Figure 1.13), each composed of interlobular bile ducts, the 
hepatic artery and the hepatic portal vein, and in the middle is a central/hepatic vein. 
Afferent blood vessels and lymphatics go along with the pathway formed by the septae, 
whereas efferent vessels have a separate direction. Distributing branches of blood 
vessels go around the lobule periphery. Smaller vascular channels lined with highly 
fenestrated endothelial cells, named sinusoids, are found within the lobule between 
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hepatocytes and are populated with phagocytic Kupffer cells, endothelial cells and 
stellate cells. The sinusoids originate from the portal triads and drain into the central 
vein. The space of Disse is a space between the endothelium and hepatocytes that 
functions to collecting lymph for delivery to lymphatic capillaries.  
    The functional unit of the liver is the hepatic acinus (Figure 1.12B), which is in the 
middle of the line connecting two portal triads and extends outwards to the two adjacent 
central veins. According to the location and the hepatic metabolism, the acinus can be 
divided into three zones: zone 1 (periportal), zone 2 (midzonal) and zone 3 
(centrilobular). The periportal zone 1 is closest to the portal triads and receives the most 
oxygenated blood. Conversely, the centrilobular zone 3 is relatively more sensitive to 
ischaemic injury because of its poor oxygenation.  
 
 
 
Figure 1.12 Schematic drawing of the structure of a hepatic lobule (A), and an 
acinus (B).  
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    Hepatocytes have large numbers of mitochondria, Golgi membranes, rough and 
smooth endoplasmic reticulum, glycogen granules and vesicles containing very low-
density lipoprotein, reflecting their vigorous involvement in metabolism, as well as 
contributing to endocrine and secretory functions. Hepatocytes make up approximately 
60% of liver cells, occupy about 80% of liver volume, and also contribute to the 
majority of liver functions. 
    The remaining non-parenchymal cells are located in the sinusoidal area and only 
make up about 6.5% of the liver volume. Many different cell types line hepatic 
sinusoids including sinusoidal endothelial cells, Kupffer cells and HpSCs. 
    Bile is secreted from the basal surface of hepatocytes, collected in canaliculi. The 
bile acids flow towards the periphery of lobules and into bile ductules and interlobular 
bile ducts, and eventually are collected in the hepatic duct outside the liver.  
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Figure 1.13 A portal triad in human normal liver. (A) Schematic drawing of the 
structure of a portal triad and its anatomic relationship with the hepatic vein and 
the different cell types in the liver. The triad is located on the periphery of 
hepatic lobules, and consists of a bile duct, a portal vein and a hepatic artery. 
(B) H&E of a portal triad within a human normal liver.  
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1.6.1.3 Liver function 
The liver carries out many functions including synthesis, metabolism, absorption, 
degradation and storage. For example, the liver performs several roles in carbohydrate 
metabolism, including gluconeogensis, glycogenolysis and glycogenesis. The 
hepatocytes contribute to lipid metabolism including cholesterol synthesis and 
lipogenesis. It can also synthesize a large part of the amino acids and is responsible for 
the mainstay of protein metabolism, synthesis and degradation. The albumin produced 
in the liver can maintain blood serum osmolarity. The angiotensinogen produced by the 
liver is vital for maintaining an adequate blood pressure. Hepatocytes can also produce 
thrombopoietin as well as coagulation factors crucial for haemostasis. Hepatocytes take-
up and store nutrients, vitamins and minerals absorbed from the intestine. The liver can 
breakdown many hormones, haemoglobin and many toxic substances. It is also a 
fundamental site for drug metabolism and responsible for the immunoreaction 
throughout the reticuloendothelial system of the liver. 
    Bile salts produced by the liver act to emulsify dietary fat and facilitate the uptake 
of vitamins A, D, E and K. Bile produced by hepatocytes provides the means to excrete 
cholesterol from the body and also helps to remove blood-borne waste products. 
 
1.6.2 Liver cirrhosis 
The definition of cirrhosis is the histological development of regenerative nodules 
(RNs) surrounded by fibrous bands in response to chronic liver injury (Schuppan and 
Afdhal, 2008). In general, the entire liver must be involved. These RNs were thought to 
be formed by fibrotic isolation, and the regenerative response of hepatocytes may 
produce a spherical confrontation to these nodules. Although many diseases can cause 
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liver injury, only those with certain characteristics lead to cirrhosis. The injury should 
not to be too severe, otherwise the liver fails quickly without enough time to develop 
fibrosis. Typically, diseases that can cause repeated minor liver injuries with 
progressive damage lead to cirrhosis. In this section, the aetiologies, the microscopic 
features and the pathogenesis of liver cirrhosis will be further discussed. 
 
1.6.2.1 Aetiologies of liver cirrhosis 
Liver cirrhosis is an advanced stage of liver fibrosis, believed to result from the 
repetition of the wound-healing process, causing an abnormal continuation of 
fibrogenesis. Table 1.6 outline the major causes of chronic liver diseases (Wallace et al., 
2008). Besides the major causes listed in Table 1.6, liver cirrhosis can also occur in 
some specific conditions. For example, iron overload-induced liver fibrosis can be 
observed in multiple transfused patients with HIV infections (Goldin et al., 1993). 
These diseases can result in liver fibrosis and eventually cause liver cirrhosis at variable 
rates depending on the cause of liver disease, environmental factors as well as host 
factors.  
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Table 1.6 Major diseases that can cause liver cirrhosis. 
Disease Cause 
Infectious diseases  
        Hepatitis B Hepatitis B virus (HBV). Passed through infected body fluids. 
        Hepatitis C Hepatitis C virus (HCV). Passed through infected body fluids. 
        Hepatitis D Hepatitis D virus (HDV). Passed through infected body fluids. 
 
Autoimmune diseases  
        Primary biliary cirrhosis Immune-mediated attack of the small intrahepatic bile ducts. 
Cause unknown. 
        Autoimmune hepatitis Immune-mediated attack of hepatocytes. 
 
Inherited   
        Wilson’s disease Mutations in a copper-transporting gene, cause copper 
accumulation in the liver. 
        Hereditary        
        haemachromatosis 
Homozygous mutation in HFE gene. The body absorbs too 
much iron stored in liver, leading to toxicity. 
        Cystic fibrosis Homozygous mutation in the CFTR genes. 
 
Dietary  
        Non-alcoholic  
        steatohepatitis (NASH) 
Fat accumulation in the liver with hepatic inflammation in the 
absence of alcohol consumption. 
 
Chemical   
        Alcohol Elevation of ROS with hypoxia production of acetaldehyde. 
Increased gut permeability to endotoxin. 
 
Other  
        Budd-Chiari syndrome Obstruction of hepatic venous outflow due to thrombosis. 
        Gallstones Accumulation of stones in gall bladder and bile ducts. 
        Primary sclerosing    
        cholangitis 
Progressive loss of bile ducts due to inflammation. Cause 
unknown. 
Reproduced from Wallace et al., 2008. 
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1.6.2.2 Microscopic features of liver cirrhosis 
A microscopic diagnosis of cirrhosis is defined as a fibrous subdivision of the liver 
parenchyma with isolation of parenchymal islands. Although the presentation of 
cirrhosis varies, it can be roughly divided into micronodular and macronodular 
cirrhosis. 
    Generally, micronodular cirrhosis arises from subdivision of parenchymal acini. 
Because the diameter of acini is about 1mm, the cirrhotic nodules may be less than 1mm 
in diameter. The tiny nodules may enlarge as they regenerate, however, the surrounding 
fibrous tissue may confine their expansion. Eventually every acinus is affected, so it is 
normal to see an absence of anatomically intact acini. The smallest portal tracts are 
connected to their adjacent terminal hepatic veins by fibrous septae, so the zones 1, 2 
and 3 of the acinus are transected by fibrous bands. RNs may form concurrently or 
subsequently. Based on the aetiologies, fibrosis may occur predominantly in one zone. 
For example, fibrosis may be around the portal tracts (zone 1) in haemochromatosis, or 
around the terminal hepatic venules (zone 3) in alcoholic disease. However, cirrhosis 
has not developed if fibrosis is confined only to these zones. 
    The microscopic features of macronodular cirrhosis are highly variable. In general, 
the histology shows large nodules delimited by fibrous septae in which multiple hepatic 
acini are incorporated into single nodules. In the early stage of evolution, residual portal 
tracts and acini may be evident. Cell plates within the nodules do not have the regular 
radial orientation present between portal tracts and hepatic veins. The hepatic veins are 
usually dilated and increased in number. It is very difficult to diagnose the disease if 
only a needle biopsy is available, however, the possibility of macronodular cirrhosis 
must be considered when abnormal cell plate patterns and dilated veins with excess 
numbers are present. 
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1.6.2.3 Pathogenesis of liver cirrhosis 
Liver cirrhosis is a dynamic process controlled not only by destructive processes such as 
progressive parenchymal fibrosis, the severe disruption of vascular architecture and 
distortion of the normal lobular architecture, but also by the reconstruction from the 
regeneration of hepatocytes and resorption of fibrous tissue. The main pathogenic 
elements include the deposition of collagen, arterialization of sinusoids, obliteration of 
portal and hepatic veins, disruption of vascular physiology, regeneration of hepatocytes 
and resorption of fibrosis tissue (Odez and Goldblum, 2009). 
    Collagen deposition and accumulation is the predominant feature of cirrhosis. 
Excess collagen type 1 and 3 accumulate in the portal tracts, in the spaces of Disse, and 
in the regions of necroinflammatory collapse. Several-fold increases of collagen, 
glycoproteins, and proteoglycans can be measured in cirrhosis (Murata et al., 1985). 
Many cells are now believed to contribute to collagen production by transformation to 
active myofibroblasts in cirrhosis (Figure 1.14) including stellate cells, portal 
fibroblasts, BM cells, circulating fibrocytes and EMT from hepatocytes and 
cholangiocytes (Friedman, 2008). It was generally considered that stellate cells play the 
key role in liver fibrogenesis, although the different sources of activated myofibroblasts 
are likely to reflect differing contributions with disease progression and among different 
aetiologies. For example, portal fibroblasts appear to be especially important in 
cholestatic liver diseases and ischaemia (Beaussier et al., 2007). In contrast, BM-
derived cells may be progressively recruited over time, so that these cells can represent 
a substantial fraction of the total fibrogenic population in more chronic injury (Russo et 
al., 2006). In normal liver, HpSCs stay quiescent and reside in the subendothelial space 
of Disse in the sinusoidal walls. However, during hepatic injury, the immuno-response 
stimulates the transformation of quiescent stellate cells to become myofibroblasts. For 
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example, in genetic haemochromatosis, even though the inflammation is not a 
conspicuous histological finding, changes in the liver’s immune system are present and 
are thought to be factors in activating stellate cells (Bridle et al., 2003; Hubscher, 2003). 
These activated stellate cells lose their fat globules, express α-SMA, and begin 
proliferation and collagen synthesis. They produce collagens and ECM, deposited in the 
space of Disse, giving an appearance known as sinusoidal fibrosis. Collagen is 
eventually deposited along the entire length of the sinusoid with time, and these excess 
collagen depositions result in vascular and architectural alterations. 
    Capillarization occurs in the cirrhotic liver. The term refers to a constellation of 
ultrastructural changes including an increase in basement membrane material, a 
decrease in the number and size of sinusoidal endothelial fenestrations, and a loss of 
hepatocellular microvilli (Mori et al., 1993; Schaffner and Poper, 1963). ECM 
deposition in the space of Disse contributes to the loss of fenestration in the sinusoidal 
endothelial cells. Transformation of perisinusoidal stellate cells to contractile 
myofibroblasts has been thought to contribute to sinusoidal arterialization. The fibrosis 
and inflammatory response in the perivascular regions also obstructs vascular outflow, 
increases vascular resistance, and finally leads to portal hypertension. These vascular 
changes are accompanied by ECM deposition and hepatocyte loss eventually leading to 
shunt formation, vascular thrombosis and liver congestion. 
    The other feature is parenchymal extinction, a focal loss of continguous 
hepatocytes.  Hepatocytes apoptosis and necrosis takes place in all types of diseases 
that progress to cirrhosis. The condition is aggravated by a stromal reaction including 
deposition of ECM, increased vascular resistance and obstruction to the blood outflow 
(Wanless et al., 1995). The size of the extinction lesions can range from a small portion 
of an acinus to even a whole lobe.  
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    Liver has an enormous capacity for regeneration. Depending on the severity and 
aetiology of the injury, liver regeneration may occur by at least two mechanisms (Alison 
et al., 2009). Briefly speaking, with mild to moderate hepatocellular loss, mature 
hepatocytes go through replication. When extensive hepatocyte loss or hepatocyte 
function is impaired, proliferation of progenitor cells may play a role in regeneration. 
The detailed mechanisms will be discussed in the following sections. In cirrhosis, the 
regeneration shows a round appearance to the expanding contours of residual 
parenchyma. On thickening of the liver cell plates, the parenchyma expands against the 
fibrous septa and obtains a spherical shape. The hepatocyte plates abutting the fibrous 
septa are compressed and are therefore bent outward by the less-pressured plates toward 
the interior of the nodule. The size of the nodule is partly decided by the anatomic 
location of the previous fibrous septae. If the fibrosis occurs at the acinar level, the 
resulting nodules will give rise to monoacinar units, and will be small. On the contrary, 
if the ECM deposition surrounds many acinar units, the nodules may be larger and will 
retain components of pre-existing acini, including portal tracts.  
    Extensive expansion of bile ductules within the fibrous septa may occur in 
cirrhosis of almost any cause, probably with the exception of biliary obstruction 
(Masuko et al., 1964). These specific phenomena have been named ductular reactions 
(DRs) and are thought to be related to a proliferation of periportal progenitor cells 
(Falkowski et al., 2003; Zhou et al., 2007). Details will be discussed in the following 
section. 
    The resorption of fibrosis tissue may occur in cirrhosis (Wanless et al., 2000) and 
in experimental models (James et al., 1986). The mechanism of resorption of fibrous 
ECM involves activation of tissue metalloproteinases (Arthur et al., 1998). Activated 
myofibroblasts may undergo apoptosis and subside. However, even with substantial 
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resorption of ECM, restoration of the hepatic architecture to a normal state may never 
occur. 
 
 
Figure 1.14 Different cell types that can be transformed to active myofibroblasts 
and contribute to heptic fibrosis. Quiescent stellate cells are activated by 
inflammatory mediators. The activated stellate cells are further transformed to 
myofibroblasts (which contain contractile filaments). With time however, other 
cells including portal fibroblasts, BMCs (which likely give rise to circulating 
fibrocytes), and EMT from hepatocytes and cholangiocytes may also contribute 
to fibrogenic populations in the liver.  
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1.6.3 Liver stem cells 
The liver has the capacity to maintain a constant size by delicately balancing 
regeneration with overgrowth despite injury. It is often debated as to which liver stem 
cells are responsible for liver regeneration. One explanation for this controversy is the 
use of multiple definitions for liver stem cells (Duncan et al., 2009). Many definitions of 
liver stem cells have been used including: (1) cells responsible for normal liver 
turnover, (2) cell responsible for regeneration after PH, (3) cells that give rise to 
progenitor-dependent regeneration, (4) cells that produce hepatocytes or cholangiocytes 
in vitro, and (5) transplantable liver-repopulating cells. In this chapter, the potential 
stem cell populations within the liver will be discussed. 
 
1.6.3.1 Cells responsible for normal liver turnover 
In normal liver, it is believed that hepatocyte replacement occurs relatively slowly. A 
hypothesis named “the streaming liver” has been proposed to explain hepatocyte 
turnover, and that normal liver turnover is similar to intestinal regeneration, with young 
hepatocytes originating in the portal tract and then migrating toward the central vein 
(Zajicek et al., 1985). The different gene expression profiles by periportal and 
pericentral hepatocytes were thought to be a reflection of the hepatocyte maturation 
process, demonstrating a cell lineage progression. This hypothesis was supported by the 
data from Fellous et al. (Fellous et al., 2009a) that showed that clonal patches of normal 
human hepatocytes (having the same mtDNA mutation) were found to originate from 
periportal regions and seemingly expanding towards pericentral areas, suggesting a 
pattern of hepatocyte differentiation and/or movement.  
    Evidence against the streaming liver hypothesis, however, also exists. Rat 
retroviral marked hepatocyte migration was not found for up to 15 months after PH 
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(Bralet et al., 1994). This opinion was not shared by advocates of the ‘streaming liver 
hypothesis’ (Zajicek, 1995). Furthermore, it has been suggested that the different gene 
expression profiles between periportal and pericentral hepatocytes is dependent on the 
direction of blood flow rather than a maturation process (Thurman and Kauffman, 
1985). Despite the debate on the contribution of liver stem cells in normal liver 
turnover, the evidence suggests that most liver maintenance is reliant on hepatocyte 
division and cell division of bile duct epithelial cells (Ponder, 1996). 
 
1.6.3.2 Cells responsible for regeneration after partial hepatectomy 
Liver regeneration after two-thirds PH in rodents has become a useful model of 
studying regenerative organ growth (Michalopoulos, 2010). The regenerative capacity 
of the liver is well demonstrated by this model and that the remnant liver can grow to 
compensate for the entire liver mass within 10 days (Grisham, 1962). This 
reconstruction process is mediated by mature hepatocytes. It suggests that hepatocytes 
are the cells that normally undertake the burden of regenerative growth after liver 
injury, so they can be considered as the functional stem cells under most circumstances. 
Classic thymidine labelling experiments showed that effectively all hepatocytes in the 
remaining liver restore the original cell numbers by dividing once or twice within 3 – 4 
days (Bucher and Swaffield, 1964). Following hepatocyte division, the other cell types 
in the liver also undergo a wave of mitosis, so that the original number of all cells in the 
liver can be restored efficiently. Several growth factors have been identified as 
important factors in mediating hepatocyte regeneration. The most important signals are 
interleukin-6, HGF, TNFα, transforming growth factor α, and epidermal growth factor 
(Michalopoulos, 2010). Although much less is known about how liver regeneration is 
terminated once the appropriate liver mass is achieved, it has been suggested that Hippo 
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kinase signalling pathway may play a role as a “size checkpoint” operating at the level 
of the liver mass (Dong et al., 2007). 
 
1.6.3.3 Hepatic progenitor cells 
Although hepatocytes have a significant proliferative potential, it was thought that adult 
liver contains a regenerative compartment that can be activated under extreme 
conditions. In the condition of overwhelming liver injury, chronic liver injury, or large-
scale hepatocyte senescence, a potential stem cell compartment becomes activated from 
within the smallest branches of the intrahepatic bile ducts. For example, in chronic 
hepatitis C, the proliferation rate of hepatocytes increases with progressive histological 
damage until cirrhosis is reached, then the proliferation rate begins to fall (Falkowski et 
al., 2003). This fall probably reflects replicative senescence (Marshall et al., 2005), 
although the decreased blood flow may also play a part. An activation of the stem cell 
compartment occurs concurrently with the reduction of hepatocyte proliferation. This 
phenomenon, named an “oval cell reaction” in rodents or a “ductular reaction” in 
humans, is an amplification of a cholangiocyte-derived population into either 
hepatocytes or cholangiocytes (Alison et al., 1996; Alison et al., 2009; Duncan et al., 
2009; Falkowski et al., 2003; Zhou et al., 2007). The extent of this reaction is dependent 
on the severity of the damage in both humans (Lowes et al., 1999) and mice (Kofman et 
al., 2005). It has been suggested that oval cells/hepatic progenitor cells (HPCs) are 
derived from the canal of Hering (CoH) (Figure 1.15). In rodents, this canal barely 
extends beyond the limiting plate, while in human liver the CoH can extend to the 
proximate third of the lobule (Theise et al., 1999).  
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Figure 1.15 The oval cell response (A) in rodents, and the ductular reaction (B) 
in human liver. (A) In rodents, the stem cell niche is the CoH located close to 
the portal area. Once the oval cell response is activated by liver injury, the oval 
cells proliferate and then these biliary-derived cells can differentiate to 
hepatocytes, losing their biliary (CK7/19+) phenotype. (B) The same course of 
events recognised as a ductular reaction in human liver occurs at the same 
location but at some distance away from the portal area. 
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    Many markers have been used to identify oval cells/HPCs and these are 
summarized in Table 1.7 (Alison et al., 2009). Some markers like Dlk may signal 
impending hepatocyte differentiation (Tanimizu et al., 2004). Oval cells co-express 
markers of bile duct epithelium (CK19) and hepatocytes (albumin) in rats. Furthermore, 
high levels of α-fetoprotein (AFP) are also expressed, thus they may look like foetal 
hepatoblasts in their gene expression profile (Shinozuka et al., 1978). An established 
experimental procedure to induce an oval cell response in rats is to pre-treat rodents 
with 2-acetylaminofluorene (2-AAF) before a two-thirds PH (the 2-AAF/PH protocol). 
2-AAF inhibits hepatocytes from entering the cell cycle in response to the subsequent 
PH, and therefore, the burden of regeneration is shifted to the biliary cell compartment 
that is resistant to the effects of 2-AAF. The oval cell response is induced within the 
remnant liver, and the cells of the oval cell response (identified by CK19 
immunostaining) are smaller than the larger bile ducts from which the response 
originates. The results showed that almost all ductules differentiated into hepatocytes 
within 14 days at the low dose of 2-AAF (2.5 mg.kg-1.day-1) (Alison et al., 1996).  It 
therefore has been considered that oval cells behave as bi-potential progenitors (capable 
of producing both hepatocytes and bile ducts), despite the fact that most of the 
experimental evidence has actually come from in vitro studies (Spagnoli et al., 1998; 
Strick-Marchand et al., 2004). Recently, the evidence of bi-potential progenitors in the 
oval cell response has been provided in an in vivo transgenic mouse model using Foxl1 
as a marker for genetic lineage tracing (Sackett et al., 2009). Furthermore, the 
maturation of oval cells/HPCs is likely to be regulated by paracrine signals from Thy-1+ 
mesenchymal cells that are in close contact with the expanding ductules (Kamo et al., 
2007), while the differentiation of oval cells in the rat can be accelerated by external 
influences like triiodothyronine (T3) (Laszlo et al., 2008). 
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Table 1.7 Markers used for the identification of oval cells/HPCs.  
A6 antigen (mouse marker) 
ABCG2/BCRP1 (breast cancer resistance protein) 
AFP (α-fetoprotein) 
Cadherin 22 
CD24, CD34, CD44, CD133 
Chromogranin A 
CK7, CK14, CK19 
c-Kit (CD117) 
Claudin7 
Connexin 43 
Dlk (δ-like protein) 
DMBT1 (deleted in malignant brain tumour 1) 
E-cadherin 
Flt-3 ligand 
Fn14 (TWEAK receptor) 
GGT (γ-glutamyltranspeptidase) 
GST-P (placental form of glutathione-S-transferase) 
M2-PK (muscle type pyruvate kinase) 
MUC1 
NCAM-1/CD56 (neural cell adhesion molecule-1) 
OV-1, OV-6, OC2, OC3, OC4, OC5, OC10 
PTHrP (parathyroid hormone related peptide) 
Thy-1 (CD90) * 
Many of these markers are also expressed on normal biliary epithelial cells. 
Reproduced from Alison et al., 2009. * Controversial. 
 
    Oval cells/HPCs have been reported to express some antigens traditionally 
associated with haematopoietic cells (c-kit, flt-3, CD34), leading to the hypothesis that 
some oval cells are directly derived from a precursor of BM origin. An experiment 
using three different protocols in dipeptidyl peptidase 4 (DPP4)-deficient mutant rats 
has demonstrated that no oval cells were found to be of BM origin (Menthena et al., 
2004). On the other hand, another study using the same DPP4-mutant rats but with 
carefully manipulated protocols showed that approximately 20% of oval cells were 
derived from BM cells (Oh et al., 2007). This conflict of opinion may be caused by the 
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time of administration of monocrotaline. Monocrotaline is able to inhibit both 
hepatocyte regeneration and BM activation. Only if this chemical is given before BM 
transplantation, will the BM contribute to the oval cell population. This hypothesis has 
also been tested in another model, stimulating the oval cell reaction by feeding rats with 
an ethionine-supplemented, choline-deficient diet. The result showed 3 - 4% of oval 
cells expressed the same marker as the donor BM-GFP, while these same cells also 
expressed the recipient feature, the Y chromosome. It was concluded that these cells are 
created by cell fusion (Kubota et al., 2008). Although the question of whether BM-
derived oval cells/HPCs exist still remains, it is generally accepted that oval cells are 
derived from oval cell precursors in the bile duct epithelium, and that BM-derived oval 
cells originate by cell fusion. 
    Different signalling events occur based on different phases of the oval cell 
response: activation, proliferation, migration and differentiation (Erker and Grompe, 
2007). Some factors involved in the oval cell response are summarised in Figure 1.16. 
These factors were identified by either genetic studies in the mouse or in vitro studies of 
oval cell lines in culture. During oval cell activation, multiple epithelial, haematopoietic 
and mesenchymal cell types are present, and in many cases it is difficult to know which 
cells transmit and which cells receive important molecular signals. Furthermore, the 
factors that affect the oval cell response can do so either directly acting on the 
proliferating epithelial cells, or indirectly by signalling to a non-epithelial type, which 
might, then act on the oval cells in turn.  
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Figure 1.16 A timeline showing the stages of oval cell response, and the 
signalling events involved in each stage. Reproduced from Erker and Grompe, 
2007. Abbreviations: LIF, leukaemia inhibitory factor; OSM, onocostatin M; Cox-
2, cyclooxygenase-2; IFN, interferon; LT-β, lymphotoxin-β; SCF, stem cell 
factor; TNF, tumour necrosis factor; TWEAK, TNF-like weak inducer of 
apoptosis; TGF, transforming growth factor; HGF, hepatocyte growth factor; 
FGF-1, fibroblast growth factor-1; SDF-1, stromal cell-derived factor-1; Dlk/Pref-
1, delta-like protein/preadipocyte factor-1.  
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1.6.4 Liver stem cell niche?
1.6.4.1 The portal area is the stem cell niche based on the streaming liver theory 
Controversy still looms over the existence of a stem cell niche in normal liver. 
Hepatocytes are normally proliferatively quiescent, with a turnover rate of 1 in 20,000 
to 40,000 cells according to BrdU incorporation studies (Sell, 2001). At the same time, 
they also play a major role in regeneration after liver injury occurs, leading to the 
question of whether stem cell populations and a stem cell niche exists in the normal 
liver. However, it has often been suggested that there is a slowly renewing hepatocyte 
population initially formed adjacent to the portal tract, streaming all together toward the 
terminal hepatic vein (Zajicek et al., 1985). This so-called “streaming liver” hypothesis 
is based on [3H]-TdR LRC studies in rats (Baratta et al., 1996; Zajicek et al., 1985). The 
migration of hepatocytes was followed by examining the location of labelled [3H]-TdR 
hepatocytes over time. One hour after labelling, the average labelled hepatocyte was 75 
µm from the portal area, while labelled hepatocytes were on average over 140 µm away 
from the portal rim after 4 weeks. Thus, it was concluded that hepatocytes ‘streamed’ at 
a velocity of ~2 µm/day from the portal tract towards the central vein – thus the concept 
of the streaming liver was born. In some early studies of liver regeneration, the wave of 
mitosis is observed to start in the periportal region (zone 1) about 1 day after injury, 
then moving along the acinus until it enters the pericentral region (zone 3) after 48 
hours (Fabrikant, 1968; Grisham, 1962). It leads to the idea that the position of 
hepatocytes within the hepatic lobule may control their temporal response to 
proliferative stimuli. Based on the streaming liver model, the pattern of the kinetics of 
DNA synthesis starts from the higher proliferating capacity of young hepatocytes 
located around the portal area. Further supportive evidence came from research using 
mtDNA mutations as markers for conducting cell lineage tracing in normal human liver 
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(Fellous et al., 2009a). Patches composed of hepatocytes with the same mtDNA 
mutation were observed, indicating the clonal expansion ability of normal hepatocytes. 
Furthermore, these patches abutted the portal tracts and expanded laterally as they 
spread toward the hepatic veins. These data suggested that clonal proliferative units 
exist in the human liver, an origin from a periportal niche is most likely, and that the 
trajectory of the units is compatible with a migration of cells from the periportal regions 
to the hepatic veins. 
    However, not all researchers agree that the liver is a constantly cycling system with 
an identical stem cell niche, for example a study tracing the fate of normal hepatocytes 
using genetic pulse labelling of cells in vivo (Bralet et al., 1994). The β-galactosidase-
labelled hepatocytes were observed at 3 time points (3 days, 15 days and 15 months) 
after a two-thirds PH in rats. The positive cells were distributed throughout the liver 
parenchyma and with time clustered to form distribution patterns that remained 
unmodified/static over time. However, according to the streaming hypothesis, cords of 
β-galactosidase positive cells should have been observed, spanning between the portal 
space and the central vein. After 15 months, these labelled cell clusters were only seen 
in zone 1 and 2, again disagreeing with the streaming hypothesis. No proliferative niche 
was discovered since labelled cell clusters were distributed throughout the liver, and 
also no evidence of cell streaming was observed. It was therefore concluded that liver 
mass is maintained solely by replication of randomly distributed pre-existing 
hepatocytes. 
 
1.6.4.2 The putative stem cell niche when hepatocyte function is impaired 
It has been shown that hepatocytes have the regenerative ability to restore the liver mass 
after PH, with no need for a stem cell involvement (Fabrikant, 1968; Grisham, 1962). 
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However, when existing hepatocytes have impaired proliferative function caused for 
example, by 2-AAF exposure, oval cells/HPCs are thought to be stimulated. These cells 
reside within the portal tract region, more specifically in the bile ducts/CoH, providing a 
new influx of fresh cells (Alison et al., 1996). Oval cells emanate from smaller 
interlobular ducts and the CoH to amplify the biliary population, which are able to 
differentiate into hepatocytes. According to these findings, these areas where oval 
cells/HPCs arise are referred to as liver stem cell niches. 
    In order to locate the liver stem cell niche in detail, an improved LRC experiment 
has been performed using BrdU labeling to trace cells in an acetaminophen-overdose 
injury mouse model (Kuwahara et al., 2008). Because of their allegedly slowly cycling 
nature, stem cells may be identified by BrdU long-term retention after acetaminophen 
overdose, causing acute fulminant hepatic failure known to stimulate the oval cell 
reaction. This method highlighted four distinct cell compartments that retained the BrdU 
label, unraveling several subtle and entangled mechanisms utilized for cell renewal 
(Figure 1.17). After 8 weeks, undefined LRCs were observed around the CoH, which 
may relate to slowly cycling HPCs thought to be located in the putative CoH stem cell 
niche. Furthermore, LRCs identified as hepatocytes were also observed to increase in 
number near the periportal regions. The proportions of CoH-LRCs to hepatocyte-LRCs 
may help to explain that peribiliary LRC-hepatocytes are directly derived from CoH-
LRCs. This theory is further supported by the observation that some of the LRC-
hepatocytes also retain the ductal marker expression. In addition, LRC-cholangiocytes 
were also observed, however it is difficult to see how these function as HPCs for 
hepatocyte regeneration. Finally they observed peribiliary cells referred to as “null 
cells”, since they were unidentified, showed no hepatobiliary (AFP, albumin, OV6, and 
cytokeratin), haematopoietic (CD34, Sca1, Thy1, and CD45) or mesenchymal marker 
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(desmin and vimentin) expression. Their appearance in models of periportal injury, 
rather than the typical centrilobular injury, may suggest that they play a role in liver 
regeneration when the CoH stem cell niche is disrupted or obliterated along with 
destruction of the periportal hepatocytes. 
 
 
Figure 1.17 An illustration of the microanatomical locations of asymmetric 
dividing LRC cells identified by Kuwahara et al., 2008 (1) Within the CoH, (2) 
peribilary hepatocytes, (3) intra-ductular, and (4) peribiliary “null” cells. 
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Chapter 2: Materials and Methods 
2.1 List of equipment, consumables, reagents and solutions 
2.1.1 Equipment 
ABI 3100 Genetic Analyser Applied Biosystems 
Agarose gel Electrophoresis System Amersham 
AlphaImage series 2200 Software Flowgen 
Autoclave Astell 
Balance; Sartorius Basic Satorius 
BD LSR II FACS analyser  Becton-Dickinson 
Bench-Top Microcentrifuge Sigma 
Bench-Top Centrifuge 3-15 Sigma 
Cryostat (Cryo-star HM560M) Microm International 
Cyto-Tek centrifuge Electron Microscopy Science 
General Purpose Incubator Philip Harris 
Heat Block Techne 
Laser-microdissection Systems Leica 
Leica DM5000 Fluorescence Microscope Leica Microsystems 
Leica Sledge Microtome Leica Microsystems 
NANOpureII Water Purification System Barnstead 
NIH-ImageJ software NIH 
ABI PRISM® 7700 Sequence Detection System Applied Biosystems 
pH Meter Jenway 
4 Peaks software Mekentosj.com 
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Thermal Cycler (9700) Applied Biosystems 
Zeiss Axioplan Light Microscope Zeiss 
 
2.1.2 Consumables 
Cell strainer 70 µm Becton-Dickinson 
Coverslips (22x22mm, 22x40mm, 22x50mm) Merck 
Disposable scalpels Swann-Morton 
Eppendorf Tubes (1.5ml) Biogene 
Eppendorf Tubes (2.0ml) Biogene 
Eppendorf 0.5 µl -10 µl Pipettes Merck 
Falcon Tubes (15ml and 50ml) Costar 
Gilson Pippetteman (P20, P200, P1000) Anachem 
Heparin-coated tubes Sarstedt 
Microscope Slides (76x76x1.0-1.2 mm) Merck 
QiAamp DNA micro kit Qiagen 
Thin-Walled PCR Tubes (0.2 ml and 0.5 ml) Biogene 
Vernaid dressing towel Vernon-Carus Ltd 
Whatman Grade 1 Filter Paper Merck 
 
2.1.3 Reagents 
2.1.3.1 Tissue preparation reagents 
Iso-pentane Merck 
Liquid Nitrogen BOC 
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OCT Cryoembedding Matrix Raymond Lamb 
 
2.1.3.2 Cell isolation and culture reagents 
Blood lysing solution Becton-Dickinson 
Collagenase type IV Sigma 
Deoxyribonuclease Roche 
Dispase Roche 
E4 medium Cancer Research UK 
Foetal bovine serum (FBS) Sigma 
Hank’s balanced salt solution (HBSS) Cancer Research UK 
 
2.1.3.3 Fluorescence-activated cell sorting reagents 
AF647 conjugated goat anti-rabbit Ig Invitrogen 
Aqua stain dye Invitrogen 
BD Perm/Wash buffer BD Pharmingen 
PE-conjugated monoclonal mouse CD45 antibody BD Pharmingen 
Rabbit anti-mouse collagen 1 (Col1) antibody Millipore 
 
2.1.3.4 Histological and histochemical reagents 
Avidin/Biotin Blocking Kit Vector 
Bovine Serum Albumin Sigma 
Bovine trypsin BDH 
Calcium Chloride Sigma 
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Cytochrome c Sigma 
3,3’Diaminobenzidine Tetrahydrochloride Sigma 
Disodium Hydrogen Phosphate Sigma 
DPXTM BDH 
Eosin “yellowish” Merck 
Erythrosin B Merck 
Ethanol AnalaR Merck 
Formaldehyde Merck 
Haematoxylin Merck 
HistoclearTM National Diagnostics 
Hydrogen Peroxide BDH 
Hyperladder IVTM Bioline 
Methanol AnalaR Merck 
Mouse anti-OXPHOS complex IV subunit I Invitrogen 
Normal rabbit serum Dako 
Normal swine serum Dako 
NitroBlue Tetrazolium (NBT) Sigma 
Paraformaldehyde (PFA) Sigma 
Phenazine Methosulphate (PMS) Sigma 
Phosphate Buffered Saline Tablets Sigma 
Rabbit anti-mouse Biotin DakoCytomation 
Rabbit anti-mouse Cy3 (555 - fluorophore) Dako 
Retrivagen A BD Bioscience 
Sirius red VWR international 
Sodium Azide Sigma 
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Sodium Chloride Sigma 
Sodium Citrate Sigma 
Sodium Malonate Sigma 
Sodium Succinate Sigma 
Streptavidin / HRP DakoCytomation 
Swine anti-rabbit Biotin DakoCytomation 
Triton X-100 Sigma 
Vector Mount (DAPI) FITC (488 - fluorophore) Vector Laboratories 
Vector Red substrate Vector Laboratories 
Xylene BDH 
 
2.1.3.5 In situ hybridisation reagents 
FITC-labelled Y chromosome paint Cambio 
Glycine Sigma 
Pepsin Sigma 
Sodium thiocyanate  Sigma 
Vectashield Hard Set mount medium Vector 
 
2.1.3.6 Molecular biology reagents 
Agarose MP Roche 
Amplitag Gold DNA Polymerase Applied Biosystems 
BigDye® Terminator v3.1 cycle sequencing kit Applied Biosystems 
Bromophenol Blue Sigma 
Deoxynucleotide Triphosphates Roche 
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DNA Ladder 1kb Gibco BRL 
DNA Oligonucleotide Synthesis MWG Biotech UK Ltd 
DyeEx 2.0 spin kit Qiagen 
Ethidium Bromide Merck 
Ethylenediaminetetreacetic Acid (EDTA) Sigma 
ExoSAP-IT USB 
Polyoxyethylenesorbitan Monolaurate (Tween 20) Sigma 
Proteinase K Invitrogen 
Superscript II reverse transcriptase Invitrogen 
Tris HCl Sigma 
 
2.1.4 Solutions 
All solutions listed and others mentioned in the text were prepared in nanopure (18 
Mega Ohms activity) water and subsequently autoclaved. 
Acid Alcohol 1% (v/v) concentrated HCL diluted in 70% ethanol. 
DNA Loading Buffer 0.25% (w/v) Bromophenol Blue 
0.25% (w/v) Xylene Cyanol 
30% (v/v) Glycerol 
Eosin Solution 1% (w/v) eosin ‘yellowish’ 
0.4% (w/v) erythrosine B 
0.2% (w/v) phloxin B 
Formal Calcium 3.6% (v/v) Formaldehyde 
1.1% (w/v) Calcium Chloride 
Meyer’s Haematoxylin 1% (w/v) haematoxylin 
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50% (w/v) potassium alum 
0.2% (w/v) sodium iodate 
1% (w/v) citric acid 
50% (w/v) chloral hydrate 
Phosphate Buffer, pH7.4 95 ml 0.2 M Disodium Hydrogen Phosphate 
405 ml 0.2 M Sodium Dihydrogen Phosphate 
500 ml Water 
Phosphate Buffered Saline 
(PBS) 
Prepared from tablets 
1 tablet in 200 ml water 
Peroxidase Block 3% hydrogen peroxide diluted in methanol. 
Peroxidase Developing 
Solution 
4 mM 3,3’-diaminobenzidene tetrachloride 
0.01% (v/v) hydrogen peroxide diluted in 0.1 M 
phosphate buffer pH 7.4 
Scott’s Tap Water 30 mM LiCO3, 
160 mM MgSO4 
 
 
2.2 Tracing bone marrow-derived cells in an experimental pancreatitis 
mouse model 
2.2.1 Mice 
2.2.1.1 C57/BL6 and BALB/C wild type strains 
Two WT mouse strains and two transgenic mouse strains were used in this study. The 
WT strains were C57/BL6 and BALB/C and both were obtained from Charles River 
Laboratories (Wilimington, Maine, USA). 
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2.2.1.2 Col1α1r/r transgenic mouse strain  
The Col1α1r/r transgenic mice, in which a mutation that encodes amino acid 
substitutions that prevent collagenase cleavage in the alpha1 (I) chain of type 1 collagen 
was engineered in a C57/BL6 background, obtained from St Mary's Hospital, Imperial 
College, London, UK, originally derived from the Whitehead Institute for Biomedical 
Research and Department of Biology (Cambridge, Massachusetts, USA) in 1990 (Krane 
et al., 1996; Wu et al., 1990).  
 
2.2.2 Bone marrow transplantation 
All procedures were carried out following Institutional and Home Office (HO) 
guidelines. Before transplantation, mice were given acidified drinking water (to pH 2.8-
3.2 with hydrocholoric acid) for one week to prevent Pseudomonas growth. Six to eight 
week-old female recipient mice underwent whole body gamma irradiation with 10 Gy in 
a divided dose four hours apart, to ablate their BM, followed immediately by tail vein 
injection of male whole BM (2 × 106 cells). Thereafter, mice were fed with normal 
mouse chow ad libitum with free access to unlimited acidified drinking water. 
 
2.2.3 Blood, bone marrow and organ collection 
2.2.3.1 Blood  
Terminal peripheral blood (PB) was collected by cardiac puncture from the ventricle 
using 23-G size needles and collected into heparin-coated tubes. Fresh blood collected 
in heparin-coated tubes was mixed thoroughly to prevent coagulation and spun down 
briefly. Blood was stored on ice and used within two hours of collection. All animals 
were sacrificed by a Schedule one method. 
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2.2.3.2 Bone marrow  
After cervical dislocation, the femurs and tibias were dissected out using a disposable 
scalpel, cleaned and collected in Bijou tubes containing sterile x1 phosphate buffered 
saline (PBS). 
 
2.2.3.3 Organs 
Pancreata, spleen, liver and small intestine from these groups of mice were also 
acquired fresh. For immunohistochemical (IHC) studies, these tissues were fixed in 4% 
paraformaldehyde (PFA) overnight before storing in 70% alcohol. They were then 
processed and paraffin-embedded for further studies. For cell isolation, pancreata were 
harvested freshly and put in fresh sterile E4 medium with 10% heat-inactivated foetal 
bovine serum (FBS). For mRNA extraction, pancreata were acquired and put into liquid 
nitrogen immediately, and pancreatic mRNA was extracted within 24 hours by an acid 
guanidium thiocyanate-phenol-choloroform method. 
 
2.2.4 Isolation and culture of pancreatic activated myofibroblasts 
Pancreatic activated myofibroblasts were isolated by the method described by Saotome 
et al. (Saotome et al., 1997). The pancreatic tissue was evaluated to be normal by light 
microscopic observation. Resected pancreatic tissue was cut into small pieces in HBSS 
using a sterile razor blade. HBSS containing 3 U/ml dispase, 0.05% type IV 
collagenase, and 10 µg/ml deoxyribonuclease was injected into the specimens using a 
27-G needle, and the specimens were shaken for 30 minutes at 37°C. After 
centrifugation for 5 min at 400 rpm, the supernatant was washed twice with E4 medium 
containing 10% FBS and then the precipitate with the 5 ml of same medium was seeded 
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into culture dishes. The isolated cells were cultured at 37°C in 8% CO2 and the culture 
medium was changed every 2 days. After reaching confluence, the monolayers of cells 
were trypsinized and passaged. All studies were performed on passage three to five. The 
purity of the cells was assessed by cytoplasmic staining for α-SMA. 
 
2.2.5 Isolation of peripheral blood and bone marrow cells 
2.2.5.1 Peripheral blood 
Fresh blood collected in heparin-coated tubes was mixed thoroughly and spun down 
briefly. A volume of 200 µl of blood was aliquoted into separate 15ml Falcon tubes. 
Next, 1.8 ml of lysing solution was added to each tube, vortexed and left to incubate for 
3 minutes in the dark. After incubation, 13 ml of x 1 PBS were added to each tube to 
dilute the lysing solution and spun down at 2000 rpm for 4 minutes. The resultant 
supernatant was removed and pellet was resuspended in x 1 wash buffer (PBS/0.1% 
NaN3/1.0% FBS) for further analysis. 
 
2.2.5.2 Bone marrow 
Bones (femurs and tibias) from a single mouse were cleaned with sterile vernaid 
dressing towel and the ends of these bones trimmed with a pair of sterile scissors. BM 
cells were collected by flushing the bones with PBS with 2% FBS using a 23-G needle. 
After flushing each part of the bone, the cells were collected in a 10 ml Falcon 
polystyrene tube. Next the cells were filtered with a 70µm cell strainer into another 10 
ml Falcon polystyrene tube and centrifuged at 2000 rpm for 4 minutes. The resulting 
pellet was resuspended in x 1 wash buffer for further analysis. 
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2.2.6 Fluorescence-activated cell sorting analysis 
2.2.6.1 Markers of fibrocytes 
Fluorescence-activated cell sorting (FACS) analysis was carried out to quantify the 
content of fibrocytes from BM and PB respectively. Fibrocytes were defined as double 
immuno-positive cells expressing the CD45 surface marker combined with intracellular 
expression of collagen I. 
 
2.2.6.2 Staining for FACS analysis 
After cells were isolated from PB and BM, around 1 × 106 cells diluted in wash buffer 
were incubated for 30 minutes in the dark at 4°C with a PE-conjugated monoclonal 
antibody against mouse CD45. After washing twice, the Aqua stain dye was added and 
incubated in the dark for 30 minutes at 4°C. Then the cells were fixed in 4% PFA for 20 
minutes at 4°C and the cell membrane permeabilised by 1 x BD Perm/Wash buffer for 
15 minutes. After permeabilising and washing, the cells were incubated for 30 minutes 
in the dark at 4°C with a rabbit anti-mouse collagen 1 (Col1) antibody. After washing 
twice, the cells was incubated with AF647 conjugated goat anti-rabbit Ig for 30 minutes 
in the dark at 4°C. After washing, the cells were resuspended in washing buffer and 
ready for FACS analysis. 
 
2.2.6.3 Analysis and gating strategies 
Cells were analysed on a BD LSR II FACS analyser. The dead cells were excluded by 
positive staining of the Aqua stain dye. The compensation gating strategies and the 
quadrant markers were set according to the controls at that time point by Dr. Kirsty 
Sharrock (blind manner). The cells staining with antibodies against both CD45 and 
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intracellular Col1 were measured as a percentage of the total cell number. Each analysis 
included at least 10 000 events. 
 
2.2.6.4 Morpholgy of fibrocytes from peripheral blood 
To examine the morphology of fibrocytes from PB, the FACS-isolated cells were re-
suspended in PBS and spun down to sections at 500 rpm for 10 minutes in a Cyto-Tek 
centrifuge. The sections were air dried for 1 day and then were processed for either 
haematoxylin/eosin staining or in situ hybridization (ISH) for Y chromosome detection.  
 
2.2.7 Immunohistochemistry 
Sections cut at 4 µm were dewaxed, incubated in 1.8% v/v hydrogen peroxidase in 
methanol to block endogenous peroxidases, or incubated in 20% v/v acetic acid in 
methanol to block alkaline phosphatase, then taken through graded alcohols to PBS.  
For antigen retrieval, sections were either 1) microwaved (700W) in 0.01M citrate 
buffer at pH 6 for 10 minutes, or 2) microwaved (700W) in 2mM 
ethylenediaminetetraacetic acid solution at pH 9 for 10 minutes, or 3) incubated with 
bovine trypsin (100 mg bovine trypsin, 100 mg calcium chloride, 100 ml distilled water, 
pH 7.8) at 37ºC for 10 minutes, or 4) microwaved (700W) in RetrivagenA for 10 
minutes. 
    To reduce non-specific background staining, sections were next pre-incubated with 
either 1) normal rabbit serum or swine serum at a dilution of 1/25 for 15 minutes; the 
choice of which depended on the second layer used – rabbit serum for second layer of 
rabbit origin and swine serum for second layer of swine origin, or 2) 1% bovine serum 
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albumin for 30 minutes. For intracellular protein staining, sections were incubated with 
0.2% Triton-X 100 for 10 minutes. 
    After PBS washing, sections were incubated for 35 minutes with the primary 
antibodies which included 1) anti-Ki-67 (Dako) at a 1/200 dilution, 2) anti-BrdU 
(Abcam) at a dilution of 1/500, 3) anti-CD45 (BD Pharmingen) at a 1/20 dilution, 4) 
anti- α-SMA (Sigma-Aldrich) at a dilution of 1:4000, 5) anti-amylase (Sigma-Aldrich) 
at a 1/20 dilution, 6) anti-endomucin (Santa Cruz Biotechnology, CA, USA) at a 1/300 
dilution, 7) anti-Collagen1 (Millipore) at a 1/50 dilution, 8) anti-F4/80 (Serotec, 
Kidlington, UK) at a 1/100 dilution, 9) anti-insulin (Sigma-Aldrich) at a 1/1000 
dilution, 10) anti-CK19 (Dako) at a 1/100 dilution, 11) anti-vimentin (Sigma-Aldrich) at 
a 1/50 dilution, 12) anti-desmin (Dako) at a 1/50 dilution, 13) anti-GFAP (Dako) at a 
1/100 dilution. 
    Secondary layers, after PBS washing, were either 1) biotinylated swine anti-rabbit 
Ig (Dako) at a 1/500 dilution for 35 minutes, 2) biotinylated rabbit anti-mouse Ig (Dako) 
at a 1/300 dilution for 35 minutes, 3) biotinylated rabbit anti-rat Ig (Vector Laboratory, 
UK) at a 1/100 dilution for 35 minutes, 4) biotinylated goat anti-rat Ig (Jackson 
Laboratory) at a 1/250 dilution for 35 minutes, 5) AF350 conjugated donkey anti-rabbit 
Ig (Invitrogen) at a 1/50 dilution for 60 minutes, 6) Cy5 conjugated goat anti-mouse Ig 
(Zymed Laboratory) at a 1/50 dilution for 60 minutes. 
    For the third layer, after PBS washing, streptavidin-peroxidase at a 1/500 dilution 
or streptavidin-alkaline phosphatase at a 1/50 dilution was applied to sections for 35 
minutes. Slides were developed in 3,3’-diaminobenzidine (DAB) plus 0.3% v/v 
hydrogen peroxide or vector red substrate. Then slides were counterstained lightly with 
haematoxylin, dehydrated and mounted in DPX-type mount. 
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2.2.8 In situ hybridization for the Y chromosome 
Sections were cut at 4 µm and incubated in 1 M sodium thiocyanate for 10 minutes at 
80ºC to improve access of probe to DNA. Following PBS washing, sections were 
digested in 0.4% w/v pepsin in 0.1 M hydrochloric acid for 4 minutes at 37ºC to 
improve further access of the Y chromosome probe. The length of pepsin digestion 
required depended on the extent of tissue fixation. The protease reaction was quenched 
in 0.2% w/v glycine in double concentration PBS and sections were then rinsed in PBS, 
post-fixed in 4% w/v PFA in PBS, dehydrated through graded alcohols, and lastly air 
dried. A fluorescein isothiocyanate (FITC)-labelled Y chromosome paint was used in 
the supplier’s hybridisation mix. The probe mixture was added to the sections, sealed 
under glass with rubber cement, heated to 60ºC for 10 minutes, and then incubated 
overnight at 37ºC in a humidified chamber.  
    The next day, all slides were washed in 0.5 x standard saline citrate at 37ºC. For 
the direct detection of the Y chromosome, all sections following washing with PBS, 
were cover-slipped with Vectashield Hard Set mount medium with or without 4’,6-
diamidine-2’-phenylindole dihydrochloride. 
 
2.2.9 RNA preparation and real-time PCR 
The expression of mRNA for Col1α1 and GAPDH in total RNA was determined by 
quantitative real-time PCR. Total RNA was extracted from mice that received a BM 
transplant from WT or Col1α1 mice by an acid guanidium thiocyanate-phenol-
chloroform method. First strand cDNA was synthesized from 2.5 µg of total cellular 
RNA with oligo (dT) primer and superscript II reverse transcriptase. All primers and 
probes were designed by Taqman Primer Express program, and quantification of mRNA 
was performed by the ABI PRISM® 7700 Sequence Detection System. 
 133 
2.2.10 Scoring of pancreatitis and measuring of pancreatic fibrosis 
2.2.10.1 Scoring of acute pancreatitis 
The severity of acute pancreatitis was graded as previously reported by Van Laethem et 
al. (Table 2.1) (Van Laethem et al., 1998). The assessment was performed by two 
qualified pathologists independently in a blind manner. 
 
Table 2.1. Histological scoring of acute pancreatitis 
Condition Score Indication 
Oedema 0 
1 
2 
3 
Absent 
Focally increased between lobules 
Diffusely increased between lobules 
Acini disrupted and separated 
Inflammatory cell infiltrate 0 
1 
2 
3 
Absent 
In ducts (around ductal margins) 
In the parenchyma (in <50% of the lobules) 
In the parenchyma (in >50% of the lobules) 
Acinar necrosis 0 
1 
2 
3 
Absent 
Periductal necrosis (≤ 5%) 
Focal necrosis (5% - 20%) 
Diffuse parenchymal necrosis (20%- 50%) 
 
2.2.10.2 Scoring of chronic pancreatitis 
The severity of chronic pancreatitis was graded as previously reported by Demols et al. 
(Table 2.2) (Demols et al., 2002). The assessment was performed by two qualified 
pathologists independently in a blind manner. 
 
 
 
 
 134 
Table 2.2. Histological scoring of chronic pancreatitis 
Condition Score  Indication 
Tissue architecture changes 0 
1 
2 
3 
4 
 
 
 
 
 
Absent 
Rare 
Minimal (<10%) 
Moderate (<50%) 
Major (>50%) 
Glandular atrophy 0 
1 
2 
3 
 
 
 
 
Absent 
Minimal (<10%) 
Moderate (<50%) 
Major (>50%) 
Pseudo-tubular complexes 0 
1 
2 
3 
 
 
 
 
Absent 
Minimal (<10%) 
Moderate (<50%) 
Major (>50%) 
Fibrosis 0 
2 
4 
 
 
 
Absent 
Only within areas 
Diffuse 
 
2.2.10.3 Measuring of pancreatic fibrosis 
Sirius red was used for intrapancreatic collagen staining. Quantitative analysis of 
collagen deposition was performed by digitalized image analysis with the NIH-ImageJ 
software (Rangan and Tesch, 2007).  The total pancreatic tissue area was distinguished 
from the background according to a difference in light density. The total amount of 
collagen (stained in red) was measured and finally expressed as a percentage of the total 
pancreatic surface. 
 
2.2.11 Statistics 
Results are expressed as mean ± Standard error of the mean (SEM). Mean values of the 
experimental groups were compared by Student’s unpaired t-tests. P values of less than 
0.05 were considered to be statistically significant. 
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2.3 Using mitochondrial DNA mutations as clonal markers in human 
liver and pancreas 
2.3.1 Surgical human tissue collection and ethical approval 
2.3.1.1 Liver 
The normal human liver samples were obtained from hepatic resections for metastatic 
colorectal carcinoma, with samples collected > 10 cm from the tumour resection 
margin. The cirrhotic liver samples were obtained from hepatic resections for 
hepatocellular carcinoma, with sample collected > 10 cm from the tumour resection 
margin. These samples were either fixed in 4% PFA, embedded in paraffin wax or snap 
frozen in isopentane previously cooled in liquid nitrogen. The research project was 
explained to the patients prior to surgery and their informed written consent was 
obtained. All samples were coded to maintain confidentiality. Multicentre ethical 
approval was sought and obtained as per the requirements of the United Kingdom 
Human Tissue Act (2006). Ethical approval was granted from the Redbridge and 
Waltham Forest Local REC to use human tissue collected from the Royal London 
Hospital REC (REC reference number 2006/Q0601/33). 
 
2.3.1.2 Pancreas 
The normal human pancreas tissue samples were obtained from histologically normal 
pancreata of patients undergoing pancreaticoduodenectomy for periampullary tumours. 
The chronic pancreatitis tissue samples were obtained from patients undergoing 
pancreatectomy for intractable chronic pancreatitis. These samples were either fixed in 
4% PFA, embedded in paraffin wax or snap frozen in isopentane previously cooled in 
liquid nitrogen. The research project was explained to the patients prior to surgery and 
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their informed written consent was obtained. All samples were coded to maintain 
confidentiality. Multicentre ethical approval was sought and obtained as per the 
requirements of the United Kingdom Human Tissue Act (2006). Ethical approval was 
granted from the Redbridge and Waltham Forest Local REC to use human tissue 
collected from the Royal London Hospital REC (REC reference number 
2006/Q0601/33). 
 
2.3.2 Human tissue preparation 
2.3.2.1 Fixed tissues 
After fixation in 4% PFA for 24 hours, these tissues were stored in 70% alcohol and 
were ready for paraffin block preparation and sectioning. The tissue was transferred to 
70% ethanol and then to toluene on a ‘Shandon Excelsior Processor’, and embedded in 
paraffin wax. Using a Leica sledgemicrotome and floated onto a 57ºC water bath to 
remove creases, these embedded tissue blocks were sectioned at a thickness of 4µm.  
Tissue sections were positioned onto glass microscope slides, dried at 37 ºC for > 1 hour 
and stored at room temperature in a sealed slide box. 
 
2.3.2.2 Frozen tissues 
After snap freezing (15 seconds) in isopentane previously cooled to -160ºC in liquid 
nitrogen, these tissues were cooled in liquid nitrogen and then stored at -80ºC. The 
frozen tissue samples were mounted in OCT on an aluminium chuck, in preparation for 
sectioning. By using a Cryo-star HM 560 M cryostat, sections were cut at ~15 µm.  
These sections were air-dried for 1 hour at room temperature and stored in sealed slide 
box at -80ºC. 
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2.3.3 Immunohistochemistry 
2.3.3.1 Haematoxylin and eosin staining procedure 
Frozen sections were allowed to air dry for 30 minutes at room temperature and were 
fixed in -20ºC acetone for 6 minutes. Paraffin sections were dewaxed in xylene and 
rehydrated through decreasing concentrations of alcohol (100%, 95% and 70%) ending 
in distilled water. 
    After washing in running tap water for 1 minute, the sections were immersed in 
Meyer’s haematoxylin for 1 minute and rinsed in tap water. Then the sections were 
immersed in acid alcohol for approximately 10 seconds following immersion in Scott’s 
tap water for 30 seconds to fix the staining before rinsing in cold water. The sections 
were again washed in running tap water and then immersed in eosin solution for 30 
seconds. Sections were washed for the last time in running tap water, dehydrated in a 
graded ethanol series (70%, 95% and 100%), immersed in two changes of Histoclear, 
then finally mounted and coverslipped in DPX. 
 
2.3.3.2 Counterstaining protocol 
A light haematoxylin counterstain was applied to tissue sections by immersion in 
Meyer’s haematoxylin for 1 minute and rinsed in tap water, followed by immersion in 
acid alcohol for approximately 10 seconds. Following a second rinse in tap water, 
sections were immersed in Scott’s tap water solution for 30 seconds to fix the stain and 
then rinsed in cold tap water. Sections were rapidly dehydrated through graded ethanols 
(70%, 95% and 100%) for a further 2 minutes and then immersed in xylene.  Finally, 
sections were mounted and coverslipped in DPX. 
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2.3.3.3 Immunohistochemical staining of cytochrome c oxidase deficient cells 
As mentioned before, CCO is a core enzyme involved in the electron transport chain, 
and relevantly it is predominantly encoded within the mitochondrial genome. The 
mtDNA mutation predominantly affects the expression of CCO. The CCO negative cell 
phenotype may be exploited to identify cells that potentially house identical mtDNA 
mutations, indicating that those cells are clonally derived. Thus, by following CCO 
negative cells it may be possible to track clonal cell units that could help provide 
information on the origins and movements of cells within human tissues. Because CCO 
(complex IV subunit I) immunohistochemistry on frozen tissue sections detects the 
same CCO deficient cells as the CCO and SDH enzyme histochemical assay (Taylor et 
al., 2003), this technique was developed for fixed paraffin embedded tissue. Before 
routine use of an antibody, serial ranges of dilutions were tested on positive control 
sections to establish the optimal dilution. Normal serum and secondary antibodies were 
used at the recommended concentrations. 
 
2.3.3.4 CCO, CK19 and insulin immunohistochemical staining procedure 
Immunohistochemistry was performed on either 4 µm paraffin sections or 15 µm frozen 
sections. Paraffin sections were dewaxed in xylene, blocked for endogenous peroxidases 
and rehydrated through decreasing concentrations of alcohol (100%, 95% and 70%), 
ending in distilled water. Then antigen retrieval was performed on the paraffin-fixed 
tissues by boiling the slides in 0.1 M citrate buffer for 10 minutes. Whereas frozen 
sections were allowed to air dry for 30 minutes at room temperature and were fixed in -
20ºC acetone for 6 minutes.  Slides were then washed for 3 x 5 minutes in PBS. The 
sections were treated with an avidin and biotin block for 10 minutes each and washed 
for 3 x 5 minutes in PBS. The relevant primary antibody (Table 2.3) was applied to the 
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sections for 60 minutes in a humid chamber at room temperature. The slides were then 
washed for 3 x 5 min in PBS. Following this the sections were incubated for 35 minutes 
at room temperature with the respective biotinylated secondary antibody (Table 2.4) and 
then washed for 3 x 5 minutes in PBS. The sections were then incubated in 1:500 
streptavidin/HRP for 30 minutes at room temperature and subsequently washed for 3 x 
5 minutes in PBS. Peroxidase activity was demonstrated by incubating the sections in 
hydrogen peroxidase developing solution at room temperature for 2 - 5 minutes. 
Sections were then washed in PBS, and counterstained in haematoxylin. Finally the 
sections were dehydrated in escalating grades of ethanol (70%, 95% and 100%), cleared 
with xylene, and mounted in DPX. Isotype-matched and primary antibody controls 
showed there was a lack of non-specific staining. 
 
Table 2.3. Primary antibody specificity and dilution for CCO, CK-19 and Insulin 
1o Antibody Reactivity Dilution 
CCO  Mouse anti-human 1:400 
CK19 Mouse anti-human 1:100 
Insulin Mouse anti-human 1:500 
 
Table 2.4. Secondary antibody specificity and dilution for CCO, CK19 and 
Insulin 
2o Antibody Reactivity Dilution 
CCO Rabbit anti-mouse 1:300 
CK19 Rabbit anti-mouse 1:300 
Insulin Rabbit anti-mouse 1:300 
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2.3.4 Enzymatic histochemistry 
2.3.4.1 Dual CCO and SDH enzyme histochemistry 
One characteristic feature of mtDNA disease and ageing is tissue containing CCO 
deficient cells, and these cells have been notably identified in skeletal and cardiac 
muscle (Brierley et al., 1997; Brierley et al., 1998; Cottrell et al., 2001a; Cottrell et al., 
2001b; Muller-Hocker, 1989, 1990; Muller-Hocker et al., 1992). Because the catalytic 
subunits of CCO (I, II, III and IV) are largely mtDNA encoded, CCO deficiency can be 
used as a marker for mtDNA mutations. We can perform a double enzyme 
histochemical stain for CCO followed by a secondary stain for SDH. Because SDH is 
entirely encoded by nuclear DNA and is thus unaffected by mutations within mtDNA, 
therefore when CCO activity is absent, SDH activity should remain. In this dual CCO 
and SDH assay, sections are first incubated in the CCO medium, the cells with CCO 
activity are stained brown, while the cells that lack CCO activity are then stained blue 
by a subsequent incubation in the SDH medium, helping to facilitate the clear 
visualisation of CCO negative cells.  
    Cytochrome c oxidase histochemistry (Old and Johnson, 1989): The CCO reaction 
medium oxidises DAB using it as an electron donor, reducing cytochrome c in the 
electron transport chain. The reduced cytochrome c molecule is then oxidised by CCO 
enzyme activity. Oxidative polymerisation and cyclisation of DAB gives rise to a brown 
insoluble indamine polymer. This stain only works when CCO is present to oxidise the 
cytochrome c so that it is capable of accepting electrons from DAB. The specificity of 
this reaction can be revealed by using a specific inhibiter of CCO i.e. sodium azide, 
which acts as a terminal electron transport chain block. 
    Succinate dehydrogenase histochemistry (Old and Johnson, 1989): The SDH 
reaction medium reduces NitroBlue tetrazolium (NBT) using it as an electron acceptor, 
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oxidising SDH in the electron transport chain. When it is reduced, NBT forms insoluble 
microcrystalline blue formazan. The phenazine methosulphate (PMS) is present to act as 
an intermediate electron carrier between the SDH and NBT to help accelerate the 
reaction. Sodium succinate provides a plentiful supply of the SDH substrate, enhancing 
the reduction of NBT. The specificity of this reaction can be revealed by using a 
specific inhibiter of SDH i.e. sodium malonate, which acts as a terminal electron 
transport chain block. 
 
2.3.4.2 CCO reaction medium 
The CCO reaction medium was prepared by mixing 200µl of cytochrome c stock 
solution (500µM cytochrome c in 0.2 M phosphate buffer pH 7.0) and 800µl of DAB 
stock solution (5mM DAB in 0.2 M phosphate buffer pH 7.0), finally catalase (20µg/ 
ml) was added to the solution. 500µl of medium was applied to each tissue section and 
incubated for 30 minutes at 37oC. 
 
2.3.4.3 SDH reaction medium 
The SDH reaction medium was prepared by mixing 800µl NBT stock solution (1.875 
mM NBT 0.2 M phosphate buffer pH 7.0), 100µl sodium succinate stock solution (1.3 
M sodium succinate in 0.2 M phosphate buffer pH 7.0) and 100µl PMS stock solution 
(2 mM PMS in 0.2 M phosphate buffer pH 7.0). 500µl of this medium was applied to 
each tissue section and incubated at 37oC for 60 minutes. 
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2.3.4.4 Dual CCO and SDH histochemistry 
Prior to cryosectioning, these frozen human tissue samples were mounted in OCT 
compound. Sequential serial sections were cut at 15µm. The sections were air-dried at 
room temperature for at least 30 minutes prior to staining. The sections were incubated 
at 37oC in CCO incubation medium for 30 minutes. Following incubation the sections 
were washed 3 x 5 minutes in PBS. Each slide was dried with tissue paper, taking care 
not to touch the section and then incubated in the SDH reaction medium at 37oC for 60 
minutes. Following incubation, the sections were washed 3 x 5 minutes in PBS. After 
immersion in absolute alcohol for 10 minutes to help remove any excess blue/purple 
monoformazan reaction product of the SDH reaction, the sections were then dehydrated 
in escalating grades of ethanol (70%, 95% and 100%). The sections were then cleared in 
two changes of Histoclear and mounted in DPX with a glass coverslip or left to air dry 
for > 40 minutes and kept in a sealed slide box at -20 oC. 
 
2.3.5 Cell isolation and mitochondrial DNA extraction 
Single cells from within CCO deficient patches, as well as single cells from CCO 
positive regions were microdissected and collected by a Leica laser microdissection 
(AS-LMD) system. Each group of cells was collected in a UV-treated sterile 0.5 ml 
PCR tube and then centrifuged (7000 x g for 10 minutes). The cells were then lysed in 
20 µl of lysis buffer (50 mM Tris.HCL, pH 8.5/1 mM EDTA/0.5% Tween-20/200 ng/ml 
proteinase K) at 65oC for 3 hours and then at 95oC for 10 minutes to denature the 
proteinase K and stop the reaction. 
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2.3.6 Entire mitochondrial DNA genome amplification 
The entire mitochondrial genome was sequenced using the DNA extracted from single 
cell lysates, as a DNA template.  The first round of the PCR reaction amplified the 
entire mitochondrial genome by separating it into 9 distinct fragments of overlapping 
primer pairs (see chapter 2.3.7 for primer positions and sequences) to obtain ~ 2KB 
products. All PCR reactions were performed using a mastermix containing 1 x PCR 
buffer (10mM Tris-HCl pH 8.3, 1.5 mM MgCl2, 50 mM KCl, 0.001% wt/vol gelatine), 
0.2 mM dNTPs, 0.6 µM primers, 1 U AmpliTaq Gold® DNA Polymerase and 1 µl 
single cell lysate.  The PCR cycle programme is shown in Table 2.5. 
 
Table 2.5. Cycling programme for 1st round PCR. 
Cycles Procedure Temperature Time 
1 Initial Denaturation 95oC 10 minutes 
38 Denaturation 
Primer annealing 
Extension 
94oC 
58oC 
72oC 
45 seconds 
45 seconds 
2 minutes 
1 Final Extension 72oC 8 minutes 
 
        The 9 fragments (~ 2KB) amplified in the first round PCR serve as templates 
for the second round PCR reactions to amplify the mitochondrial genome using a series 
of 36, M13 tagged (Forward - 5’-TGTAAAACGACGGCCAGT-3’, Reverse - 5’-
CAGGAAACAGCTATGACC) overlapping oligonucleotide primer pairs (see chapter 
2.3.7 for primer positions and sequences). This allows direct sequencing of the PCR 
products using a universal M13 primer. All PCR reactions were performed using 1 x 
PCR buffer (10 mM Tris-HCl pH 8.3, 1.5 mM MgCl2, 50 mM KCl, 0.001% wt/vol 
gelatine), 0.2 mM dNTPs, 0.6 µM primers and 1 U AmpliTaq Gold® DNA Polymerase. 
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1 µl of each primary PCR product was used as DNA template. The PCR cycle 
programme used is shown in Table 2.6.  
 
Table 2.6. Cycling programme for 2nd round PCR. 
Cycles Procedure Temperature Time 
1 Initial Denaturation 95oC 10 minutes 
30 Denaturation 
Primer annealing 
Extension 
94oC 
58oC 
72oC 
45 seconds 
45 seconds 
1 minute 
1 Final Extension 72oC 8 minutes 
 
2.3.7 Primer sequences for mitochondrial DNA sequencing 
2.3.7.1 First round primers 
First Round Primers 
Primers Primer Position Size (incl. primer) 
 Forward Reverse  
A 627-646 3087-3068 2460 
B 2395-2415 4653-4633 2258 
C 4489-4508 6468-6450 1979 
D 6113-6133 8437-8417 2324 
E 8128-8147 10516-10487 2388 
F 9821-9841 12101-12080 2280 
G 11866-11887 13924-13904 2038 
H 13721-13742 15997-15978 2276 
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I 15659-15680 868-847 1778 
 
First Round Primers 
Primer Sequence 
A Forward 
A Reverse 
GCTCACATCACCCCATAAAC 
GATTACTCCGGTCTGAACTC 
B Forward 
B Reverse 
ACCAACAAGTCATTATTACCC 
TGAGGAAATACTTGATGGCAG 
C Forward 
C Reverse 
CCGTCATCTACTCTACCATC 
GGACGGATCAGACGAAGAG 
D Forward 
D Reverse 
AATACCCATCATAATCGGAGG 
GGTGATGAGGAATAGTGTAAG 
E Forward 
E Reverse 
AACCACTTTCACCGCTACAC 
AGTGAGATGGTAAATGCTAG 
F Forward 
F Reverse 
ACTTCACGTCATTATTGGCTC 
ATAGGAGGAGAATGGGGGATAG 
G Forward 
G Reverse 
ACCCCCCACTATTAACCTACTG 
GGTAGAATCCGAGTATGTTGG 
H Forward 
H Reverse 
TATTCGCAGGATTTCTCATTAC 
AGCTTTGGGTGCTAATGGTG 
I Forward 
I Reverse 
CCCATCCTCCATATATCCAAAC 
GGTTAGTATAGCTTAGTTAAAC 
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2.3.7.2 Second round primers 
Second Round Primers 
Primers Primer Position Size (incl. primer) 
1 721-740 1268-1248 548 
2 1157-1177 1709-1689 553 
3 1650-1671 2193-2175 544 
4 2091-2111 2644-2625 536 
5 2549-2569 3087-3068 539 
6 3017-3036 3374- 3356 558 
7 3533-3351 4057-4037 558 
8 4005-4025 4577-4556 573 
9 4518-4537 5003-4983 486 
10 4950-4969 5481-5462 532 
11 5367-5386 5924-5906 558 
12 5875-5895 6430-6410 556 
13 6378-6398 6944-6924 567 
14 6863-6882 7396-7376 534 
15 7272-7293 7791-7773 520 
16 7744-7763 8301-8283 558 
17 8196-8215 8740-8720 545 
18 8656-8676 9201-9183 546 
19 9127-9146 9661-9641 535 
20 9607-9627 10147-10128 541 
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Second Round Primers 
21 10085-10104 10649-10629 565 
22 10534-10553 11109-11089 576 
23 11054-11074 11605-11586 552 
24 11541-11561 12054-12034 514 
25 12001-12019 12545-12527 545 
26 12498-12517 13009-12991 538 
27 12940-12959 13453-13435 514 
28 13365-13383 13859-13839 495 
29 13790-13809 14374-14356 585 
30 14331-14350 14857-14838 527 
31 14797-14815 15368-15349 572 
32 15316-15334 15896-15877 581 
D1 15758-15777 16294-16274 537 
D2 16223-16244 129-110 476 
D3 15-34 389-370 375 
D4 323-343 771-752 449 
 
Second Round Primers 
Primer Sequence 
1 Forward 
1 Reverse 
TGTAAAACGACGGCCAGTTCACCCTCTAAATCACCAG 
CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG 
2 Forward TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC 
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Second Round Primers 
2 Reverse CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG 
3 Forward 
3 Reverse 
TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG 
TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG 
4 Forward 
4 Reverse 
TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC 
CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG 
5 Forward 
5 Reverse 
TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC 
CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC 
6 Forward 
6 Reverse 
TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG 
CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG 
7 Forward 
7 Reverse 
TGTAAAACGACGGCCAGTCCTTAGCTCTCACCATCGC 
CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC 
8 Forward 
8 Reverse 
TGTAAAACGACGGCCAGTAATAAACACCCTCACCACTAC 
CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG 
9 Forward 
9 Reverse 
TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG 
CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG 
10 Forward 
10 Reverse 
TGTAAAACGACGGCCAGTTCCATCATAGCAGGCAGTTG 
CAGGAAACAGCTATGACCTGTAGGAGTAGCGTGGTAAGG 
11 Forward 
11 Reverse 
TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC 
CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAAC 
12 Forward 
12 Reverse 
TGTAAAACGACGGCCAGTCACTCAGCCATTTTACCTCAC 
CAGGAAACAGCTATGACCATGGCAGGGGGTTTTATATTG 
13 Forward 
13 Reverse 
TGTAAAACGACGGCCAGTTTAGGGGCCATCAATTTCATC 
CAGGAAACAGCTATGACCAAGAAAGATGAATCCTAGGGC 
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Second Round Primers 
14 Forward 
14 Reverse 
TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC 
CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG 
15 Forward 
15 Reverse 
TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG 
CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG 
16 Forward 
16 Reverse 
TGTAAAACGACGGCCAGTTAACATCTCAGACGCTCAGG 
CAGGAAACAGCTATGACCTACAGTGGGCTCTAGAGGG 
17 Forward 
17 Reverse 
TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC 
CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC 
18 Forward 
18 Reverse 
TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC 
CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG 
   19 
Forward 
19 Reverse 
TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC 
CAGGAAACAGCTATGACCATTAGACTATGGTGAGCTCAG 
20 Forward 
20 Reverse 
TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG 
CAGGAAACAGCTATGACCTAGCCGTTGAGTTGTGGTAG 
21 Forward 
21 Reverse 
TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC 
CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG 
22 Forward 
22 Reverse 
TGTAAAACGACGGCCAGTATCGCTCACACCTCATATCC 
CAGGAAACAGCTATGACCATGATTAGTTCTGTGGCTGTG 
23 Forward 
23 Reverse 
TGTAAAACGACGGCCAGTCTAATCTCCCTACAAATCTCC 
CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC 
24 Forward 
24 Reverse 
TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG 
CAGGAAACAGCTATGACCCGTGTGAATGAGGGTTTTATG 
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Second Round Primers 
25 Forward 
25 Reverse 
TGTAAAACGACGGCCAGTACAATGGGGCTCACTCACC 
CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG 
26 Forward 
26 Reverse 
TGTAAAACGACGGCCAGTCATGTGCCTAGACCAAGAAG 
CAGGAAACAGCTATGACCCTGATTTGCCTGCTGCTGC 
27 Forward 
27 Reverse 
TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC 
CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG 
28 Forward 
28 Reverse 
TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC 
CAGGAAACAGCTATGACCGTTAGGTAGTTGAGGTCTAGG 
29 Forward 
29 Reverse 
TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC 
CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG 
30 Forward 
30 Reverse 
TGTAAAACGACGGCCAGTCAACCACCACCCCATCATAC 
CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC 
31 Forward 
31 Reverse 
TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC 
CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG 
32 Forward 
32 Reverse 
TGTAAAACGACGGCCAGTAGCCCTAGCAACACTCCAC 
CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG 
D1 Forward 
D1 Reverse 
TGTAAAACGACGGCCAGTATCGGAGGACAACCAGTAAG 
CAGGAAACAGCTATGACCGTGGGTAGGTTTGTTGGTATC 
D2 Forward 
D2 Reverse 
TGTAAAACGACGGCCAGTCTCAACTATCACACATCAACTG 
CAGGAAACAGCTATGACCAGATACTGCGACATAGGGTG 
D3 Forward 
D3 Reverse 
TGTAAAACGACGGCCAGTCACCCTATTAACCACTCACG 
CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG 
D4 Forward TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC 
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Second Round Primers 
D4 Reverse CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG 
 
2.3.8 Agarose gel electrophoresis and DNA quantification 
5 µl of second round PCR product was mixed with 2 µl of loading dye (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol). This was loaded 
onto a 1.5% (w/v) agarose gel, containing ethidium bromide, and electrophoresed at 100 
volts for 45 minutes in 1x TAE (0.8 mM Tris acetate, 0.02 mM EDTA, 0.4µg/ml 
ethidium bromide) with hyperladder IV. The PCR amplified DNA fragments were 
visualised on an AlphaImager 2200 and an ultraviolet digital image of the gel obtained.  
 
2.3.9 ExoSAP purification of PCR products 
It is necessary to remove residual single-stranded DNA and excess dNTPs using 
ExoSAP-IT (USB) on ice (5 µl PCR product, 2 µl ExoSAP-IT) because they interfere 
with the cycle sequencing reaction. Two hydrolytic enzymes comprise ExoSAP-IT: 
exonuclease I and shrimp alkaline phosphatase. Exonuclease I degrades residual single-
stranded DNA. The shrimp alkaline phosphatase hydrolyzes remaining dNTPs. The 
thermocycler programme used is shown in Table 2.7. 
 
Table 2.7. Cycling programme for ExoSAP extraction of excess dNTPs and 
single stranded DNA. 
Cycles Procedure Temperature Time 
1 Ambient temperature 37oC 15 minutes 
1 Denaturation 80oC 15 minutes 
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2.3.10 Cycle sequencing and DNA precipitation 
All the 36 PCR products were sequenced using the universal primer M13 to help 
incorporate BigDye® Version 3.1 terminator during cycle sequencing chemistries. The 
PCR programme used is shown in Table 2.8. 
 
Table 2.8. Cycling programme for cycle sequencing reaction. 
Cycles Procedure Temperature Time 
1 Initial Denaturation 96oC 1 minute 
25 Denaturation 
Primer annealing 
Extension 
96oC 
50oC 
60oC 
20 seconds 
20 seconds 
4 minutes 
 
    The DNA was purified using the DyeEx 2.0 spin kit and the pellet then washed in 
70% (v/v) ethanol, and air-dried.  The pellet was then resuspended in 10 µl of HiDi® 
and an ABI prism 3100 Genetic Analyzer was used to analyse the sequence for direct 
comparison with the revised Cambridge reference sequence (rCRS), using 4 Peaks 
software. 
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Chapter 3: Tracing Bone Marrow-Derived Myofibroblasts in 
an Experimental Chronic Pancreatitis Mouse Model 
3.1 Introduction 
3.1.1 Background 
It has been thought that BM cells have the ability to generate a range of cell types, such 
as cardiomyocytes (Orlic et al., 2001), and hepatocytes (Alison et al., 2000) after organ 
damage. However, the controversy remains because many of the claims for BMDC 
plasticity have simply been difficult to produce by others. Despite this, there is an 
increasing body of evidence that cells from BM do contribute to the process of fibrosis 
via transdifferentiation into circulating fibrocytes and myofibroblasts in many organs, 
including lung, liver, kidney, intestine and tumours (Lin et al., 2008).  
    In the pancreas, the myofibroblasts are considered to originate mainly from PaSCs, 
and have been demonstrated to play an important role in the pathophysiology of major 
disorders of the pancreas, including chronic pancreatitis and cancer (Omary et al., 
2007). Several early studies have shown that the involvement of myofibroblasts in the 
regulation of each pathological stage of development of fibrogenesis occurs through 
their production of chemokines, ECM-like molecules such as type I, III, IV collagen and 
fibronectin, and proteolytic enzymes such as MMPs (Bachem et al., 2005; Haber et al., 
1999; Inatomi et al., 2007; Phillips et al., 2003; Shimada et al., 2002). It has been 
thought that these activated myofibroblasts are mainly derived from quiescent PaSCs. 
However, whether BM cells can contribute to these activated PaSCs and/or 
myofibroblasts is not clear.  
    At the beginning of my PhD, research addressing the contribution of BMDCs in 
the pancreas was scarce. Most of the research was focused on BMDCs to islet cells, but 
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the results were inconsistent. In the pancreas, our laboratory demonstrated that BMDCs 
could contribute to the fibrotic area in the tumour microenvironment in a mouse model 
of insulinoma (Direkze et al., 2004). However, the research in tracing BMDC lineages 
in chronic pancreatitis had not been published at that time. In order to trace BMDCs in 
chronic pancreatitis, BMDCs from male donor mice were transplanted into female 
recipient mice. After 6 weeks to allow for reconstruction of the haematopoietic system, 
these female mice then received repeated cerulein adminstrations in order to cause 
chronic pancreatitis and fibrosis. The pancreas was harvested, and then the BMDCs 
were traced by ISH for Y chromosome detection.   
    Cerulein is a cholecystokinin analogue, and it initiates an acute pancreatitis through 
premature intracellular activation of zymogens in the acinar cells. This leads to the 
activation of a cascade of digestive zymogens, which finally results in acinar cell 
necrosis and mild pancreatic oedema, and this is followed by an inflammatory response. 
The cerulein-induced acute pancreatitis model is one of the most well-studied animal 
models for this disease (Niederau et al., 1985; Wildi et al., 2007). This well-established 
method involves giving six to seven intraperitoneal injections of cerulein (50 µg/kg 
body weight) at hourly intervals (Jurkowska et al., 1992a; Jurkowska et al., 1992b; 
Konturek et al., 1997). It normally causes a mild, necrotising pancreatitis in mice, which 
is self-limiting and highly reproducible. It has been demonstrated that chronic 
pancreatitis and fibrosis can be achieved by inducing this cerulein-induced acute 
pancreatitis either three times a week for 3 consecutive weeks (Nagashio et al., 2004) or 
twice a week for 10 consecutive weeks (Neuschwander-Tetri et al., 2000). In this 
model, the pancreas is observed to progressively accumulate ECM surrounding acinar 
units and in the interlobular spaces. Atrophy and transdifferentiation of acinar units to 
duct-like tubular complexes occurs, as well as the dilatation of intraacinar lumina. 
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Furthermore, activated PaSCs are also seen in and around areas of fibrosis 
(Neuschwander-Tetri et al., 2000).  
    According to the above data, a chronic pancreatitis experimental model created by 
inducing acute pancreatitis by six intraperitoneal injections of cerulein (50 µg/kg body 
weight) at hourly intervals, twice a week for 6 to 10 consecutive weeks, was proposed 
to the HO for obtaining an animal Project licence. However, for some reason, I was only 
allowed to inject cerulein to mice once a day, three days a week for up to 10 weeks. 
Because of this HO-advised change, we had to evaluate whether this permissable 
protocol could actually cause fibrosis in the pancreas.  
    During the period of the experiment, observations on the role of BMDCs in 
chronic pancreatitis were published by another group (Marrache et al., 2008). In their 
pancreatitis model, cerulein (50 µg/kg) was administrated intraperitoneally once an hour 
for seven consecutive hours, twice a week for 10 weeks, and once a week for 35 
additional weeks. Mice were sacrificed at baseline (4 weeks after BM transplantation), 
and 6, 20, 30 and 45 weeks after the beginning of cerulein treatment. The results 
showed that BMDCs did engraft in the pancreas and most of the BMDCs were desmin 
positive and contributed to approximately 5% of the PaSC population at the different 
time points. Furthermore, PaSCs derived from BM could be activated, as demonstrated 
by α-SMA expression, suggesting a role in tissue repair. BMDCs could also be found in 
pancreatic ducts, based on dolichos biflorus agglutinin and CK19 staining, but at a 
much lower frequency, 0.62% and 0.11% respectively. Finally, they did not observe any 
BMDCs expressing acinar (amylase), endocrine (chromogranin A) or vascular (CD31) 
markers. 
    Although this research has demonstrated the contribution of BMDCs, particularly 
the BM-derived PaSCs in chronic pancreatitis, a few questions still remain. First, the 
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fibrotic response in their model was quite severe because of the high frequency (seven 
times a day, two days a week for the first 10 weeks and one day a week for another 35 
weeks) and long duration (from 6 weeks up to 45 week) of cerulein administration. The 
contribution of BMDCs to the mild fibrotic response was not be demonstrated. 
Furthermore, they have not shown that these BMDCs actually functionally contribute to 
ECM deposition in chronic pancreatitis.  
    Because only one cerulein injection per day was allowed in our group, we had the 
chance to study mild chronic pancreatitis. Furthermore, we can test whether these 
BMDCs can functionally contribute to the ECM deposition in the pancreas by 
transplanting BM from Col1α1r/r mice. The Col1α1r/r transgenic mice have a mutation 
that encodes amino acid substitutions that prevent collagenase cleavage in the alpha1 (I) 
chain of type 1 collagen (Issa et al., 2003). If BMDCs do contribute to ECM deposition 
in chronic pancreatitis, then the amount of Col1 deposition should increase in mice 
receiving BM from Col1α1r/r transgenic mice because no collagen from BMDCs will be 
degraded. 
 
3.1.2 Hypothesis 
We hypothesize that BMDCs can contribute to the pancreatic myofibroblast population 
in mild chronic pancreatitis. Furthermore, these BMDCs may functionally contribute to 
pancreatic fibrosis. 
 
3.1.3 Aims of this study 
First, my aim is to confirm that mild chronic pancreatitis in the mouse can be produced 
by the protocol of low dose cerulein. Secondly, the contribution of BMDCs, specifically 
 157 
to pancreatic myofibroblasts, in a mouse model of mild chronic pancreatitis will be 
assessed. Finally, the functional role of BMDCs will be evaluated by transplantation of 
BM from Col1α1r/r transgenic mice into WT mice. 
 
3.2 Study Design  
3.2.1 Developing the mild chronic pancreatitis mouse model 
The first step was to test whether the low dose cerulein schedule can cause mild 
pancreatic fibrosis in sex-mismatched BM transplanted chimaeric mice. BM from WT 
male mice was transplanted in to 6 - 8 weeks old C57/BL6 WT female mice after lethal 
irradiation. Six weeks after the BM transplant, the chimaeric mice received an 
intraperitoneal injection of 50 µg/kg cerulein (Sigma-Aldrich, UK) twice a week for up 
to 10 weeks. Control mice received comparable injections of 0.9% sodium chloride 
(saline). Groups of mice that had received a BM transplant from C57/BL6 mice were 
killed at 6 and 10 weeks after the onset of cerulein treatment, always at 48 hours after 
the last injection (cerulein, n=4; control, n=4 at each time point) (Figure 3.1). 
 
 
Figure 3.1. The study design for developing the cerulein-induced mild chronic 
pancreatitis mouse model.  
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3.2.2 Determining the functional role of BM-derived myofibroblasts  
To determine the functional role of BM-derived myofibroblasts, 6 - 8 week old 
C57/BL6 WT female mice received a lethal dose of irradiation and were rescued with 
BM from either WT male mice or Col1α1r/r male mice. Six weeks after the BM 
transplant, mice received an intraperitoneal injection of 50 µg/kg cerulein twice a week 
for up to 10 weeks. Control mice received comparable injections of 0.9% sodium 
chloride (saline). Groups of mice that had received BM from WT or Col1α1r/r mice 
were killed after 10 weeks of injections of cerulein or saline (WT, n=4; Col1α1r/r, n=4; 
control, n=3) (Figure 3.2). 
 
 
Figure 3.2. The study design for detecting BM-derived myofibroblasts and 
determining the functional role of BMDCs in the cerulein-induced mild chronic 
pancreatitis mouse model.  
 
3.3 Results 
3.3.1 Development of mild chronic pancreatitis  
In the low dose cerulein chronic pancreatitis model, a loss of normal weight gain was 
observed in mice receiving cerulein during the 10 weeks of treatment (Figure 3.3).  
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    Histologically, the morphology of the pancreas was normal in the saline-treated 
mice (Figure 3.4A). On the other hand, in the cerulein-treated mice, characteristic 
pathological features of chronic pancreatitis including atrophy of acinar cells, 
lymphocytic infiltration, and mild fibrotic change were observed (Figure 3.4A-F). The 
histological scoring of mice receiving 10 weeks cerulein was performed and a statistical 
significant difference was observed between the cerulein treated mice and the control 
mice (control 0 vs cerulein 4.2 ± 0.84, p < 0.05) (Figure 3.5). Irradiation, applied in 
order to facilitate the BM transplant, did not cause chronic pancreatitis as determined by 
morphology and Sirius red staining. 
    Pancreatic myofibroblasts were detected by expression of α-SMA and their 
location. They were observed around acinar cells and blood vessels (Figure 3.4 G-J). 
The number of myofibroblasts was significantly increased in the cerulein-treated mice 
compared to the control mice (0.02 ± 0.01 vs 2.55 ± 1.58/50 acinar cells, p< 0.05), 
suggesting that myofibroblasts were activated as part of the inflammatory reaction. All 
vascular structures expressing α-SMA were excluded from the quantitative analysis.  
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Figure 3.3. Changes in body weight of BM transplanted mice. Values represent 
ratio of weekly body weight to initial body weight and are mean ± standard error 
of the mean (SEM) (n=4 mice per group). Asterisks indicate a significant 
difference between the two groups, p < 0.05. 
 
 
 
Figure 3.4. Histology of the pancreas in each experimental group. H&E staining 
shows the development of pancreatic damage (A-C). Collagen staining (Sirius 
Red) demonstrates faint collagen deposition in the pancreas over the 10-week 
period (D-F). Immunostaining for α-SMA shows that activated myofibroblasts 
surrounding acinar cells appear predominantly in the area of inflammation and 
fibrosis (G-J). 
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Figure 3.5. Chronic pancreatitis histological scores for mice receiving 10 weeks 
cerulein or saline administration. Values are mean ± SEM (n=4 mice per group). 
*p < 0.05. 
 
3.3.2 Contribution of BM-derived myofibroblasts 
To determine the contribution of BMDCs to the pancreas, sex-mismatched BM 
transplantation was performed. Donor-derived cells were tracked by ISH for Y 
chromosome detection. In the pancreas of the female mice that received a male BM 
transplant followed by cerulein injections for 10 weeks, cells that were double positive 
for α-SMA and Y chromosome were observed, whereas they were not seen in the 
control mice (Figure 3.6). The percentage of α-SMA/Y chromosome positive cells 
amongst the total α-SMA positive cells was 7.22 ± 3.63% (n=4).  
    To support these in vivo observations of BM-derived myofibroblasts, pancreatic 
myofibroblasts were isolated from the pancreas, and then ISH for Y chromosome 
detection was performed on isolated cells. Some myofibroblasts isolated from the 
pancreas of cerulein treated mice were Y chromosome positive, whereas the Y 
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chromosome was not seen in myofibroblasts isolated from the pancreas of the saline 
injected mice (Figure 3.7). 
 
 
Figure 3.6. BM-derived pancreatic myofibroblasts in the female pancreas of 
mice that received whole BM transplants from male donors followed by cerulein 
injections for 10 weeks. The Y chromosome was detected as a green dot in the 
cell nucleus. Red staining of the cytoplasm reflects α-SMA-positive cells 
(arrowheads). BM-derived myofibroblasts (arrow) were not observed in the 
control mice (A) but were seen in areas of inflammation and fibrosis (B-D). 
Abbreviations: V, vessel; AC, acinar cell. 
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Figure 3.7. Pancreatic myofibroblasts isolated from the pancreas of cerulein 
treated female mice (A, B and D) or normal male mice (C). (A) Phase-contrast 
light microscopic observation of isolated pancreatic myofibroblasts. (B) 
Immunostaining for α-SMA on these cells. (C) ISH for the Y chromosome on 
isolated myofibroblasts from male mice; all of the myofibroblasts contain the Y 
chromosome. (D) In the female mice receiving a BM transplant from male mice 
and having cerulein-treatment for 10 weeks, some myofibroblasts have the Y 
chromosome (arrows). 
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3.3.3 Effects of a different phenotype of BM on pancreatic fibrogenesis  
To test the hypothesis that BMDCs are not just bystanders, but they can actually 
contribute to the fibrosis during pancreatic injury, the effect of BM from Col1α1r/r male 
mice was assessed. The results showed that the pancreata of mice that were recipients of 
Col1α1r/r BM had extensive pericellular fibrosis, whereas the pancreata of mice that 
were recipients of WT BM  developed more restricted linear collagen deposition 
(Figure 3.8). BM-derived myofibroblasts were observed by ISH for the Y chromosome 
in the pancreata of female mice receiving Col1α1r/r male BM (Figure 3.9). The 
measurement of fibrotic areas, based on Sirius red staining, illustrated that recipients of 
Col1α1r/r male BM had more fibrosis (p< 0.05, Table 3.1). 
    Quantitative RT-PCR analysis of mRNA expression of Col1α1, a precursor of type 
I collagen, known to be a major component of ECM in pancreatic fibrosis, was also in 
line with the histological observations. The levels of Col1α1 mRNA expression were 
approximately 1.5-fold higher in pancreata of the Col1α1r/r BM recipients compared 
with those receiving WT BM (Figure 3.9). The number of myofibroblasts was also 
significantly increased in the pancreata of the Col1α1r/r BM recipients compared with 
those receiving WT BM. The percentage of BM-derived myofibroblasts within the total 
myofibroblast population was relatively higher in the Col1α1r/r BM recipients, however, 
the difference was not significant (Table 3.1). 
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Figure 3.8. Histology of the pancreas from female mice that received BM 
transplants from male WT (A and C) or Col1α1r/r mice (B and D) followed by 
cerulein injections for 10 weeks. H&E staining and Sirius red staining shows 
that more severe fibrosis develops in the mice transplanted with BM from 
Col1α1r/r mice. 
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Figure 3.9. Immunofluorescent staining for α-SMA (red) and ISH for the Y 
chromosome (green) in the pancreas from female mice receiving Col1α1r/r BM. 
BM-derived myofibroblasts (arrows) are observed in these inflamed tissues (A, 
100X; B and C, 400X). 
 
 
Table 3.1. Histological analysis of the pancreas from female mice that had 
received BM from either WT or Col1α1r/r male mice. 
   (A)           (B)               (C) 
BM from WT   BM from WT       BM from Col1α1r/r 
(No injury)    (Cerulein 10w)     (Cerulein 10w) 
 
Sirius Red Staining (%) 
 
 
Number of myofibroblasts 
(/ 50 acinar cells) 
 
Percentage of BM-derived 
myofibroblasts  
 
0.02 ± 0.01        2.94 ± 2.01 *        6.65 ± 3.62 * †  
 
 
2.14 ± 1.72        5.29 ± 2.64 *        8.11 ± 2.62 * †  
 
 
        0         8.64 ± 4.45 *        10.05 ± 5.21 *   
 
 
 
Values are mean ± SEM (n=4 mice per group). *p < 0.05 versus (A); † p < 0.05 
versus (B). 
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Figure 3.10. Real-time PCR analysis of mRNA expression in the pancreas. 
Total RNA was extracted from the pancreas of the mice that have received 
different BM genotypes followed by cerulein injections for 10 weeks. The mRNA 
expression of Col1α1 was measured by quantitative PCR and expression levels 
were normalized to the level of GAPDH. Values are mean ± SEM (n=4). *p < 
0.05. This result reveals that the level of mRNA for Col1α1 is relatively higher in 
the mice transplanted with Col1α1r/r BM. 
 
3.3.4 Proliferation of acinar cells 
To evaluate the influence of Col1α1 r/r BM on the proliferation of acinar cells after 
injury, we assessed by IHC the expression of Ki67. After 10 weeks of cerulein 
administration, the number of Ki67 positive acinar nuclei was increased compared with 
the saline-treated mice (control; 1.90% ± 1.58 vs. cerulein; 3.91% ± 1.7, p < 0.05). 
However, there were no significant differences between two groups of mice that 
received BM from either Col1α1r/r or WT mice followed by cerulein injections (WT; 
3.91% ± 1.7 vs. Col1α1r/r; 4.09% ± 1.7, p > 0.05) (Figure 3.11).  
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Figure 3.11. Immunostaining for Ki67 in normal pancreas (A) and in the 10w 
cerulein-treated pancreas (B). (C) The percentage of Ki67 positive acinar cells 
in the mice that received BM from either WT or Col1α1r/r mice followed by 10 
weeks cerulein treatment. Values are mean ± SEM (n=4), n.s: no significance. 
 
3.4 Discussion 
Using sex-mismatched BM transplantation from male mice to female mice, the 
contribution of BMDCs to the population of pancreatic myofibroblasts in mild chronic 
pancreatitis was examined. We show here that BMDCs contribute to the population of 
α-SMA positive myofibroblasts in the pancreas after low dose cerulein treatment. 
BMDCs accounted for about 8% of α-SMA (myofibroblasts) positive cells in the 
pancreata of mice in this mild chronic pancreatitis model. This was confirmed by an ex 
vitro study that also demonstrated that some myofibroblasts isolated from the pancreas 
were BM-derived. Furthermore, our data suggested that the BM-derived myofibroblasts 
were actually functional, contributing to pancreatic fibrosis. The pancreata from mice 
receiving Col1α1 r/r BM had more collagen deposition and an increased number of 
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myofibroblasts, compared to the recipients of WT BM. Furthermore, the results of 
quantitative real-time PCR showed that the levels of Col1α1 mRNA expression in the 
pancreas from the recipients of Col1α1 r/r BM were approximately 1.5-fold higher that 
those in the recipients of WT BM. As far as we know, this is the first report that BM-
derived myofibroblasts can functionally contribute to pancreatic fibrosis. 
    The original idea of the experiment was to create a severe pancreatic fibrosis 
model and examine the role of BMDCs in this model. However, because of the legal 
restriction to the cerulein dosage, it was unlikely to produce severe pancreatic fibrosis. 
It has been reported that cerulein induced acute pancreatitis is self-limiting and animals 
spontaneously recover (Lugea et al., 2006; Willemer et al., 1992). Furthermore, the 
cerulein dose allowed was very low, being only one-third to one-fifth of the total dose 
of cerulein that had been used in earlier studies (Kunzli et al., 2008; Nagashio et al., 
2004). It was therefore difficult to predict whether this dose of cerulein can actually 
cause chronic pancreatitis with fibrosis. However, according to our histological and 
collagen staining data, I demonstrated that mild chronic pancreatitis with focal fibrosis 
could be created by the repetition of a single dose of cerulein (50 µg/kg) given by 
intraperitoneal injection twice a week for 10 consecutive weeks. I also observed 
activated myofibroblasts within these inflamed and fibrotic tissues. Our data showed 
that among these activated myofibroblasts around 8% were derived from BM. The 
percentage of BM-derived myofibroblasts was similar to the previous report by 
Marrache et al. (Marrache et al., 2008) demonstrating that BM contributed to about 6% 
of α-SMA positive cells in C57/BL6 mice treated with cerulein for 45 weeks, while a 
recent report has claimed that BM-derived myofibroblasts account for about 20% of the 
total population of activated myofibroblasts in C57/BL6 mice treated with a different 
cerulein adminstration protocol for 6 weeks (Watanabe et al., 2009). The reason for the 
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discrepancy is unclear, but it might reflect different experimental protocols, including 
BM transplantation, cerulein doses and duration for treatment (Table 3.2). Different 
cerulein doses produce varying degrees of pancreatic inflammation and fibrosis, and the 
different protocols of BM transplantation suggests dissimilar degrees of radiation injury 
to the pancreas and different levels of reconstruction of the haematopoietic system.  
Despite all of these differences, all data suggest that BM contributes in part to the 
activated myofibroblast population in the process of chronic pancreatitis and fibrosis. 
 
Table 3.2 Different protocols of sex-mismatched BM transplantation and 
cerulein-induced chronic pancreatitis in mouse models. 
 My protocol 
 
Marrache et al. 2008 Watanabe et al. 2009 
BM transplantation 
 
   
Irradiation dose 
 
10 Gy 12 Gy 7 Gy 
The number of 
transplanted BM cells 
 
2 X 106 5 X 106 1 X 107 
Gap between irradiation 
and cerulein injection 
 
6 weeks 4 weeks 8 weeks 
Cerulein treatment 
 
   
Dose (50 µg/kg) Once a day  
 
Seven times a day 
 
Six times a day 
Frequency &  
Duration 
Twice a week for 
10 weeks 
 
Twice a week for 10 
weeks, then once a 
week for 35 weeks 
Three times a week 
for 6 weeks 
 
 
    It has been thought that the engraftment of BM-derived myofibroblasts is likely to 
vary with different tissues and states of injury (Lin et al., 2008). In a model of liver 
injury, up to 70% of myofibroblasts originated from the BM, and the proportion was 
constant throughout the developing cirrhosis (Russo et al., 2006). In other organs such 
as colon, lung, skin and kidney, the percentage of BM-derived myofibroblasts also 
increases in relation to inflammation or fibrosis, ranging from 30-45%, 17-41%, 0.07-
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4% and 0-30%, respectively (Bamba et al., 2006; Broekema et al., 2007; Direkze et al., 
2003; Li et al., 2007b). In this study, because of the low dose of cerulein, the pancreata 
from mice receiving 6 weeks cerulein injections showed little inflammation and fibrosis, 
and we were not able to measure the BM-derived myofibroblast population at different 
time points. However, it has been reported that the percentage of BM-derived 
myofibroblasts does not change significantly at different time points during cerulein 
treatment (Marrache et al., 2008). Furthermore, the percentage was reported to decrease 
from approximately 20% to 15% at 3 weeks and 12% at 6 weeks after cessation of 
cerulein treatment (Watanabe et al., 2009). These data may suggest that BM-derived 
myofibroblasts are a transient population. Apart from BM cells, myofibroblasts have 
been thought to be transdifferentiated from various cells including locally residing 
mesenchymal cells, endothelium, epithelium and circulating fibrocytes (Hinz et al., 
2007). In the pancreas, PaSCs are considered to be the major source of activated 
myofibroblasts during the inflammatory and fibrotic process (Omary et al., 2007). 
Although many different markers such as vimentin, desmin, GFAP and nestin are all 
expressed in PaSCs, desmin is considered to be the most useful marker (Omary et al., 
2007). By using desmin immunostaining, a recent report suggested that about 8.7% of 
quiescent PaSCs are derived from BM (Watanabe et al., 2009).  In another study, it 
was claimed that BM-derived desmin-positive PaSCs were constantly maintained at 
around 5% of the total desmin-positive cell population during the course of chronic 
pancreatic fibrosis (Marrache et al., 2008). Therefore it would seem reasonable to 
monitor desmin positive cells in our experiment. However, we did not use this marker 
for two reasons, and instead we focused on the α-SMA positive (myofibroblasts) 
population. First, it has been suggested that around 20 - 40% of activated PaSCs, i.e. α-
SMA positive cells, also express desmin (Apte et al., 1998; Bachem et al., 1998). Thus, 
 172 
if desmin was used as a marker for BM-derived PaSCs in our study, we would be 
unsure as to whether these desmin positive BMDCs represent quiescent BM-derived 
PaSCs, activated BM-derived PaSCs, or myofibroblasts directly derived from the BM. 
Secondly, the activated myofibroblast is the cell that produces ECM and contributes to 
pancreatic fibrosis. Because of above reasons, we concentrated directly on the role of 
BM-derived myofibroblasts.  
    Although a contribution of BM to myofibroblasts has been shown in various 
organs including pancreas, analysis of the individual functional role of BM-derived 
myofibroblasts, separate from resident myofibroblasts, which is a significant issue, has 
not been fully investigated. A functional contribution of BMDCs to fibrosis has been 
demonstrated by the observation that genetically modified BM cells can alter the 
severity of chronic inflammation in the intestine, fibrosis in the liver, and 
neovascularisation in tumours (Bamba et al., 2006; Nolan et al., 2007; Russo et al., 
2006). Our data showed that mice receiving BM from Col1α1r/r mice developed 
extensive pericellular fibrosis, suggesting that BMDCs could behave functionally in 
chronic pancreatitis. Furthermore, there was increased collagen deposition and Col1α1 
mRNA expression, as measured by quantitative RT-PCR. The excessive collagen 
deposition in the recipients of Col1α1 r/r BM is most likely because these Col1α1 r/r 
BMDCs can functionally secrete mutant Col1, resistant to collagen degradation by 
collagenases. The percentage of BM-derived myofibroblasts was also increased in the 
recipients of Col1α1 r/r BM, but the reason for this is not clear. On the other hand, the 
proliferation of acinar cells was not different between the two BM transplant groups. 
These results might indicate that factors that influence inflammation and regeneration 
such as chemokines and growth factors secreted from BM cells are not different 
between the two sorts of BM cells. 
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    It has been proposed that BM-derived mesenchymal cells play more crucial or 
different roles compared with resident mesenchymal cells. For example, Nolan et al. 
demonstrated that specific ablation of BM-derived endothelial cells can remarkably 
reduce tumour growth despite the fact that the contribution of these cells was only 10-
30%, suggesting a critical role of these cells for tumour neovascularisation (Nolan et al., 
2007). In the kidney, it has also been shown that BM-derived renal myofibroblasts have 
the ability to produce pro-collagen 1 and contribute to ECM deposition (Broekema et 
al., 2007). Furthermore, by inducing liver fibrosis in Col1α1r/r mice, Issa et al. 
demonstrated that the myofibroblasts in Col1α1r/r mice were not only producing Col1 
that was resistant to collagenase degradation, but the cells also became more resistant to 
apoptosis (Issa et al., 2003). Decreased hepatocyte regeneration was also seen in that 
study, which was considered to result from the accumulation of undegraded collagen1. 
Our observations are in line with these observations since collagen deposition was 
increased in recipients of Col1α1r/r BM cells Furthermore, the number of BM-derived 
myofibroblasts was modestly increased in the pancreata of mice transplanted with 
Col1α1r/r BM, which might be due to increased resistance to apoptosis.  
    In conclusion, our results suggest that BM cells can contribute to pancreatic 
myofibroblasts in chronic pancreatitis with mild fibrosis. Moreover, the Col1α1r/r BM 
cells could alter the fibrotic reaction, suggesting a functional role of the BMDCs. 
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Chapter 4: Tracing Bone Marrow-Derived Fibrocytes in an 
Experimental Pancreatitis Mouse Model  
4.1 Introduction 
4.1.1 Background 
The previous work in chapter 3 demonstrated the role of BM-derived myofibroblasts in 
mild chronic pancreatitis. However, it might not be the complete story about the 
contribution of BMDCs to chronic pancreatitis. It has been thought that circulating 
fibrocytes exist and contribute to organ fibrosis. These fibrocytes are defined as 
fibrogenic cells that produce collagen and express leukocyte common antigen (CD45), 
the haematopoietic stem cell marker (CD34), and myeloid antigens (CD11b, CD13) 
(Bellini and Mattoli, 2007). Because of their expression of haematopoietic markers, they 
are widely thought to originate from BM. They constitutively produce ECM and ECM-
modifying enzymes (Abe et al., 2001; Bucala et al., 1994; Chesney et al., 1998), and can 
further differentiate into active myofibroblasts both in vitro and in vivo under 
permissive microenvironmental conditions (Abe et al., 2001; Pilling et al., 2003; Pilling 
et al., 2006; Schmidt et al., 2003). It has been demonstrated that circulating fibrocytes 
participate in many human fibrotic diseases such as hypertrophic scars (Yang et al., 
2005), systemic sclerosis (Postlethwaite et al., 2004), and nephrogenic systemic fibrosis 
(Cowper and Bucala, 2003). They also play a role in pulmonary disease especially that 
characterized by repeated inflammation and repair, like asthma (Schmidt et al., 2003), 
and interstitial pulmonary fibrosis (Mehrad et al., 2007). They have been demonstrated 
to contribute to fibrotic diseases by producing both ECM components and ECM 
degrading enzymes such as matrix metalloproteinase-9 (Chesney et al., 1998; Hartlapp 
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et al., 2001; Pilling et al., 2003), and further differentiating into myofibroblasts (Abe et 
al., 2001; Mori et al., 2005; Pilling et al., 2006; Schmidt et al., 2003). 
    In the pancreas, CD34-positive fibrocyte-like cells have been detected in tissue 
specimens from patients with chronic pancreatitis (Barth et al., 2002; Kuroda et al., 
2004). The accumulation of these cells seems to be related to a parallel increase in the 
number of α-SMA positive myofibroblasts (Barth et al., 2002). It has been hypothesized 
that BM-derived myofibroblasts in different tissues including lung, stomach, 
oesophagus, skin, kidney and adrenal capsule may develop from circulating fibrocytes 
(Direkze et al., 2003; Mori et al., 2005; Schmidt et al., 2003).  However, the 
contribution of these circulating fibrocytes has not been clearly demonstrated in chronic 
pancreatitis. 
    In the previous work, one cerulein injection per day was demonstrated to produce 
mild chronic pancreatitis in mice. However, after further consideration by the HO we 
were given permission to inject cerulein six times a day at hourly intervals. This 
allowed us to produce chronic pancreatitis with adequate fibrosis. Instead of using the 
previous mild chronic pancreatitis model, the protocol of inducing chronic pancreatitis 
with fibrosis was changed to six cerulein injections a day, twice a week for 6 
consecutive weeks. The reason for choosing more frequent injections was because 
chronic pancreatitis/severe inflammation was more likely to recruit this rare fibrocyte 
population.  
 
4.1.2 Hypothesis 
We hypothesize that fibrocytes exist in the PB, and that the numbers of circulating 
fibrocytes change after acute and chronic pancreatitis. Furthermore, fibrocytes are a 
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possible source of BMDCs in the pancreas, and participate in the inflammatory and 
fibrotic process.  
 
4.1.3 Aim of this study 
The first aim was to confirm that circulating fibrocytes are BM-derived. Secondly, I 
wanted to discover the morphology of the isolated fibrocytes from PB. Thirdly, I wished 
to describe the changes in fibrocytes in BM and PB. Finally, I wanted to know whether 
these fibrocytes can engraft the pancreas from the peripheral circulation and contribute 
to pancreatic inflammation and fibrosis, presumably by differentiating into 
myofibroblasts.  
 
4.2 Study Design 
The procedures for animal experiments were performed under British HO procedural 
and ethical guidelines (Fig. 4.1). Six to eight week-old WT C57/BL6 female recipient 
mice (The Charles River Laboratory, Wilimington, Maine, USA) underwent whole 
body lethal gamma irradiation with 10 Gy in a divided dose four hours apart, to ablate 
their BM, followed immediately by tail vein injection of wide type male whole BM (2 × 
106 cells), re-suspended in 0.1ml sterile PBS with 2% FCS. Six weeks after the BM 
transplantation, four mice were given 6 intraperitoneal injections of 50 µg/kg cerulein 
(Sigma-Aldrich, UK) at hourly intervals for 1 day to induce acute pancreatitis. The mice 
in the control group (n=4) of the acute pancreatitis experiment received six 
intraperitoneal injections of vehicle (saline) at hourly intervals for 1 day. BM, PB and 
pancreas were harvested at 24 hours after the first injection. Chronic pancreatitis was 
induced in four mice by the same protocol of cerulein injections being repeated twice a 
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week for 6 consecutive weeks. The mice in the control group (n=4) of chronic 
pancreatitis received the same experimental protocol except cerulein injections were 
replaced by saline. Tissues were harvested at 48 hours after the last injection.  
 
 
Figure 4.1. The study design for detecting fibrocytes in PB, BM and pancreatic 
tissue in the cerulein induced acute pancreatitis and chronic pancreatitis mouse 
model. 
 
4.3 Results 
4.3.1 Development of acute and chronic pancreatitis 
In our model of chronic pancreatitis induced by cerulein, the mice showed loss of the 
normal weight gain observed in the control mice during the 6-week period of treatment 
(Figure 4.2).  
    Histologically, in the saline-treated mice, the morphology of pancreas was normal 
(Figure 4.3, A & D). On the other hand, the morphology of pancreata from the mice 
with one day cerulein treatment showed focal oedema between lobules, an inflammatory 
cell infiltrate in the parenchyma and a few peri-ductal necrotic cells but without 
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collagen deposition, acinar atrophy or structural change, which are the characteristic 
features of acute pancreatitis (Figure 4.3, B & E).  
    Tissue damage with the atrophy of acinar cells, deformed architecture, pseudo-
tubular complex formation, and intra-lobular collagen deposition and severe fibrotic 
change, which are the characteristic features of chronic pancreatitis were found in the 
pancreata of mice receiving six consecutive weeks of cerulein treatment (Figure 4.3, C 
& F). Irradiation, required for the BM transplant, did not cause either acute or chronic 
pancreatitis as determined by morphology and Sirius red staining. 
 
 
 
Figure 4.2. Changes in body weight of BM transplanted mice during the 6-week 
period of cerulein or saline treatment. Values represent the ratio of weekly body 
weight to initial body weight and are the mean ± SEM (n=4 mice per group). * p 
<0.05, † p <0.01 between two groups. 
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Figure 4.3. Histology of the pancreas from saline (control group) or cerulein 
treated female mice that received male BM transplants. H&E staining and 
collagen staining in the pancreas from the control group showed normal 
pancreatic structure and collagen distribution (A & D, 200X). The development 
of acute pancreatic inflammation with normal collagen deposition in the 
pancreas from 1-day cerulein treated mice (B & E, 200X). Large scale collagen 
deposition, inflammation, acinar cell atrophy, and structural changes in the 
pancreas were demonstrated in the mice receiving cerulein over the 6-week 
period (C & F, 200X). 
 
 
4.3.2 Changes in the fibrocyte population in PB and BM 
To analyze the changes in the fibrocyte population in PB and BM, FACS was used for 
measuring the percentage of CD45+Col1+ cells in mice after either 1-day (Figure 4.4) 
or 6-weeks (Figure 4.5) cerulein administration. The percentage of fibrocytes in the PB 
of mice that received cerulein injections for one day was 0.128 ± 0.033%, which was 
lower than the control group that received vehicle injections for one day (0.370 ± 
0.058%, p < 0.05). On the other hand, the percentage of fibrocytes in the BM of mice 
receiving cerulein injections for one day was 0.083 ± 0.017%, which was slightly higher 
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than in the control group (0.056 ± 0.003%). but this difference was not significant. In 
the chronic pancreatitis group, a decline in the fibrocyte population in PB was seen in 
mice that received six weeks of cerulein injections (0.222 ± 0.144%) compared to the 
controls (0.868 ± 0.167%, p < 0.05). Furthermore, a significant reduction in fibrocytes 
in the BM was also found between mice receiving six weeks of cerulein injections 
(0.023 ± 0.009%) and vehicle controls (0.515 ± 0.122%, p < 0.05). 
 
 
 
Figure 4.4. CD45+Col1+ cells as a percentage of nucleated cells after 1-day of 
cerulein injections (black bars) or saline injections (gray bars), acquired by 
FACS in PB and in BM. Results were statistically analyzed by t test (n=4 per 
group). 
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Figure 4.5. CD45+Col1+ cells as a percentage of nucleated cells after 6-weeks 
of cerulein injections (black bars) or saline injections (gray bars), acquired by 
FACS in PB and in BM. Results statistically analyzed by t test (n=4 per group).  
 
4.3.3 The morphology of fibrocytes of BM origin isolated from PB 
To evaluate the morphology of fibrocytes and to find whether these fibrocytes were 
derived from BM, the CD45+Col1+ cells were isolated by FACS, spun down on slides 
and then stained with haematoxylin or subjected to ISH for Y chromosome detection. 
We found the isolated fibrocytes had two distinct morphologies. One showed round 
nuclei with a small rim of blue cytoplasm which was similar to lymphocytes, while the 
other showed segmented nuclei with abundant cytoplasm which was either similar to 
monocytes or to segmented neutrophils (Figure 4.6, A-C). The Y chromosome could be 
detected in these cells, confirming that these fibrocytes were BM-derived (Figure 4.6D). 
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Figure 4.6. The morphology of CD45+Col1+ fibrocytes isolated by FACS from 
PB (A) showed two morphologies (B&C). The Y chromosome was detected in 
most of these cells (D). 
 
4.3.4 The contribution of BM-derived fibrocytes to pancreatitis 
To determine the contribution of the BM-derived fibrocytes in cerulein-induced acute 
and chronic pancreatitis, we performed double IHC staining. In the pancreas of the mice 
that received a BM transplant followed by either cerulein injections for one day or 6 
weeks, CD45+ cells were found only in Col1 stained areas (Figure 4.7, B-D), but were 
not detected in control mice (Figure 4.7A). Furthermore, two different morphologies of 
CD45+ cells were found in the pancreas. Most showed a round shape, a typical shape of 
leukocytes, while a few of them had a spindle-shape, a typical shape of myofibroblasts. 
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For the purpose of quantifying CD45+Col1+ fibrocytes, we detected CD45+α-SMA+ 
cells that were also BM-derived, employing immunofluorescence combined with ISH 
for the Y chromosome. BM-derived CD45+Col1+ cells were detected in the pancreas 
from cerulein-injected mice (Figure 4.8A). We sought to quantify the extent of the 
contribution of fibrocytes to the CD45+ cell population. To do so, we measured the 
fraction of CD45-expressing cells that co-expressed collagen (scanning 10 high power 
magnification fields (400x) per mouse). The percentage of CD45/Col1 positive cells 
amongst the total CD45 positive cell population was 9.47 ± 1.22% in the pancreas from 
mice in the cerulein-induced acute pancreatitis group (one day treatment) and 17.51 ± 
3.31% in the pancreas of mice from the cerulein-induced experimental chronic 
pancreatitis group (6 weeks treatment, n=4, Table 4.1). Furthermore, to test the 
hypothesis that CD45+ cells can further differentiate into myofibroblasts, we examined 
the double CD45/α-SMA positive cells (Figure 4.8B). A few of the CD45+ cells co-
expressed α-SMA in the chronic pancreatitis group (4.51 ± 2.97), while such cells could 
not be detected in the acute pancreatitis group or the control group (n=4, Table 4.1).  
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Figure 4.7. IHC double staining of CD45 (red) and Col1 (brown) of the pancreas 
from female mice that received BM transplants from male WT donor mice 
followed by vehicle injections for 6 weeks (A, 200X), or cerulein injections for 1 
day (B, 200X) or 6 weeks (C, 200X and D, 400X). CD45+ cells were found only 
in the Col1 stained areas after acute pancreatitis and chronic pancreatitis. 
Arrows show spindle-shaped CD45+ cells. Arrowheads show CD45+ cells with 
a round shape typical of leukocytes. 
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Figure 4.8. Immunofluorescence staining combined with ISH for the Y 
chromosome in chronic pancreatitis. (A) Arrow shows BM-derived CD45+Col1+ 
fibrocytes (CD45, red; Col1, yellow; DAPI, blue; 600X). (B) Arrowhead shows 
CD45+α-SMA+ cells (CD45, red; α-SMA, yellow; Col1, blue; 600X).  
 
 
Tables 4.1: The histologic analysis of fibrocytes in acute and chronic 
pancreatitis. 
 
The number of CD45+ cells per 50 acinar cells and the percentage of Col1+ 
cells and α-SMA+ amongst the CD45+ cells are shown as percentages ± SEM 
(n=4 mice).  
 
 
 
 
 Acute pancreatitis Chronic pancreatitis 
CD45+ cells/ 50 acinar cells 0.71 ± 0.16 1.40 ± 0.29 
Col1+cells/ CD45+cells (%) 9.47 ± 1.22 17.51 ± 3.31 
α-SMA+cells/ CD45+cells (%) 0 4.51 ± 2.97 
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4.4 Discussion 
4.4.1. Fibrocytes are a rare population in BM and PB 
The results showed that the collagen-producing CD45+Col1+ fibrocytes can be detected 
by FACS, and comprised a rare population of PB (0.62 ± 0.17%, n=8) and BM (0.29 
±0.14%, n=8) in the normal C57/BL6 WT control mice in our experiment. Fibrocytes 
were initially estimated to comprise 0.1-0.5% of the circulating population of non-
erythrocytic cells. However, this estimate was based on the number of fibrocytes 
isolated from culture of PB mononuclear cells (Bucala et al., 1994; Chesney et al., 
1998). From our data acquired by FACS, fibrocytes made up about 0.62% of the 
nucleated cells in the PB, which was compatible with previous estimatates based on cell 
culture. Further studies have revealed that fibrocytes might actually originate from a 
circulating precursor, a small subpopulation of CD14+ mononuclear cells (Abe et al., 
2001; Pilling et al., 2003), and become CD14-negative collagen-producing fibrocytes 
after culture. This begs the question as to whether collagen-producing fibrocytes do 
exist in the PB and BM. However, collagen-producing cells were isolated from PB and 
BM by using FACS in our experiments because the isolated cells were CD45+Col1+ 
cells. These findings confirmed that collagen-producing cells do exist in the circulating 
blood and BM, although the percentages were very low (0.62% and 0.29%, 
respectively).  
 
4.4.2. The morphology of fibrocytes and BM-derived characteristics 
Previous studies have demonstrated that fibrocytes are BM-derived (Mori et al., 2005), 
although these studies were based on cells isolated from culture. After culturing, these 
cultured fibrocytes were spindle shaped in morphology. The true morphologies of 
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fibrocytes in circulating blood are still unclear. In our study, the BM origin of the 
circulating fibrocytes was established by using ISH for Y chromosome detection. 
Furthermore, because these mice received a BM-transplantation 6 weeks before cerulein 
injection, detecting the Y chromosome in these circulating fibrocytes indicates that the 
turnover time of circulating fibrocytes must be less than 6 weeks, since these cells 
would all be female at the time of transplantation 6 weeks beforehand. Interestingly, 
unlike the spindle shape observed for cultured fibrocytes, two different morphologies of 
circulating fibrocytes were demonstrated. Some cells had round nuclei with a small rim 
of blue cytoplasm which was similar to lymphocytes, while the other cells had 
segmented nuclei with abundant cytoplasm, not unlike monocytes or segmented 
neutrophils. It is still unclear whether these two distinct morphological types of 
fibrocytes function differently. In the previous studies, cultured fibrocytes expressed 
monocyte markers (CD11a, CD11b, CD14, CD32 and CD64), while the B lymphocyte 
marker (CD19) and T lymphocyte markers (CD3, CD4, CD8, CD25 and CD56) were 
never found (Bellini and Mattoli, 2007). The explanation could be that a depletion of 
lymphocytes occurred during the procedure of “purification” of the cultured fibrocytes, 
so that lymphocyte markers could not be found in these cultured fibrocytes. However, in 
our study, a possible subpopulation of lymphocyte-like fibrocytes seems to exist in the 
circulating blood, and these cells warrant further investigation. 
 
4.4.3. Fibrocytes traffick into inflammatory and fibrotic pancreatic tissue 
Our results indicate that circulating fibrocytes can traffick into pancreatic tissues in 
cerulein-induced acute inflammation and fibrosis. It has been demonstrated in a tracking 
experiment in murine models (Abe et al., 2001; Schmidt et al., 2003) that injected 
fibrocytes, not precursor cells, can rapidly migrate into inflamed sites, suggesting that 
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fibrocytes in tissue can come from either precursors cells or circulating collagen-
producing fibrocytes. While three studies (Frid et al., 2006; Haudek et al., 2006; Varcoe 
et al., 2006) suggested that the fibrocytes detected in tissues differentiated from 
circulating precursors at the tissue sites and not beforehand in the PB, in our study, 
collagen-producing CD45+Col1+ fibrocytes were found in the PB. Furthermore, the 
percentage of CD45+Col1+ fibrocytes in PB was decreased after both acute pancreatitis 
and chronic pancreatitis compared to control groups, suggesting these cells were 
trafficking into inflammatory and fibrotic tissues.  
 
4.4.4. Fibrocytes were detected in acute inflammatory and fibrotic pancreatic 
tissues and differentiated into myofibroblasts 
Our data showed that CD45+Col1+ cells were detected in acute pancreatitis and chronic 
pancreatitis, but none were found in the normal pancreas of control groups, suggesting 
they had immigrated into the tissues as part of the inflammatory response. The Y 
chromosome could also be detected in these CD45+Col1+ fibrocytes indicating that 
these cells were BM derived, and none of these BM-derived cells were found in the 
normal pancreas from control mice. Furthermore, these CD45+Col1+ cells were spindle 
shaped and located in the collagen-rich areas indicating they might produce ECM and 
differentiate into myofibroblasts. Some of the CD45+ fibrocytes (~4.5%) co-expressed 
α-SMA in the chronic pancreatitis model, suggesting a contribution to the 
myofibroblast population during chronic pancreatitis. 
    It has been reported by Barth et al. (Barth et al., 2002) that CD34+ fibrocyte-like 
cells can be found in human neoplastic and inflammatory pancreatic lesions. 
Interestingly, these CD34+ cells were also detected in normal pancreas, encircling 
acinar, ductal and vascular structures, and characterized by having long-dendrite-like 
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projections. Furthermore, the number of CD34+ fibrocyte-like cells parallelled the 
increased accumulation of α-SMA myofibroblasts in chronic pancreatitis. However, in 
our study, CD45+Col1+ cells were not seen in the normal pancreas. This difference 
might be explained because of the different species (mouse or human) analyzed.  
 
4.4.5. Conclusion 
In our experiments, we have demonstrated that collagen-producing CD45+Col1+ 
fibrocytes are BM-derived cells, but comprise only a rare population in BM and PB. A 
possible subpopulation of lymphocyte-like CD45+Col1+ fibrocytes exists in the 
circulating blood. These fibrocytes can migrate into acute inflammatory and fibrotic 
pancreatic tissue, are generally located in the collagen-rich areas and further may 
contribute to chronic pancreatitis by differentiation into myofibroblasts. 
 190 
Chapter 5: The influence of bone marrow-secreted IL-10 on 
experimental pancreatic fibrosis 
5.1 Introduction 
5.1.1 Background 
Cytokines are defined as biologically active molecules that occur naturally and 
influence the survival, proliferation, migration or other aspects of immature or mature 
cells. They are produced by a wide variety of non-haematopoietic and haematopoietic 
cell types including BM, and can have autocrine, paracrine and endocrine effects. 
Among the various cytokines, IL-10 is considered as an anti-inflammatory cytokine and 
is mainly expressed and secreted by a variety of cell types derived from BM, such as T 
cells, monocytes/macrophages, dendritic cells, B cells, and natural killer cells. The anti-
inflammatory effect of IL-10 is thought to be achieved by inhibiting production of pro-
inflammatory cytokines and chemokines from monocytes/macrophages, which are 
involved in the recruitment of additional monocytes, neutrophils, dendritic cells, and T 
cells to sites of injury or infection (Moore et al., 2001). In the inflammatory bowel 
diseases (IBDs), IL-10 secreted from activated macrophages and Th2-type T cells, is 
believed to play an important role in down-regulating Th1-type immune responses by 
suppressing the activation of macrophages and inhibiting the synthesis of tumour 
necrosis factor (TNF)-α, IL-6, and IL-8 by macrophages or activated monocytes.  
Furthermore, mice homozygous for the IL-10 gene mutation spontaneously develop 
chronic IBD after 3 months of age under specific-pathogen-free conditions, showing 
intestinal histology of focal transmural inflammation, mucosal proliferation, focal 
ulceration, and extensive inflammatory cell infiltration, sharing some features with 
Crohn’s disease (Sellon et al., 1998).  
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    In the pancreas, IL-10 also plays an anti-inflammatory role. It has been 
demonstrated that pre-treatment of IL-10 could decrease the severity of cerulein-
induced acute pancreatitis in mice, mainly by inhibiting cellular necrosis. This effect is 
not related to a decrease of pancreatic inflammation but most likely to the inhibition of 
pro-inflammatory mediator secretion by local inflammatory cells (Van Laethem et al., 
1995). Furthermore, in a mouse model of cerulein-induced acute pancreatitis, the level 
of IL-10 in serum and mRNA expression in lung, liver and pancreas were all elevated 
during acute pancreatic inflammation. Blocking endogenous IL-10 production by pre-
treatment with an anti-IL-10 monoclonal antibody increased the severity of acute 
inflammation suggesting a protective role of endogenous IL-10 in acute pancreatitis 
(Van Laethem et al., 1998). In chronic pancreatitis, using IL-10 KO mice, Demols et al. 
has demonstrated that IL-10 could modulate proliferation and fibrosis in a cerulein-
induced chronic pancreatitis mouse model (Demols et al., 2002).  
    BM-derived myofibroblasts have been demonstrated to participate in chronic 
pancreatitis (Marrache et al., 2008; Watanabe et al., 2009). However, whether these 
BM-derived myofibroblasts are affected by endogenous cytokines of BM origin, i.e. 
BM-secreted cytokines can influence the number of myofibroblasts derived from BM, is 
not clear. It has been demonstrated that WT BM transplantation can ameliorate the 
severity of IBD in IL-10 KO mice, suggesting that IL-10 secreted by BM plays an anti-
inflammatory role in IL-10 KO colitic mice (Bamba et al., 2006). Similarly, in the 
chronic pancreatitis mouse model, the lack of IL-10 could increase inflammation and 
fibrosis (Demols et al., 2002). However, this study was performed on IL-10 KO 
background mice, and obviously the role of IL-10 secreted by BM in the pancreatitis is 
not well explored. Whether BM-secreted IL-10 can attenuate inflammation and fibrosis 
in pancreatitis and furthermore, can change the number of myofibroblasts derived from 
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BM is still a mystery. In this study, it was proposed to look at the inflammation, fibrosis 
and recruitment of BM-derived myofibroblasts in the context of an absence in IL-10 
secreted by the BM.  
 
5.1.2 Hypothesis 
The hypothesis is that the IL-10 cytokine of BM origin not only can change the severity 
of inflammation and fibrosis, but also can affect the BM-derived myofibroblasts in a 
BM transplanted mouse model of cerulein-induced pancreatic inflammation and 
fibrosis. 
 
5.1.3 Aim of this study 
The aim of this study is to compare the severity of cerulein-induced pancreatic 
inflammation, fibrosis and the change in BM-derived myofibroblasts in the pancreas of 
female mice receiving either a WT male BM or an IL-10 KO male BM cell 
transplantation. I also aim to see whether BM-secreted IL-10 can affect the recovery of 
pancreatic fibrosis in these mice after a period of time without exposure to cerulein. 
 
5.2 Study Design 
The procedures for animal experiments were performed under British HO procedural 
and ethical guidelines (Figure 5.1). Six to eight week-old WT BALB/C WT female 
recipient mice (The Charles River Laboratory, Wilimington, Maine, USA) underwent 
whole body lethal gamma irradiation with 10 Gy in a divided dose four hours apart, to 
ablate their BM, followed immediately by tail vein injection of either WT (group B and 
 193 
D) or IL-10 KO (group A and C) male whole BM (2 × 106 cells), re-suspended in 
0.1mL sterile PBS with 2% FCS. After six weeks, the mice received either cerulein or 
vehicle (saline) injections to induce pancreatitis. There were four mice in each group. 
Acute pancreatitis was induced by 6 intraperitoneal injections of cerulein (50µg/kg) 
given at hourly intervals for 1 day. Pancreatic fibrosis was induced by the same protocol 
of cerulein injections being repeated twice a week for 3 and 6 consecutive weeks. Blood 
and tissues were harvested at 24 hours after the first injection on day 1 (acute groups), 
week 3 (middle groups), week 6 (chronic groups) and week 9 (recovery groups) for 
further analysis. 
 
 
Figure 5.1. The study design for determining the role of BM-secreted IL-10 in 
the cerulein-induced acute pancreatitis and pancreatic fibrosis mouse model.  
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5.3 Results 
5.3.1 The changes of body weight, pancreatic weight and blood sugar in WT BM 
and IL-10 KO BM transplanted mice 
In our model of chronic pancreatitis induced by cerulein, both the mice that received 
either WT BM or IL-10 KO BM transplantation showed loss of the normal weight gain 
during the 6-week period of treatment, and regained their body weight after cessation of 
cerulein injections (Figure 5.2). However, there was no statistical significance between 
both groups in the body weight change. These data suggest that the long duration of 
cerulein injections causes body weight loss in mice, while IL-10 KO BM does not affect 
body weight in this experimental model. 
    The pancreatic weight was measured at day 1 (acute groups), week 3 (middle 
groups), week 6 (chronic groups) and week 9 (recovery groups) (Figure 5.3). In control 
mice receiving saline injections for 6 weeks, the pancreatic weights of mice receiving 
WT BM or IL-10 KO BM were 188 ± 5.72mg or 184.5 ± 4.65mg respectively. After 1-
day of cerulein injections, the pancreatic weight was not significantly altered (WT BM 
group 182.5 ± 7.29mg, p > 0.05; IL-10 KO BM group 190.5 ± 7.66mg, p > 0.05) 
compared to the control mice. However, weight decreased significantly compared to 
control mice after 3 weeks of cerulein injection in mice receiving either WT BM cells 
(82.5 ± 4.79 mg, p <0.01) or IL-10 KO BM cells (88 ± 5.37 mg, p < 0.01). The 
pancreatic weights were decreased even further after 6 weeks of cerulein injections (WT 
BM group 60 ± 2.16mg; IL-10 KO BM group 53.25 ± 4.77mg), and only slightly 
increased at 3 weeks after the last cerulein treatment (WT BM group 66 ± 6.66mg; IL-
10 KO group 84 ± 7.29mg). Overall, no statistical significance was found between the 
two groups (WT and IL-10 KO BM transplant recipients) at any time point. These data 
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suggested that chronic cerulein administration does induce pancreatic atrophy, 
unaffected by the IL-10 KO phenotype of the BM.  
    Blood sugar was also measured at different time points (Figure 5.4). In control 
mice receiving saline injections for 6 weeks, levels in mice receiving WT BM or IL-10 
KO BM were 88.75 ± 4.21mg/dL or 112.75 ± 11.47mg/dL, respectively. At day 1 and 
week 3, the blood sugar levels were higher in IL-10 KO BM recipients than in WT BM 
recipients (both p < 0.05), but these differences were not significant at week 6 and week 
9. These data might suggest that the IL-10 KO BM phenotype affects blood sugar in 
acute pancreatitis and the early stages of chronic pancreatitis, but not in the late stage of 
chronic pancreatitis.  
 
 
Figure 5.2. Changes in body weight of WT BM (blue line), and IL-10 KO BM 
(red line) transplanted mice during the 6-week period of cerulein injection and 
the 3-week recovery period. Values represent the ratio of weekly body weight to 
initial body weight and are means ± SEM (n=4 mice per group).  
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Figure 5.3 Changes in pancreatic weight of WT BM (blue bar), and IL-10 KO 
BM (red bar) transplanted mice. Values represent the mean of pancreatic 
weight ± SEM (n=4 mice per group). 
 
Figure 5.4 Change in sugar level of WT BM (blue bar), and IL-10 KO BM (red 
bar) transplanted mice. Values represent the mean of blood sugar ± SEM (n=4 
mice per group). 
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5.3.2 The histological changes in WT BM and IL-10 KO BM transplanted mice  
Histologically, in the saline-treated mice, the morphology of the pancreas was normal in 
mice receiving either WT BM or IL-10 KO BM (Figure 5.5). However, IHC staining of 
F4/80 (macrophage marker) showed more infiltrated macrophages in the pancreas from 
mice receiving IL-10 KO BM (4.15 ± 0.28 per high power field (HPF, 400X)) 
compared to the mice receiving WT BM (1.93 ± 0.26 per HPF, p < 0.05) (Figure 5.11 
A, B and H). This suggests that the lack of IL-10 secreted from the BM causes subtle 
inflammatory cell infiltration without obvious histological changes. 
         
 
Figure 5.5. Histology of the pancreas from saline (control groups) treated 
female mice that received either WT (A) or IL-10 KO (B) male BM transplants.  
H&E staining of the pancreas from the control group showed normal pancreatic 
structure (200X).  
 
    After cerulein injection for 1 day, the morphology of the pancreas from the mice in 
both groups showed very mild focal oedema between lobules, inflammatory cell 
infiltration in the parenchyma but without collagen deposition, acinar atrophy or 
structural change, which are the characteristic features of acute pancreatitis (Figure 5.6, 
A and B). The acute pancreatitis histological score showed no significant differences 
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between WT BM (2.25 ± 1.03) and IL-10 KO BM (3 ± 1.47, p > 0.05) groups (Figure 
5.7 A). 
    The tissue changes of atrophy of acinar cells, deformed architecture, pseudo-
tubular complex formation, intra-lobular collagen deposition and severe fibrotic change, 
which are the characteristic features of chronic pancreatitis were found not only in the 
pancreas of mice receiving 3 and 6 weeks of cerulein treatment, but also in the pancreas 
of mice that had 3 weeks rest after 6 weeks of cerulein (Figure 5.6, C-H). The 
histological scores of chronic pancreatitis including architectural changes, glandular 
atrophy and pseudotubular complexes showed no significant differences between mice 
receiving WT BM and IL-10 KO BM, indicating that the lack of IL-10 secreted from 
the BM did not affect chronic pancreatitis (Figure 5.7 B-D). 
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Figure 5.6. Histology of the pancreas from cerulein treated female mice that 
received either WT or IL-10 KO male BM transplants. The development of mild 
acute pancreatic inflammation from 1-day cerulein treated mice (A and B, 
200X). Acinar atrophy, architectural changes and pseudotubular complexes 
were found in mice receiving cerulein for 3 and 6-weeks and persisted for 3 
weeks after 6 weeks of cerulein injections (C-H, 200X). 
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Figure 5.7 Histological scoring of acute pancreatitis (A), and chronic pancreatitis 
(B-D) in mice that received either a WT BM (blue bar) or a IL-10 KO BM (red 
bar) transplantation. Values represent the mean of scores ± SEM (n=4 mice per 
group).  
 
5.3.3 Collagen deposition in WT BM and IL-10 KO BM transplanted mice 
One of characteristic features of chronic pancreatitis is collagen deposition. In the 
control groups, the percentage of collagen deposition (defined by Sirius red positive 
staining) to the total pancreatic area was 1.68 ± 0.21% and 1.79 ± 0.13% in mice that 
received a WT BM or an IL-10 KO BM transplant respectively (p > 0.05). This result 
suggests that the lack of BM IL-10 does not affect normal collagen deposition.  
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    Sirius red staining was also performed on all experimental groups (Figure 5.8). The 
1-day cerulein injection did not cause further collagen deposition in either WT BM or 
IL-10 KO BM groups (Figure 5.8, A and B), while continuous cerulein injections for 3 
and 6 weeks induced progressive intra-lobular collagen deposition (Figure 5.8, C-F). 
Even following 3 weeks rest, the excessive intra-lobular collagen deposition remained 
(Figure 5.8, G and H). In mice receiving a WT BM transplant, the areas occupied by 
collagen in the acute, middle, chronic and recovery groups were 1.24 ± 0.15%, 7.63 ± 
0.34%, 12.42 ± 0.23%, and 12.54 ± 0.42% respectively. In mice receiving a IL-10 KO 
BM transplant, the areas were 1.37 ± 0.13%, 7.43 ± 0.38%, 13.68 ± 0.63%, and 18.35 ± 
1.13% (Figure 5.8, I). Similar degrees of collagen deposition were observed in mice that 
had WT BM after 6 weeks of cerulein and after 3 weeks recovery (12.42 ± 0.23% and 
12.54 ± 0.42%, p > 0.05), suggesting that there was no immediate resolution of 
collagen. On the other hand, the area occupied by collagen increased significantly in the 
3 weeks after cerulein cessation in the mice with a IL-10 KO BM transplant (13.68 ± 
0.63% and 18.35 ± 1.13%, p < 0.05), suggesting that the lack of IL-10 secreted from the 
BM causes further collagen deposition.  
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Figure 5.8 Sirius red staining of the pancreas from cerulein treated female mice 
that received either a WT male BM or an IL-10 KO male BM transplant (A - H). 
Figure A and B show normal collagen deposition between lobules after cerulein 
injection for 1 day. Figures C-H show progressive collagen deposition with time. 
(I) Sirius red positive areas to the total area. Only in the recovery group is 
collagen deposition in the IL-10 KO group significantly higher than that in the 
WT BM group (p < 0.01).  
 
5.3.4 BM-derived myofibroblasts in the pancreas of WT BM and IL-10 KO BM 
transplanted mice 
Because increased collagen deposition was found in the IL-10 KO BM transplanted 3 
weeks after the last cerulein injections, we wanted to know whether active 
myofibroblasts, the major collagen producing cells in the pancreas, are increased in 
number and are of BM derivation. Active myofibroblasts were identified by IHC for α-
SMA in both WT BM and IL-10 KO BM transplanted mice in both the chronic and 
recovery groups. In order to detect BM-derived myofibroblasts, ISH for Y chromosome 
detection was then performed after the IHC for α-SMA (Figure 5.9, B-D). The spleen 
was used as a positive control of ISH for Y chromosome detection (Figure 5.9A), and 
the total number of myofibroblasts per HPF (400x) was calculated (Figure 5.9E). In 
mice receiving a WT BM transplant, the numbers of myofibroblasts in the chronic and 
recovery groups were 10.08 ± 1.07 and 11.61 ± 0.99, respectively. In mice receiving a 
IL-10 KO BM transplant, the numbers were 10.14 ± 0.21 and 11.73 ± 0.86 (Figure 
5.9E). There was no difference between WT BM and IL-10 KO BM transplanted mice 
in the number of active myofibroblasts, suggesting that the lack of IL-10 secreted from 
the BM has no affect. Furthermore, BM-derived myofibroblasts were recognised 
(Figure 5.9, B-D), and percentages counted (Figure 5.9F). In mice receiving a WT BM 
transplant, the percentages of BM-derived myofibroblasts in the chronic and recovery 
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groups were 9.27 ± 2.17% and 6.69 ± 1.12%, respectively. In the IL-10 KO BM 
recipients, the percentages were 9.15 ± 0.98% and 11.90 ± 1.27% (Figure 5.9F). 
Interestingly amongst the recovery groups, the percentage of BM-derived 
myofibroblasts was increased in the pancreas of the IL-10 recipients compared to those 
with WT BM (6.69 ± 1.12% and 11.90 ± 1.27%, p <0.05). This finding might suggest 
that IL-10 secreted from the BM plays a role in suppressing BM cell transdifferentiation 
into myofibroblasts, however, it is impossible to know whether the suppression of BM-
derived myofibroblasts was achieved by direct and/or indirect effects of IL-10. 
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Figure 5.9 BM-derived α-SMA-positive cells in the pancreas from cerulein 
treated female mice that received either a WT or an IL-10 KO male BM 
transplant. (A) ISH for the Y chromosome in the spleen of mice that received a 
WT male BM transplant. (B) IHC for α-SMA (red) and ISH for the Y 
chromosome shows BM-derived myofibroblasts in the pancreas from a mouse 
that received a WT male BM transplant (arrow, 400X). (C and D) Active 
myofibroblasts illustrated by α-SMA expression (red), while a small brown dot in 
the nucleus indicates there are BM-derived myofibroblasts in the pancreas from 
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those mice that received an IL-10 KO BM transplant (arrow). (E) The number of 
myofibroblasts per HPF (400X) in mice receiving either a WT BM (blue bars) or 
IL-10 KO BM (red bars) in both the chronic and recovery groups. (F) The 
percentage of BM-derived myofibroblasts in the same groups.  
 
5.3.5 The inflammatory cell response in the pancreas of WT BM and IL-10 KO 
BM transplanted mice 
IL-10 is considered as an anti-inflammatory cytokine, therefore it is reasonable to think 
that the lack of IL-10 secreted by the BM would cause a more severe infiltration of 
inflammatory cells with chronic damage. To investigate this, the numbers of 
macrophages and T lymphocytes were counted.  
    T lymphocytes (CD3 positive cells) are considered as modulatory cells during 
inflammation, and immunostaining for CD3 in the spleen was used as a positive control 
(Figure 5.10G). T lymphocytes were very rare in the pancreas of mice receiving either a 
WT male BM (0.18 ± 0.05 per HPF; Figure 5.10A and H) or a IL-10 KO male BM 
(0.13 ± 0.03 per HPF; Figure 5.10B and H) in saline injection (control) groups. In mice 
transplanted with WT BM, the numbers of T lymphocytes in the chronic and recovery 
groups were 2.20 ± 1.08 and 8.33 ± 0.84 per HPF, respectively (Figure 5.10C, E and H). 
In mice transplanted with IL-10 KO BM, the numbers of T lymphocytes in the chronic 
and recovery groups were 1.73 ± 0.43 and 1.95 ± 0.26 per HPF (Figure 5.10D, F and 
H). The infiltration of T lymphocytes was significantly increased in the pancreas of the 
WT BM transplanted mice in the recovery group compared to the both WT BM 
transplanted mice in the chronic group (p < 0.05) and IL-10 KO BM transplanted mice 
in the recovery phase (p < 0.01). These observations suggest that T lymphocytes might 
play a role in modulation of the pancreatic inflammatory response after the damage 
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caused by repeated cerulein administration, while the lack of IL-10 secreted from the 
BM actually inhibits T lymphocyte infiltration. 
 
  
Figure 5.10 IHC staining for CD3 (T cell) in the pancreas from cerulein treated 
female mice that received either a WT male BM or an IL-10 KO male BM 
transplant. (A and B) shows that in saline treated mice (control groups) CD3 
positive cells are very rare. (C and D) Illustrate that T lymphocyte infiltration is 
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very modestly increased in both groups after 6 weeks of cerulein injections 
(chronic groups). (E) Illustrates increased T lymphocyte infiltration in WT BM 
transplanted mice in the recovery phase (F) T lymphocyte infiltration in the 
pancreas from an IL-10 KO BM transplanted mouse in the recovery phase. (G) 
CD3 staining in the spleen of a mouse that received a WT BM transplant in the 
control group. (H) The number of T lymphocytes per HPF. 
 
    Macrophages (F4/80 positive cells) are considered as acute inflammatory cells 
contributing to tissue destruction. They infiltrate the pancreas once acute pancreatitis is 
induced by cerulein and can be visualised by IHC using the F4/80 antibody. Staining 
with F4/80 in the spleen was used as a positive control (Figure 5.11G). Macrophages 
were very rare in the control pancreata of mice receiving WT male BM (1.93 ± 0.26 per 
HPF; Figure 5.11A and H), while in the controls with IL-10 KO male BM they were 
increased (4.15 ± 0.28 per HPF, p < 0.05; Figure 5.11B and H). In the mice with a WT 
BM transplant, the numbers of macrophages in the chronic and recovery groups were 
26.83 ± 3.05 and 15.3 ± 1.66 per HPF, respectively (Figure 5.11C, E and H), clearly a 
massive increase. In the mice with an IL-10 KO BM transplant, the numbers of 
macrophages were also increased in the chronic and recovery groups, 20.78 ± 1.31 and 
23.23 ± 2.28 per HPF (Figure 5.11D, F and H). In the recovery groups, macrophage 
infiltration was significantly increased in the IL-10 KO BM recipients compared to the 
WT BM transplanted group (p < 0.05).  
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Figure 5.11 IHC staining with F4/80 for macrophages in the pancreas from 
cerulein treated female mice that received either a WT male BM or an IL-10 KO 
male BM transplant. Figure A and B show that in saline treated mice (control 
groups), the F4/80 positive cells are rare in the pancreas of WT male BM 
transplanted mice (A), while the infiltration of F4/80-positive cells is increased in 
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the pancreas of IL-10 KO male BM transplanted mice (B). Figure C and D show 
that macrophage infiltration is significantly increased in the pancreas of both WT 
BM transplanted (C) and IL-10 KO BM (D) transplanted mice after receiving 6 
weeks of cerulein injections (chronic groups). (E) Macrophage infiltration was 
less in the WT BM transplanted mice after a 3-week recovery, but was 
unaltered in the IL-10 KO BM transplanted mice (F). (G) F4/80 staining in the 
spleen from a mouse that received a WT BM transplant but no cerulein. (H) The 
number of macrophages per HPF in mice receiving either a WT BM (blue bars) 
or an IL-10 KO BM (red bars).  
 
5.4 Discussion  
The participation of BM-derived myofibroblasts has been well documented in 
pancreatic fibrosis using the experimental cerulein induced pancreatitis mouse model 
(Marrache et al., 2008; Watanabe et al., 2009). However, the influence of cytokines on 
these BM-derived fibrogenic cells has not been well clarified. Here I demonstrate for 
the first time that the lack of IL-10 (an anti-inflammatory cytokine) secreted by BM 
cells, causes progessive collagen deposition combined with increased numbers of BM-
derived myofibroblasts, decreased T lymphocyte infiltration and persistent infiltration of 
macrophages, all at 3 weeks after the cessation of cerulein treatment.  
    Pancreatic fibrosis is defined by the overgrowth and excess deposition of ECM 
components including collagen in the pancreas. It is caused by recurrent episodes of 
pancreatic parenchymal cell necrosis followed by fibrosis, and is considered as the end 
result of chronic pancreatitis induced by various insults such as alcohol abuse, genetic 
disorders, pancreatic duct obstruction, recurrent acute pancreatitis, autoimmune 
pancreatitis and unknown mechanisms (Shimizu, 2008). Activated myofibroblasts serve 
as the primary collagen-producing cells, and are believed to be the key cellular 
mediators of fibrosis in various organs (Wynn, 2008). Previous studies have also 
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suggested that pancreatic myofibroblasts play an important role in the progression of 
pancreatic fibrosis (Masamune and Shimosegawa, 2009; Nishida et al., 2009; Saotome 
et al., 1997; Shimizu, 2008; Suda et al., 1994). In the pancreas, multiple origins are 
considered as the source of activated myofibroblasts including PaSCs (Omary et al., 
2007), BM (Marrache et al., 2008; Watanabe et al., 2009) and fibrocytes. Other studies 
have shown that BM-derived myofibroblasts contribute to the total population of 
activated myofibroblasts in the pancreas, varying from 6% to 20% in cerulein-induced 
chronic pancreatitis (Marrache et al., 2008; Watanabe et al., 2009). Our experiments 
have also confirmed this finding since ~9% of myofibroblasts in the mice treated with 
cerulein for 6 weeks were derived from the BM. However, our results also showed that 
the percentage of BM-derived myofibroblasts increased in the IL-10 KO BM 
transplanted mice treated with cerulein for 6 weeks followed by a gap of 3 weeks, 
suggesting that IL-10 may play a role in the suppression of BM cell transdifferentiation. 
Furthermore, the degree of fibrosis was also increased significantly in the IL-10 KO BM 
transplanted after the 3-week gap, suggesting that the increased number of BM-derived 
myofibroblasts may functionally contribute to pancreatic fibrosis. How IL-10 acts to 
suppress BM transdifferentiation into myofibroblasts is not answered in these 
experiments.  
    IL-10 has been shown to be a potent anti-inflammatory cytokine released during 
the course of experimental pancreatitis by decreasing the release of pro-inflammatory 
factors (Rongione et al., 1997; Van Laethem et al., 1998; Van Laethem et al., 1995). In 
these experiments, we further showed that a lack of IL-10 secreting BM cells could 
affect the inflammatory cell response during the recovery phase of cerulein-induced 
pancreatic fibrosis. The increased number of macrophages in the pancreas from the IL-
10 KO BM transplanted mice is compatible with similar findings in skin wounds 
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created on IL-10 KO mice (Eming et al., 2007). The decreased number of T 
lymphocytes in the IL-10 KO BM transplanted mice may reveal a potential role of IL-
10 secreted by BM cells on T lymphocyte regulation, and further analysis is needed to 
clarify the complex functions of IL-10 on the immune system. 
    Apart from an anti-inflammatory effect, IL-10 is also considered as an anti-fibrotic 
cytokine. It has been shown that the severity of fibrosis was increased in carbon 
tetrachloride-induced liver fibrosis in IL-10 KO mice (Louis et al., 1998). Furthermore, 
the wound healing process is accelerated in IL-10 KO mice (Eming et al., 2007). 
Increased numbers of α-SMA-positive myofibroblasts as well as macrophages were 
found in the skin wounds of IL-10 KO mice, suggesting that these two cell types 
enhance the contraction of wounds and mediate the accelerated tissue repair. In the 
cerulein-induced pancreatic fibrosis model, IL-10 KO mice have more severe 
histological lesions and fibrosis (intrapancreatic collagen content) than controls 
(Demols et al., 2002). The plasma level of TGF-β1, a key stimulatory factor for 
myofibroblast activation, as well as the number of activated myofibroblasts were 
significantly higher in IL-10 KO mice, suggesting the lack of IL-10 causes 
myofibroblast activation by increasing TGF-β1 that in turn increases the severity of 
fibrosis. However, the results from my experiments were that the severity of fibrosis, 
the number of activated myofibroblasts and inflammatory cells were the same in both 
the IL-10 KO BM and WT BM transplanted mice after 6 weeks of cerulein. Differences 
were only revealed after a gap of 3 weeks from the last cerulein injection. A possible 
explanation is that IL-10 could be secreted from other cell types apart from BM cells 
during the episodes of acute pancreatitis induced by cerulein, and this is sufficient to 
maintain basic IL-10 levels during the acute inflammatory response. Indeed, although 
IL-10 is mainly secreted by haematopoietic cells, it has been shown that IL-10 can also 
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be detected in rodent HpSCs during the course of activation in vitro (Thompson et al., 
1998). During the time without cerulein injection, the secretion of IL-10 from other cell 
types may decrease because of lack of inflammatory stimulation, and BM-secreted IL-
10 may become predominant. The hypothesis that IL-10 secreted by other cell types can 
function well enough during acute inflammation is also supported by the previous study 
of IBD in IL-10 KO mice (Bamba et al., 2006); spontaneous colitis did not occur in WT 
mice that received the IL-10 KO BM transplantation, suggesting the IL-10 secreted 
from other cell types has a protective effect. Further experiments will be needed to 
clarify the significance of IL-10 secreted by other cell types. 
    In conclusion, the degree of fibrosis, the inflammatory cell response as well as the 
number of BM-derived myofibroblasts were altered in the IL-10 KO BM transplanted 
mice in the recovery phase of pancreatic fibrosis after cerulein. These findings highlight 
a potential role of IL-10 on BM-derived myofibroblasts and fibrosis in the pancreas.  
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Chapter 6: Using Mitochondrial DNA Mutations as Clonal 
Markers for Tracing Cell Lineages in Human Liver Cirrhosis 
6.1 Introduction 
6.1.1 Background 
Cirrhosis represents end-stage liver disease whereby iterative injury caused by the likes 
of hepatotropic viruses or alcohol results in a liver composed of RNs surrounded by 
connective tissue septae. RNs are the defining pathological feature in liver cirrhosis, and 
represent a final common pathway of many chronic liver diseases (Schuppan and 
Afdhal, 2008). A number of attempts have been made to establish the clonality of RNs, 
often by examination of X chromosome-linked markers in females. For example, in 
hepatitis C virus (HCV) induced liver cirrhosis, approximately half of all RNs have 
been found to be monoclonal based on restriction fragment length polymorphism of the 
X chromosome-linked phosphoglycerokinase gene and on the random inactivation of 
the gene by methylation (Aihara et al., 1994). Another experiment, which was 
attempting to distinguish morphologically non-malignant RNs (presumed polyclonal) 
from premalignant nodules (presumed to be monoclonal), found in fact that about 45% 
of all nodules were monoclonal (Paradis et al., 1998). This was again based upon 
females with random X chromosome inactivation, looking at the methylation status of 
the HUMARA gene. However, neither of these studies considered the distribution of X-
inactivated cells in the liver. Since X-inactivation (Lyonisation) occurs relatively early 
in embryogenesis, the progeny of a single X-inactivated ES cell may be clustered 
together. Groups of cells sharing a common X-inactivation pattern are referred to as 
‘patches’, and in the human colon such patches may extend across up to 400 crypts 
(Novelli et al., 2003). Thus in the liver, a RN arising in the middle of a patch would be 
 215 
monophenotypic for an X-linked marker, but could be either monoclonally or 
polyclonally derived. 
    A second concern is the cells of origin of RNs. The broad connective tissue septae 
surrounded RNs provides a conducive environment for so-called DRs composed of 
HPCs, that represent a transit amplifying compartment of cells thought to be derived 
from a potential stem cell compartment located within the canals of Hering, the smallest 
branches of the intrahepatic biliary tree (Alison et al., 2009). The extent of this reaction 
is dependent on the severity of the damage, in both humans (Lowes et al., 1999) and 
mice (Kofman et al., 2005). HPCs that comprise DRs can express markers of both 
biliary and hepatocyte lineages in rodents (Thorgeirsson, 1996), likewise in human 
cirrhotic liver, both hepatocytic (HepPar1) and biliary markers (CK19, NCAM) are 
expressed in DRs (Zhou et al., 2007). Moreover, in an elegant 3-dimensional study of 
CK19 staining of human cirrhotic liver, it was shown that small ‘buds’ of hepatocytes in 
between connective tissue septae appeared to be directly descended from CK19-positive 
HPCs (Falkowski et al., 2003). RNs are generally considered to form through localized 
proliferation of hepatocytes and their entrapment by deposition of ECM (Wanless, 
1995). Whether these nascent hepatocyte buds can evolve into large RNs is unclear.     
    A technique using mtDNA mutations as markers for lineage tracing in human liver, 
gastrointestinal tract and other tissues was described in our lab (Fellous et al., 2009a; 
Fellous et al., 2009b). It has been shown that human gastrointestinal stem cells and their 
progeny contain non-pathogenic mutations in their mtDNA, including mutations in the 
CCO gene - a component of complex IV of the respiratory chain, that are relatively 
common. Each mitochondrion contains several hundred molecules of its own circular 
genome, and in most cells several thousand of these organelles exist. The mitochondrial 
genome is prone to mutation due to a lack of protective histones and poor DNA repair 
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mechanisms. Mutations can expand stochastically within a cell and over time cells will 
become either homoplasmic – all the mitochondria in the cell are mutated, or 
heteroplasmic – the cell contains a mixture of mutated and WT mitochondria. This 
stochastic expansion is a lengthy process, often taking many years (Elson et al., 2001), 
and for a mutated cellular phenotype to be observed, homoplasmy or a high degree (> 
80%) of heteroplasmy must be present. Thus, longstanding cells, presumably stem cells, 
are the only cells that have a sufficient lifespan to acquire mutation levels that result in a 
detectable biochemical deficiency. In the human colon, CCO-deficient crypts are rare 
before the age of 40 years (Greaves et al., 2006), and as cells migrate from the stem cell 
zone to the luminal surface to be sloughed off in a matter of days, the source of CCO 
deficiency is undoubtedly the stem cell population at the crypt base. In the normal 
human liver, my colleagues (Fellous et al., 2009a) found patches of CCO-deficient 
hepatocytes, and mtDNA sequencing of many individual hepatocytes within a particular 
patch revealed that these hepatocytes shared a unique mutation indicating a common 
cell of origin. While the founder cell of any patch of CCO-deficient cells is also likely 
to be a long-lived cell, this might not necessarily be a stem cell if, as we know, cell 
turnover is considerably slower in the liver, although the large cell patches we observed, 
each with a unique mutation(s) strongly suggests the founder cell is endowed with 
clonogenicity – a key feature of ‘stemness’. It has been reported that patches of CCO-
deficient hepatocytes are found in human cirrhotic liver (Muller-Hocker et al., 1997). 
However, whether hepatocytes within the same patch and cells within the surrounding 
DRs have the same mtDNA mutation is unknown. The methods I describe in this 
chapter allow us identify specific mutations within any CCO-deficient cells, and hence 
define the lineage relationship, if any, between one cell and the next. 
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6.1.2 Hypothesis 
We wish to explore the hypothesis that maybe the RNs are in fact descendants of HPCs 
from the DRs located within the connective tissue septae that are intimately associated 
with the nodules. Moreover, we wish to test the hypothesis that RNs are clonal 
populations. 
 
6.1.3 Aim of this study 
The aim of this study was to trace the lineage of cells forming the RNs in cirrhotic liver 
using the relatively new techniques of looking for CCO-deficient cells and subsequent 
complete mtDNA mutation analysis of such cells.  
 
6.2 Material  
Fourteen formalin-fixed, paraffin-embedded blocks and 9 frozen tissue blocks of human 
cirrhotic liver of varying aetiology (hepatitis B, hepatitis C, alcoholic liver disease, 
Wilson disease, non-alcoholic steatohepatitis [NASH] and cryptogenic cirrhosis) were 
obtained from The Royal Free Hospital, London. Multicentre ethical approval was 
obtained according to the requirements of the United Kingdom Human Tissue Act 
(2006) from the Redbridge and Waltham Forest Local Research Ethical Committee 
(REC) (Reference 2006/Q0601/33).  
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6.3 Results 
6.3.1 Immunohistochemical analysis of cytochrome c oxidase 
Immunostaining of human cirrhotic liver showed that most of the RNs we analysed 
were composed of either only CCO-positive hepatocytes or CCO-deficient hepatocytes 
(Figure 6.1), while RNs composed of both CCO-deficient and –positive hepatocytes 
(CCO-mixed nodules) were rare (< 3%) in our cohort group (Table 6.1). The presence 
of wholly CCO-deficient RNs suggests that most RNs are monoclonal in origin based 
on our previous experience (Fellous et al., 2009a). Overall, ten of the 14 cases of liver 
cirrhosis had CCO-negative RNs. Within these 10 cases, 526 nodules were analyzed. 
Most of the RNs showed either homogeneous CCO-immunoreactivity or a complete 
lack of it, while only 2.9% of all RNs were mixed, despite the different aetiologies of 
cirrhosis. These nodules of variable size all had clear fibrotic boundaries and were 
surrounded by many DRs. The cells of DRs also had CCO activity; CCO-positive DRs 
were found mainly around CCO-positive nodules, while CCO-deficient DRs could be 
easily found around CCO-deficient nodules (Figure 6.2). However the finding of CCO-
deficient DRs adjacent to CCO-deficient RNs does not in itself indicate the two 
populations are clonally related, and proof requires the finding of common mtDNA 
mutations as described in Figures 6.3 to 6.7. Although we found that most DRs were 
homogeneous in CCO immunoreactivity, some DRs contained clearly demarcated 
CCO-positive and -deficient cells (Figure 6.2C) suggesting that clones can evolve 
within a DR. 
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Figure 6.1. Three different types of RNs based on the IHC staining for CCO 
expression. (A) CCO-positive nodule: a nodule contains homogeneous CCO-
positive hepatocytes. (B) CCO-deficient nodule: a nodule (denoted by dashed 
line) is composed of hepatocytes with no hepatocyte immunoreactivity. (C) 
CCO-mixed nodule: a nodule is composed of both CCO-positive and CCO-
deficient hepatocytes. 
 
Table 6.1: The analysis of CCO expression in cirrhotic RNs with different 
aetiologies 
 
Abbreviations: Alc, Alcohol; CCO, cytochrome c oxidase; HBV, hepatitis B virus; 
HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis.  
∗ Cases with one or more CCO-deficient nodules. 
† The number of nodules was counted from one section of each CCO-deficient 
case and shown as the total number found for all cases. 
 
 
Aetiology Case 
number 
CCO 
-deficient 
cases∗ 
Nodules in 
CCO-deficient 
cases † 
CCO-positive 
nodules (%) 
CCO-deficient 
nodules (%) 
 
Mixed nodules 
(%) 
 
HBV 7 7  331 256 (77.3%) 
 
63 (19.1%) 
 
12 (3.6%) 
 
Alc  4 1  68 54 (79.4%) 
 
13 (19.1%) 
 
1 (1.5%) 
 
Alc/HCV  2 1  83 69 (83.1%) 
 
13 (15.7%) 
 
1 (1.2%) 
 
NASH  1 1 44 35 (79.5%) 
 
8 (18.2%) 
 
1 (2.3%) 
 
Total 
 
14 10 526 414 (78.7%) 
 
97 (18.4%) 
 
15 (2.9%) 
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Figure 6.2. Immunostaining of CCO in cells comprising DRs surrounding RNs. 
(A) CCO-positive DRs (arrows) abutting a CCO-positive nodule. (B) CCO-
deficient DRs (arrowheads) can be seen adjacent to a CCO-deficient nodule. 
(C) Cells with CCO-activity (arrow) and without CCO-activity (arrowhead) can 
be seen in this section of biliary epithelia. 
 
6.3.2 RNs can be monoclonal 
Direct mtDNA sequencing of separate hepatocytes from within CCO-deficient RNs 
demonstrates that each can have a common cell of origin (Figures 6.3, 6.4, 6.6 and 6.7), 
without excluding the possibility, for example, that a monoclonally derived DR could en 
masse differentiate into a RN. These monoclonal RNs were not dysplastic (Figures 
6.3B, 6.4B and 6.6B), and indeed were invariably surrounded by DRs (confirmed by 
serial CK19 IHC; Figures 6.3D, 6.4D, 6.6D and 6.7C). The number of mutations in the 
mtDNA genome varied from one nodule to the next. Most of the CCO-deficient nodules 
we analyzed contained only a single mutation in their entire mtDNA genome (Figures 
6.3E, 6.4E and 6.6E), however, we also found specimens with three mutations (Figure 
6.4E) and even four mutations (Figure 6.7D) within a single CCO-deficient nodule. 
Because mtDNA mutations most likely require a long time to become established in the 
population, it is highly probable that these CCO-deficient nodules represent the progeny 
of a long-lived cell type. 
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Figure 6.3. RNs can be monoclonal. (A) An entirely CCO-deficient regenerative 
nodule (on a laser-capture membrane slide) histochemically stained 
sequentially for CCO activity (brown) and SDH activity highlighting CCO-
deficiency (blue). (B) Haematoxylin and eosin staining illustrating non-dysplastic 
morphology. (C) Three different groups of cells (1, 2 and 3) from the same 
CCO-deficient nodule and one group of cells (4) from the neighbouring CCO-
positive nodule were laser capture-microdissected and the entire mitochondrial 
genome was sequenced. (D) Cytokeratin-19 positivity highlights the surrounding 
DRs (arrowheads), and red circles denote the areas that had been 
microdissected. (E) All the CCO-deficient cells contained the same T>C 
transition mutation at position 6933bps within the MT-CO1 gene, a CCO coding 
region (black arrow), which was not detected in the neighbouring CCO-positive 
cells (white arrow).  
 
6.3.3 Neighbouring RNs can have different cellular origins  
Neighbouring nodules apparently surrounded by broad connective tissue septae in 2-
dimensional microscopic sections could in fact be a single entity that only appears 
multinodular in histologically sectioned material. To explore this possibility, mtDNA 
sequencing of three closely opposed nodules was performed (Figure 6.4). A CCO-
positive nodule had no mtDNA mutations, but of two neighbouring CCO-deficient 
nodules, one possessed a single mutation, while the other had three completely different 
mtDNA mutations (Figure 6.4E). These results illustrate that even nodules located very 
close to one another are in fact of completely separate cellular inheritance. Furthermore, 
we could easily find CCO-positive nodules next to CCO-deficient nodules (Figure 6.1B, 
6.2B, 6.3A, 6.6A and 6.7A), again illustrating the multifocal nature of the cirrhotic 
process. 
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Figure 6.4. Closely apposed RNs can have different cell origins. (A) An entirely 
CCO-deficient regenerative nodule in the middle (blue, SDH-positive), which is 
immediately adjacent to another CCO-deficient nodule (left) and to a CCO-
positive nodule (right, brown stain). (C) Two groups of cells (1 and 2) from the 
central CCO-deficient nodule, one group of cells (3) from the left CCO-deficient 
nodule and one group of cells (4) from the right CCO-positive nodule were laser 
capture-microdissected and the entire mitochondrial genome was sequenced. 
(B&D) H&E and cytokeratin-19 staining highlights the non-dysplastic 
morphology of these RNs and surrounding DRs (arrowheads), and red circles 
show the areas that have been microdissected. (E) Cells from areas 1 and 2 
from the middle CCO-deficient nodule contained the same T>C transition 
mutation at position 4313bps within the MT-T1 gene, a tRNA-Ile coding region 
(black arrow), but no mutation at locations 7070bps, 13450bps and 741bps 
(white arrows). Cells from area 3 from the left CCO-deficient nodule contained 
three different transition mutations: 7070C>T, 13450T>C and 741A>G (black 
arrowheads), while no mutation was found at position 4313bps (white 
arrowhead), the site of mutation in the centre CCO-deficient nodule. No 
mutation was detected in cells from area 4 from the CCO-positive nodule on the 
right.  
 
6.3.4 MtDNA Genotyping of a phenotypically mixed nodule  
Figure 6.5A illustrates a phenotypically mixed RN with an area of CCO activity (brown 
histochemical stain) sharply contrasting with an area of CCO deficiency (SDH activity, 
blue stain), with a further area that has a mixture of CCO-positive and -deficient cells. 
Within the CCO-deficient area, a clonal mtDNA mutation was present, but within the 
CCO-positive area there was only wild-type mtDNA, whereas in the sample taken from 
the mixed area both WT and mtDNA was present. Therefore, this mixed nodule must be 
derived from more than one cell, though the nodule could conceivably be in the process 
of monoclonal conversion if the mtDNA mutated clone was displacing or being 
displaced by the wild-type clone. 
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Figure 6.5. A phenotypically and genotypically mixed nodule. (A) A nodule 
containing a CCO-deficient area (blue staining), a CCO-positive area (brown 
staining), and a mixed area. (B) Haematoxylin and eosin staining showing non-
dysplastic morphology. (C) Cell areas 1-3 from the CCO-deficient area, areas 4-
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5 from the mixed area and areas 6-7 from the CCO-positive area were laser 
capture-microdissected and the entire mitochondrial genome was sequenced. 
(D) Cytokeratin-19 IHC highlights the surrounding DRs (white arrowheads), and 
the red circles denote the microdissected areas. (E) Cells from areas 1, 2 and 3 
from the CCO-deficient area contained the same G>A transition mutation at 
position 2690bps within the MT-RNR2 gene, a 16srRNA coding region (black 
arrow), while cells at 4 and 5 from the CCO-mixed area had a mixture of the 
same mtDNA mutation (2690 G>A) and WT DNA (black arrowhead). Cells at 6 
and 7 from the CCO-positive area had no mutation (white arrow). 
 
6.3.5 The relationship of RNs to DRs  
A RN with a single identical mtDNA in all its cells (Figure 6.6E), confirming its 
monoclonal origin, also had an abutting DR (Figure 6.6D). Sequencing of cells from 
CCO-deficient DR showed the same mutation that was present in the RN, 
demonstrating that the RN and abutting DR have a common inheritance (Figure 6.6E). 
Thus, an origin of the RN from the DR is likely though it could be argued that the DR 
could originate from metaplasia of hepatocytes within the DR.  
    Analysing a further RN with an associated DR (Figure 6.7), we again confirmed 
monoclonality (Figure 6.7E), this time with four identical homoplasmic mutations 
throughout the nodule. Moreover, these same four mutations were also present in the 
CK19-positive DR, but two of them were heteroplasmic. These observations strongly 
suggest that the hepatocytes in the RN have an origin from the DR and not vice versa 
because cells with a totally homoplasmic mutation (the hepatocytes) cannot revert to 
partially WT (the HPCs comprising the DR). 
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Figure 6.6. MtDNA genotyping indicates that RNs and DRs can have a common 
cell of origin. (A) An entirely CCO-deficient nodule (blue staining). (B) 
Haematoxylin and eosin staining showing non-dysplastic morphology. (C) Four 
groups of cells (1-4) from the same CCO-deficient nodule, three groups of cells 
(5-7) from the abutting CCO-deficient DRs, which were confirmed by 
cytokeratin-19 IHC in the next serial section (D, brown staining), and cells (8) 
from the CCO-positive nodule were laser capture-microdissected and the entire 
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mitochondrial genome was sequenced. (E) Cell areas 1-4 contained the same 
C insertion mutation between positions 9532 to 9537 within the MT-CO3 gene, 
a CCO coding region (black horizontal line). Cell areas 5-7 from the abutting 
CCO-deficient DRs showed the same mutation, while cell area 8 from the CCO-
positive nodule had no mutation (dashed line).  
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Figure 6.7. MtDNA genotyping indicates that RNs can be derived from 
cytokeratin-19 positive DRs. (A) An entirely CCO-deficient nodule (blue). (B) 
Five groups of cells (1-5) from the same CCO-deficient nodule, cells (6) from 
the adjacent CCO-deficient DRs, confirmed by cytokeratin-19 IHC on the next 
serial section (C, brown staining), and cells (7) from the CCO-positive nodule 
(brown) were laser capture-microdissected and the entire mitochondrial genome 
was sequenced. (D) Cell areas 1-5 all contained four different transition 
mutations: 2145G>A, 2269G>A, 12362C>T and 15671A>G (black arrows). (E) 
Cell area 6 from the abutting CCO-deficient ductular reaction had exactly the 
same mutations. Heteroplasmy was detected at locations 2145bps and 
2269bps (arrowheads), while the mutations at locations 12362bps and 
15671bps were homoplasmic (black arrows). (F) Cell area 7 from the CCO-
positive nodule had no mutation (white arrows).  
 
6.4 Discussion 
RNs are often accompanied by a prominent DR in liver cirrhosis, with perhaps the 
notable exception of primary biliary cirrhosis. DRs represent the progeny of a 
facultative stem cell compartment thought to be located in the canals of Hering, which 
extend into the parenchyma in humans (Theise et al., 1999). In animal models, this stem 
cell compartment becomes activated in times of regenerative demand when the ability 
of hepatocytes to enter the cell cycle is compromised. Thus, their presence in cirrhosis is 
entirely consistent with this theory, and indeed many studies of chronic HCV infection 
(Marshall et al., 2005; Paradis et al., 2001) and HBV infection (Ikeda et al., 2009) have 
charted an increasing incidence of hepatocyte senescence with increasing fibrosis, with 
senescence being assessed by expression of p21CIP1 and senescence-associated β-
galactosidase. Whether RNs are formed by simply fibrotic dissection of the existing 
parenchymal cells or whether they arise de novo from individual stem/progenitor cells is 
unknown.  
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    We have highlighted that RNs can be formed by monoclonal expansion, and not 
simply by fibrotic dissection of pre-existing liver parenchyma. Furthermore, for the first 
time, we have demonstrated that HPCs within the abutting DRs can have the same cell 
of origin as the monoclonal RN. Whether a monoclonal population of HPCs 
differentiates en masse into a population of nodular hepatocytes or if only single or a 
few HPCs differentiate prior to expansion is unclear. 
    Previous studies have alluded to the monoclonal nature of many RNs based upon 
patterns of inactivation of X-linked genes, but as previously mentioned these studies are 
confounded by a lack of knowledge concerning the patch size in human liver. In our 
study, we have used mtDNA mutations as clonal markers for tracing cell lineages. The 
monoclonal origins of CCO-deficient RNs are based on the minimal odds of finding two 
random identical mutations occurring at the same position in two separate cells being 
calculated as 2.48x109: 1, moreover we had RNs with three and even four identical 
mutations in all cells (Figures 6.4E and 6.7D).  
    Studies of human colonic crypts have suggested that it takes up to 40 years for a 
colonic crypt cell to become homoplasmic or at least display a high degree of 
heteroplasmy for a particular mutation (Greaves et al., 2006), and our own studies 
indicate that the mutant cells appear to be located close to the stem cell niche, at the 
bottom of the colonic crypt (Fellous et al., 2009b), at a ductular location in the pancreas 
(Fellous et al., 2009b), and close to the portal rim in the liver (Fellous et al., 2009a). 
Thus it seems highly reasonable to suppose that many of the mutations found in the 
hepatocytes of cirrhotic RNs have their origins in the potential stem cells located in the 
canals of Hering. It has been suggested that the finding of monoclonality may help 
separate purely RNs from those with malignant potential (Paradis et al., 1998), however 
no firm conclusions were drawn from the study. Whether the RNs we studied had 
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malignant potential is unknown, but histological examination revealed no dysplastic 
features.   
    ECM deposition and activation of matrix-producing cells occurs as an early phase 
of chronic liver injury (Van Hul et al., 2009), and it may be that the fibrotic 
environment is important for establishing the niche for the process of activation and 
differentiation of HPCs. Differentiation of HPCs to hepatocytes occurs at this fibrotic 
interface, leading to buds of intraseptal hepatocytes (Falkowski et al., 2003), and the 
RNs we see may represent further evolution of this process. In conclusion, our study has 
shown that RNs in cirrhosis can be monoclonal, with the cell of origin likely to be a 
facultative stem cell from the biliary tree.  
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Chapter 7: Using Mitochondrial DNA Mutations for Building 
a Phylogenetic Tree in Human Normal Liver 
7.1 Introduction 
7.1.1 Background 
In adult normal liver, it has been suggested that hepatocytes stream from the portal tract 
to the central vein, the “streaming liver hypothesis” (Zajicek et al., 1985). This 
hypothesis was further supported by Fellous et al. (Fellous et al., 2009a) who identified 
patches of hepatocytes containing the same mtDNA mutations, suggesting these were 
clonal proliferative units. They found that these clonal patches are invariably connected 
to portal tracts, and further suggested that these clonal patches originated from the portal 
tract area and expanded towards the central vein. By using the same methodology, De 
Alwis et al. showed in a brief communication that in the normal adult human liver, 
hepatocytes more distant from the portal tract had additional rare mtDNA mutations not 
present in cells closer to the tract, and never the other way around (De Alwis et al., 
2009). They explained these findings on the basis that some hepatocytes acquire 
additional somatic mtDNA mutations during the time that daughter cells migrate away 
from the portal area.            
    Before this finding was reported, it was logical to assume that the most long-lived 
cells would accumulate the most mtDNA mutations. Since the portal tract region is 
thought to be the location of a stem cell niche, the long-lived cells should be portally 
located stem cells and these should have a relatively high mtDNA burden that would not 
be significantly added to (because to time constraints) as a stem cell’s progeny migrate 
away the the periportal region. However, very surprisingly De Alwis found that within a 
CCO-deficient patch of hepatocytes, a common and presumed ‘founder’ single mutation 
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could be found in all hepatocytes sampled (Figure 7.1), but as more distal hepatocytes 
were analysed along a straight line trajectory from the portal tract to central vein, then 
two additional mutations were acquired. This finding may further reveal an unsuspected 
stem cell property - the maintainance of mtDNA intergrity (Alison et al., 2010). Perhaps 
stem cells in their niche have a mechanism for protecting/repairing their mtDNA 
genome, as has been proposed for stem cell genomic DNA (Cairns, 1975). It has been 
suggested that in human intestine, the detectable deficiencies in CCO only become 
apparent after the age of 40, when up to 80% of a stem cell’s mitochondrial possess the 
appropriate mutation, but the De Alwis study would suggest that once the hepatocyte 
leaves the niche, it can acquire two further mutations within a matter of months. It could 
be explained by proposing that either stem cells have an inherent mechanism in place 
that efficiently repairs most mtDNA damage or that stem cells are simply not subjected 
to the normal degree of oxidative damage, and once cells leave the niche, perhaps more 
oxidative stress and/or less efficient repair conspire to increase the mtDNA mutation 
load?  
    MtDNA has been used widely for human evolution studies because of the unique 
properties including its high copy number, maternal inheritance, lack of recombination, 
and high mutation rate (Pakendorf and Stoneking, 2005).  Furthermore, it was 
suggested recently that individual humans are characterized by a complex mixture of 
related mitochondrial genotypes in different organs rather than a single genotype (He et 
al., 2010). Since the accumulation of mtDNA mutations can occur within CCO-deficient 
patches in the normal liver (De Alwis et al., 2009), this may help us to build a 
phylogenetic tree within the patches and further clarify the possible direction of 
hepatocyte migration.  
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Figure 7.1 Sequencing revealed multiple mtDNA mutations in some CCO-
deficient regions. (A) CCO deficient region. (B) Regions dissected by laser 
capture. The sequence variants detected are listed on the right panel. The blue 
columns contain sequence data from zones A, B and F, which are increasingly 
distant from the portal tract. De novo somatic mutations are shown in red. The 
regions furthest from the portal tract contain additional mutations not present in 
the regions closest to the portal tract. Reproduced from De Alwis et al., 2009. 
  
7.1.2 Hypothesis 
The portal tract (proposed stem cell niche in normal liver) or portally located stem cells 
have the ability to protect against/repair any mtDNA mutations. The direction of 
hepatocyte migration is proposed to be from the portal tract to the central vein and this 
will be examined by building phylogenetic trees based on mtDNA mutations within 
individual patches.  
 
7.1.3 Aim of this study 
We aim to test whether hepatocytes near portal tracts have the fewest mtDNA mutations 
within a CCO-deficient patch. Furthermore, we want to clarify whether additional 
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mtDNA mutations are acquired in hepatocytes that are further away from the portal tract 
in the same patch as schematically visualised in Figure 7.2. Such a situation would lend 
support to the ‘streaming liver’ hypothesis.  
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Figure 7.2 The “supportive evidence” to the streaming liver hypothesis. The 
illustration shows the hepatocytes (1) near the portal tract (PT) have a founder 
mtDNA mutation, while an additional mtDNA mutation is progressively acquired 
in the hepatocytes (2 & 3) that are further away from the portal tract in the same 
CCO-deficient patch. The CCO-positive hepatocytes (4) have wild-type mtDNA. 
If this is established in this experiment, it will be a strong supportive evidence 
for the streaming liver hypothesis that hepatocytes migrate from PT to hepatic 
vein (HV).  
 
7.2 Material 
Seven normal liver frozen tissues were obtained from patients who had been subjected 
to PH in the Royal London Hospital because of colon cancer with liver metastasis. 
Multicentre ethical approval was obtained according to the requirements of the United 
Kingdom Human Tissue Act (2006) from the Redbridge and Waltham Forest Local 
Research Ethical Committee (REC) (Reference 2006/Q0601/33).  
 
7.3 Results 
7.3.1 More than one stem cell is located in the portal tract area 
Two different patches connected to portal tracts were analysed in this experiment. The 
portal tracts were all surrounded by either CCO-positive or –deficient hepatocytes 
(Figure 7.3A and 7.4A). In Figure 7.3 the portal tract is mainly surrounded by CCO-
deficient hepatocytes with a small region of CCO-positive cells abbuting the left side of 
the portal tract, while in Figure 7.4, the portal tracts were mainly surrounded by CCO-
positive hepatocytes. Since these portal tracts were surrounded by different phenotypes 
of hepatocytes (CCO-positive and CCO-deficient), it clearly suggests that more than 
one stem cell is located in the portal tract area.  
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7.3.2 Accumulation of mtDNA mutations can occur in hepatocytes away from the 
portal tract area 
In Figure 7.3, mtDNA analysis showed that one T to C point mutation at location 6934 
(CCO coding area) is present in hepatocytes near the portal tract (cell group 5) and this 
was also present in hepatocytes away from the portal tract (cell groups 2, 3, 4, and 6). 
However, the sequencing data from cell group 1 (also away from the portal tract) shows 
two additional partial (heteroplasmic) point mutations at locations 3415 and 3797 (both 
in the NADH dehydrogenase coding area). As expected an individual hepatocyte can 
progressively accumulate a particular mtDNA mutation in all its mitochondra moving 
from a heteroplasmic to a homoplasmic state. Thus, it is not unexpected to observe 
heteroplasmic mutations in hepatocytes away from the putative stem cell zone since 
presumably these mutations have only recently become established. Because of a failure 
of sequencing the whole mtDNA genome of other cell groups obtained from the 
periportal area, whether the other periportal CCO-deficient cells contain the same 
number of mtDNA mutations is unclear. However, because the newly accumulated 
mutations are found in only cell group 1 which is away from the portal tract, the 
possible direction of hepatocyte migration is difficult to discern, but nevertheless is not 
inconsistent with the streaming liver hypothesis. On the other hand, a common mutation 
in a CCO deficient patch that apparently surrounds the portal tract may indicate that the 
flux of cells is not simply ‘away’ from the portal space and in fact may have quite a 
lateral spread.  
    Figure 7.4 shows a pentagonal shaped patch with a margin connecting to a portal 
tract. The mtDNA analysis of cell group 1 shows only one point mutation at location 
7713. However, the mtDNA genome of cell groups (cell groups 2, 3, 4, 5 and 8) 
presumably distal from cell group 1 show the same point mutation at location 7713 and 
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and an additional point mutation at 1214. Furthermore, the mtDNA genome of cell 
groups 7 has a further additional C to T point mutation at location 11694 (NADH 
dehydrogenase coding area). Thus, we believe 7713 C>T to be the founder mutation as 
it is common to all hepatocytes and additional mtDNA mutations are acquired as cells 
migrate away from the portal rim as envisaged in Figure 7.4D. 
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Figure 7.3 Analysis of mtDNA mutation pattern within a CCO-negative patch 
connected to a portal tract in normal liver. (A) A portal tract is nearly surrounded 
by a CCO-deficient patch, while CCO-positive cells are abutting from the left 
side of this portal tract. (B) Cell groups 1 to 6 were obtained by laser capture 
microscopy from the CCO-negative area, and cell group 7 was obtained from 
the CCO-positive area. (C) H&E shows the normal liver morphology in the 
patch. (D) The proposed direction of hepatocyte migration in this patch. MtDNA 
sequencing shows one point mutation T > C, at location 6934 from cell groups 1 
to 6, while two additional point mutations at location 3415 and 3797 were found 
in cell group 1. These mutations are not seen in the sequencing data from cell 
group 7. 
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Figure 7.4 Analysis of the mtDNA mutation pattern within a pentagonal shaped 
CCO-negative patch connected to a portal tract in normal liver. (A) A 
pentagonal shaped CCO-negative patch is connected to a portal tract. (B) Cell 
groups 1 to 8 were obtained by laser capture microscopy from the CCO-
negative area, and cell group 10 was from the CCO-positive area. (C) H&E 
shows the normal liver morphology in the patch. (D) The proposed direction of 
hepatocyte migration in this patch. MtDNA sequencing shows one point 
mutation T > C, at location 7713 from cell groups 1 to 8, while an additional 
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point mutation at location 1214 was found in cell groups 2 to 8. Another 
additional point mutation at location 11694 was found in cell group 7. These 
mutations were not seen in the sequencing data from cell group 10 in the CCO-
positive region. 
 
7.3.3 Hepatocytes are not protected from acquiring new mtDNA mutations in the 
periportal region 
In Figure 7.4, hepatocyte groups 1, 4 and 7 were obtained from an area close to the 
portal tract. The mtDNA genome analysis of cell group 1 showed one point mutation. 
The mtDNA genome of cell group 4 had that same point mutation plus an additional 
one, while cell group 7 shared these two mutations but also acquired a third mutation 
(Figure 7.4). Since mtDNA mutations can be observed in hepatocytes close to the portal 
tract area, it would be reasonable to suggest that hepatocytes are not especially protected 
from acquiring new mtDNA mutations in this region.  
 
7.4 Discussion 
The previous work performed by De Alwis and colleagues (De Alwis et al., 2009) 
suggested that the periportal hepatocytes contained the fewest mtDNA mutations. They 
sequenced the entire mitochondrial genome in cells at three locations along the portal 
tract: hepatic vein axis and found more mtDNA mutations in the hepatocytes furthest 
from the portal tract. Based on this, they suggested that cells must be migrating in that 
direction. In our study, we confirmed their findings that mtDNA mutations in 
hepatocytes appear to accumulate as cells migrate away from the periportal region. This 
mtDNA mutation burden also seemed to accumulate gradually, i.e. we witnessed 
heteroplasmy in hepatocytes away from the portal rim.  
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    Building a phylogenetic tree based on mtDNA mutations and inferring the 
direction of hepatocyte migration was the other important aim of this study (Figure 7.3D 
and 7.4D). Basically, the results suggested that hepatocytes do migrate away from the 
periportal area. However, because the whole mtDNA genome was difficult to obtain 
from many groups of hepatocytes in our samples, a clear phylogenetic tree was difficult 
to establish. In the previous study (Chapter 6) we showed that a very good quality of 
mtDNA genome could be obtained from cirrhotic liver samples by using the same 
techniques and performed by the same person, however, we could not get the same good 
sequencing data from the normal liver samples. We think that the key reason for the 
difficulty in acquiring the whole mtDNA genome from the normal liver samples was the 
sample processing before collecting. The frozen cirrhotic liver tissues were collected 
from the Pathology Department of the Royal Free Hospital, London. Because of the 
purpose of quick frozen pathological diagnosis, these tissues were collected from theatre 
and immediately frozen in liquid nitrogen. However, the normal liver samples were put 
in the fridge for a few hours to several days before being frozen in liquid nitrogen. This 
difference might explain why it was difficult to get the whole mtDNA genome from 
normal liver samples. The degradation of mtDNA within hepatocytes during the period 
of storage in the fridge may have happened and so cause our failure to sequence the 
whole mtDNA genome.   
    Despite these failures, these experiments build on the previous suggestions that 
hepatic stem cells are located within the portal tract area and that more mtDNA 
mutations are acquired as hepatocytes migrate, seemingly to the perivenous region. 
Future studies should perhaps reinforce our belief that hepatocytes migrate from the 
periportal to the perivenous region by carrying out a similar analysis along the entire 
proposed trajectory from the portal rim to the hepatic vein.  
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Chapter 8: Using Mitochondrial DNA Mutations as Clonal 
Markers for Tracing Cell Lineages in Human Normal 
Pancreas and Chronic Pancreatitis 
8.1 Introduction 
8.1.1 Background 
Diabetes mellitus (DM) is a chronic disease of failed glucose homeostasis. Type 1 DM 
is the result of autoimmune attack on the endogenous β-cell population, leading to a 
lack of β-cells. Although it can be controlled by insulin replacement, the increased risk 
for chronic secondary complications such as nephropathy, neuropathy and retinopathy 
still cause enormous suffering to patients. In order to cure this disease, much hope was 
placed on approaches based on β-cell replacement. Islet transplantation has been 
considered as an option for curing DM, however, this therapy is above all hampered by 
the shortage in cadaveric donor material (Shapiro et al., 2000). Therefore, a great effort 
is being put into finding new sources of islet β-cells.  
    It has been proposed that pancreatic ductal epithelial cells have the potential to 
dedifferentiate to a progenitor cell able to produce new islets and acini (Bonner-Weir 
and Weir, 2005). In a pancreatectomy rat model, the pancreas can recover to 45% of the 
mass of the control within 4 weeks after surgery (Brockenbrough et al., 1988). A 
transient wave of DNA synthesis detected by BrdU incorporation passes through the 
ducts as a threefold increase of BrdU-positive nuclei. Furthermore, many duct cells 
express Pdx1 at 3 days following pancreatectomy (Sharma et al., 1999). The 
morphology shows small clumps of branching structures projecting from the common 
pancreatic duct, suggesting they are capable of differentiation into new pancreatic lobes 
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of exocrine and endocrine cells. Moreover, the hypothesis of a ductal origin of β-cells 
was directly tested by a lineage tracing experiment. By using a duct-specific inducible 
Cre recombinase (CAII-CreER) for labeling duct cells and their progeny permanently, it 
has been shown that duct cells do not contribute to the adult β-cell population in healthy 
adult mice. However, the CAII-expressing cells within the pancreas can act as 
progenitors that give rise to both new islets and acini normally after birth and after 
injury (ductal ligation) was shown in the same experiment (Desai et al., 2007). 
Recently, Fellous et al. (Fellous et al., 2009b) showed that in normal human pancreas 
the cells in the duct have the same mtDNA mutation as those in the neighbouring patch 
of exocrine tissue, strongly indicating that they are of the same clonal origin and further 
proposing that pancreatic duct area is the stem cell niche of the pancreas. However, 
whether the β-cells and duct cells can have the same clonal origin was not addressed in 
this study. 
    It has also been hypothesized that the renewal of β-cells can occur via surrounding 
acinar cells in vivo (Lipsett and Finegood, 2002). Following a high dose of glucose 
infusion in the rat, β-cell neogenesis was mainly related to an increase in acinar-
associated single β-cells, and a high frequency of foci of β-cells derived from acinar cell 
dedifferentiation. This indirect evidence suggested that acinar tissue, through both direct 
(acinar to β-cell) and indirect (acini to focal areas of β-cells) pathways may be 
responsible for the increased β-cell neogenesis during prolonged hyperglycaemia. 
Furthermore, in a rat pancreatic duct ligation model, cells intermediate in form between 
acinar and β-cells could also be observed by IHC, another indirect indication for a 
conversion of acinar cells to β-cells (Bertelli and Bendayan, 1997). However, not all 
evidence supports this hypothesis as observed in a transgenic mouse model, in which 
the acinar-specific elastase promoter drives the expression of a tamoxifen-inducible Cre 
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recombinase so that permanent expression of the LacZ reporter gene can be specifically 
induced in acinar cells and their progeny. When these mice underwent either partial 
pancreatectomy and exendin-4 treatment, or duct ligation or chemically-induced 
pancreatitis, β-cells failed to express beta-galactosidase (Desai et al., 2007), concluding 
that acinar-to-β-cell conversion does not occur in these animal models.  
    In humans, the hypothesis that duct cells and/or acinar cells can transdifferentiate 
into β-cells has not been tested, simply because of the lack of a good marker for tracing 
cell lineages. Since mtDNA mutations were successfully used as clonal markers in the 
human liver (Chapter 6 and 7), it was reasonable to test the hypothesis in the human 
pancreas by this method.  
 
8.1.2 Hypothesis 
Unipotential or multipotential stem/progenitor cells exist in the human pancreas and 
may give rise to clonal populations of acinar and/or islet cells. These cells might be 
variously located in pancreatic ducts, islets or acinar structures.  
 
8.1.3 Aim of this study 
We aim to test the above hypothesis by searching for patches of cells deficient in CCO 
activity and then performing mtDNA sequencing to establish clonality. This study will 
use both normal pancreatic tissue and that of chronic pancreatitis, the latter being where 
a regenerative stimulus might be operative leading to hopefully larger patches. 
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8.2 Study design 
54 normal pancreatic frozen tissues and 20 chronic pancreatitis tissues were obtained 
from patients who had been subjected to partial pancreatectomy in the Royal London 
Hospital and in the Hammersmith Hospital. Multicentre ethical approval was obtained 
according to the requirements of the United Kingdom Human Tissue Act (2006) from 
the Redbridge and Waltham Forest Local Research Ethical Committee (REC) 
(Reference 2006/Q0601/33).   
 
8.3 Results 
8.3.1 CCO-deficient patches can be detected in both the normal pancreas and in 
chronic pancreatitis 
In this study, pancreatic tissues from 74 patients were analyzed (Table 8.1). CCO-
deficient patches can be detected by enzymatic staining in both the normal pancreas and 
in chronic pancreatitis (Table 8.2; Figure 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7 and 8.8). CCO-
deficient patches were detected in 33 of 74 patients (46%). Among the 54 normal 
pancreata, CCO-deficient patches were detected in 22 patients (41%), while 11 (55%) of 
the 22 chronic pancreatitis cases contained CCO-deficient patches. Although the 
percentage of cases with CCO-deficient patches was higher in the chronic pancreatitis 
group than in the normal pancreas, the Chi-square test with Yates continuity correction 
showed no statistical significance (55% vs 41%, p = 0.4). 
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Table 8.1 General information of patients.  
Patient Condition Age Gender Presence of CCO- 
deficient patches 
1 Normal 41 M No 
2 Normal 45 F Yes 
3 Normal 46 F Yes 
4 Normal 47 F Yes 
5 Normal 48 F No 
6 Normal 50 F Yes 
7 Normal 51 M No 
8 Normal 53 F Yes 
9 Normal 53 F Yes 
10 Normal 53 M No 
11 Normal 54 F Yes 
12 Normal 57 M No 
13 Normal 58 M No 
14 Normal 59 M No 
15 Normal 59 M No 
16 Normal 60 M Yes 
17 Normal 60 F Yes 
18 Normal 60 F No 
19 Normal 60 M No 
20 Normal 61 F No 
21 Normal 61 M No 
22 Normal 61 F No 
23 Normal 61 F No 
24 Normal 62 F Yes 
25 Normal 62 F No 
26 Normal 63 F No 
27 Normal 65 M Yes 
28 Normal 65 M Yes 
29 Normal 65 F Yes 
30 Normal 65 F Yes 
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31 Normal 67 M No 
32 Normal 67 M No 
33 Normal 68 M Yes 
34 Normal 68 M No 
35 Normal 70 M Yes 
36 Normal 70 M No 
37 Normal 70 M No 
38 Normal 71 F Yes 
39 Normal 71 F No 
40 Normal 71 M No 
41 Normal 72 F No 
42 Normal 73 F Yes 
43 Normal 73 F No 
44 Normal 75 F Yes 
45 Normal 77 M Yes 
46 Normal 77 M No 
47 Normal 77 F No 
48 Normal 78 M Yes 
49 Normal 80 F No 
50 Normal 80 M No 
51 Normal 81 M Yes 
52 Normal 81 F No 
53 Normal 83 F No 
54 Normal 83 M No 
55 Pancreatitis 36 F Yes 
56 Pancreatitis 40 M No 
57 Pancreatitis 42 F Yes 
58 Pancreatitis 43 M Yes 
59 Pancreatitis 43 M No 
60 Pancreatitis 45 M Yes 
61 Pancreatitis 45 M Yes 
62 Pancreatitis 46 F No 
63 Pancreatitis 47 F Yes 
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64 Pancreatitis 49 M No 
65 Pancreatitis 52 M Yes 
66 Pancreatitis 58 M Yes 
67 Pancreatitis 58 M No 
68 Pancreatitis 58 F No 
69 Pancreatitis 59 M Yes 
70 Pancreatitis 63 M No 
71 Pancreatitis 64 F No 
72 Pancreatitis 67 F Yes 
73 Pancreatitis 71 M Yes 
74 Pancreatitis 86 M No 
 
 
Table 8.2 Analysis of CCO activity in the normal pancreas and pancreatitis. 
 Normal Pancreas Chronic Pancreatitis Total 
Sections with CCO-
deficient patches 
22 11 33 
Sections without CCO-
deficient patches 
32 9 41 
Total Number 54 20 74 
 
 
8.3.2 CCO-deficient patches can be detected surrounding auto-digested and 
necrotic areas 
In the frozen pancreatic tissues we analyzed, autolysis and necrosis was easily found in 
the H&E stained sections (Figures 8.1A, 8.2A, 8.3A and 8.4A). Although it was not 
found in every case, the CCO-deficient (blue colour) patches tended to be found in the 
necrotic areas within these tissues (Figures 8.1B, 8.2B, 8.3B and 8.4B).  These blue 
patches were typically composed by exocrine acinar cells and had a round shape with a 
central necrotic hole. Furthermore, some of these patches also had some brown-stained 
cells indicating that some acinar cells within the patches still had CCO activity. On the 
other hand, insulin-positive cells were not detected within these specific blue SDH-
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positive patches indicating that these endocrine cells still had CCO activity (Figures 
8.1C, 8.2C, 8.3C and 8.4C). Because of the special pattern of CCO-deficient patches, 
round in shape with a necrotic area in the centre, the likelihood that these patches were 
formed by clonal expansion of CCO-deficient progenitor cells is unlikely. Instead, we 
think that the CCO deficiency within these particular patches was related to the 
autolysis and necrotic reaction in these tissues, indeed in cells undergoing necrosis, 
mitochondrial disruption is one of the earliest intracellular events. However, these 
findings do not rule out the possibility of clonal expansion from pancreatic progenitor 
cells. 
 
 
Figure 8.1 Serial normal pancreatic sections stained with H&E (A), stained for 
CCO enzymatic activity (B) and IHC for insulin (C). (A) H&E staining shows 
autolysis and necrotic changes (black arrows). (B) The CCO enzymatic staining 
shows CCO-deficient (blue colour) patches that encircle auto-digested and 
necrotic areas (black arrows). (C) The insulin positive cells (brown colour, 
circled by red line) are CCO-positive. 
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Figure 8.2 Another example of serial sections of normal pancreas stained with 
H&E (A), stained for CCO enzymatic activity (B) and IHC for insulin (C). (A) 
H&E staining shows auto-digestion and necrotic changes (black arrows). (B) 
The CCO enzymatic staining shows CCO-deficient (blue colour) patches 
surrounding autolytic and necrotic areas (black arrows). (C) The insulin positive 
cells (brown colour, circled by red line) are CCO-positive cells shown by red 
circles in Figure 8.2B.  
 
 
 
Figure 8.3 Serial sections of chronic pancreatitis stained with H&E (A), stained 
for CCO enzymatic activity (B) and IHC for insulin (C). (A) H&E staining shows 
autolysis and necrotic changes (black arrows). (B) The CCO enzymatic staining 
shows CCO-deficient (blue colour) surround autolytic and necrotic areas (black 
arrows). (C) The insulin positive cells (brown colour, circled by red line) are 
CCO-positive cells as shown by red circle line on Figure 8.3B. 
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Figure 8.4 Another example of serial sections of chronic pancreatitis stained 
with H&E (A), stained for CCO enzymatic activity (B) and IHC for insulin (C). (A) 
H&E staining shows autolytic and necrotic changes (black arrows). (B) The 
CCO enzymatic staining shows CCO-deficient (blue colour) patches that 
surround auto-digested and necrotic areas (black arrows). (C) The insulin 
positive cells (brown colour, circled by red line) are CCO-positive cells as shown 
by red circle on Figure 8.4B. 
 
 
8.3.3 Insulin-positive cells did not show deficiencies of CCO activity 
According to our previous findings in the liver, the CCO-deficient patches may 
represent a clonal population if the cells carry identical mtDNA mutation(s). In order to 
discover if the CCO-deficient patches in the pancreas contain both exocrine and 
endocrine cells, we performed H&E staining, CCO/SDH enzymatic staining and IHC 
for insulin expression on serial sections. In our samples, the CCO-deficient patches did 
not extend over any insulin-positive cells, i.e. all insulin-positive cells displayed CCO 
activity. This observation suggests that insulin-positive endocrine cells are unlikely to 
have trans-differentiated from CCO-deficient acinar cells (Figures 8.5, 8.6, 8.7 and 8.8). 
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Figure 8.5 A case of normal pancreas showing that insulin-positive cells in 
normal pancreas have CCO activity. The H&E staining shows a focal area of 
small acinar cells (A,100X; D, 200X). The CCO/SDH enzymatic staining shows 
that the focal area is also CCO-deficient  (blue) (B,100X; E, 200X). C (100X) 
and F (200X) show the insulin positive cells (brown colour, circled by red line). 
These insulin-positive cells are also CCO-positive as shown by the red circles in 
Figure 8.5B. 
 
 
Figure 8.6 Another example of insulin-positive cells in the normal pancreas with 
CCO activity. The H&E staining shows normal pancreatic architecture (A,100X; 
D, 200X). The CCO/SDH enzymatic staining shows a CCO-deficient patch 
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(blue) on the right hand side of the section (B,100X; E, 200X). C (100X) and F 
(200X) show the insulin positive cells (brown colour, circled by red line). These 
insulin-positive cells are also CCO-positive cells as shown by the red circles in 
Figure 8.6B and 8.6E. 
 
 
 
Figure 8.7 A case of chronic pancreatitis shows that insulin-positive cells have 
CCO activity. The H&E staining shows pancreatic acinar atrophy, with mild 
fibrosis and necrosis (A,100X; D, 200X). The CCO/SDH enzymatic staining 
shows a CCO-deficient patch (blue) in the middle of the section (B,100X; E, 
200X). C (100X) and F (200X) show the insulin positive cells (brown colour, 
circled by red line). These insulin-positive cells are also CCO-positive as shown 
by the red circles in Figure 8.7B and 8.7E. 
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Figure 8.8 Another example of insulin-positive cells in chronic pancreatitis 
having CCO activity. The H&E staining shows acinar atrophy with several 
fibrotic bands and necrosis (A,100X; D, 200X). The CCO/SDH enzymatic 
staining shows a CCO-deficient patch (blue) in the middle of the section  
(B,100X; E, 200X). C (100X) and F (200X) illustrate insulin positive cells (brown 
colour, circled by red line). These insulin-positive cells are also CCO-positive 
cells as shown by the red circles in Figure 8.8B and 8.8E.  
 
8.3.4 CCO-positive and –negative cells within a pancreatic patch can have the 
same mtDNA mutation 
According to our previous studies in liver, CCO-deficient patches can represent the 
clonal expansion of hepatocytes. In the pancreas, if acinar cells within a CCO-deficient 
patch have the same mtDNA mutation and the cells with CCO activity (brown colour 
staining) do not have the same mutation, then it is highly likely that this CCO-deficient 
patch represents the clonal expansion of acinar cells. In order to test whether the clonal 
expansion of acinar cells can occur in human normal pancreas and chronic pancreatitis, 
mtDNA sequencing was performed. Figure 8.9 shows a CCO-deficient patch and 
mtDNA sequencing results in normal pancreatic tissue. This CCO-deficient patch was 
composed of acinar cells without any pathological features of auto-digestion and 
 259 
necrosis (Figure 8.9A, 8.9C and 8.9D). mtDNA sequencing revealed the same A to G 
point mutation (but see Discussion) at location 4761bps in all the different cell groups 
within the CCO-deficient patch (Figure 8.9E). However, before we can draw the 
conclusion that this patch is a clonal proliferative unit derived from a CCO-deficient 
progenitor cell, we have to concede that the same mtDNA mutation was also found in 
nearby CCO-positive cells (Figure 8.9E) and also in CCO-positive cells away from the 
patch (data not shown). This finding suggests that this point mutation does not affect 
CCO activity since the CCO-positive acinar cells also had mtDNA mutation, and the 
CCO deficiency is as a result of a mechanism other than this mtDNA mutation. 
Therefore, in this case, the CCO-deficient patch is unlikely to represent the full extent of 
clonal expansion as indicated by the common mtDNA mutation. We further analyzed a 
case of chronic pancreatitis (Figure 8.10). Several patches composed of CCO-deficient 
acinar cells were segregated by fibrotic bands (Figure 8.10A, 8.10C and 8.10D). The 
mtDNA sequencing revealed that these groups of CCO-deficient cells all had the same 
A to G point mutation at location 14220 (Figure 8.10B and 8.10E). However, the CCO-
positive cells also had the same mtDNA mutation (Figure 8.10B and 8.10E) as observed 
in the normal pancreas (above).   
 260 
 
Figure 8.9. MtDNA genotyping indicates that both the CCO-positive and -
deficient cells have the same mtDNA mutation in the normal pancreas. (A) An 
entirely CCO-deficient patch (blue staining). (B) Four groups of cells (1-4) from 
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the same CCO-deficient patch and one group of cells (5) from the CCO-positive 
area were laser capture-microdissected. These cells are not insulin-positive 
cells, confirmed by insulin IHC in the next serial section (D, brown staining). The 
entire mitochondrial genome was sequenced. (C) Haematoxylin and eosin 
staining shows the same focal area of small acinar cells as illustrated in Figure 
8.5. (E) Cell areas 1-4 from the CCO-deficient patch and area 5 from CCO-
positive area all contained the same A to G point mutation at location 4761 
within the MT-ND2 gene, a NADH dehydrogenase coding region (black arrow).  
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Figure 8.10. MtDNA genotyping indicates that both CCO-positive and -deficient 
cells have the same mtDNA mutation in this case of chronic pancreatitis. (A) 
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Several CCO-deficient patches are separated by fibrotic bands (blue staining). 
(B) Four groups of cells (1-4) from different CCO-deficient patches and one 
group of cells (5) from the CCO-positive area were laser capture-
microdissected. These cells were not insulin-positive cells as adjudged by 
insulin IHC in the next serial section (D, brown staining). The entire 
mitochondrial genome was sequenced. (C) Haematoxylin and eosin staining 
showing acinar cell atrophy with fibrotic bands. (E) Cell areas 1-4 from CCO-
deficient patch and 5 from CCO-positive area all contained the same A to G 
point mutation at location 14220 within the MT-ND6 gene, a NADH 
dehydrogenase coding region (black arrow).  
 
8.4 Discussion 
The origin of β-cells has not been clarified. Many cells within the pancreas have been 
proposed as precursors, most notably pancreatic duct cells. Acinar cells are the most 
abundant cells in the pancreas and have also been thought to be a possible origin of β-
cells. In this study the first aim was to discover if clonal cell units could encompass both 
acinar cells and β-cells. According to our previous results, CCO/SDH enzymatic 
staining can highlight CCO-deficient cells, and the CCO-deficient patch can represent a 
clonal expansion of cells if the cells within it contain the same mtDNA mutation. From 
the analysis of 74 patients, we found that the majority of cells within CCO-deficient 
patches in the pancreas were acinar cells, and no insulin-positive β-cells were found in 
the CCO-deficient patches. Based on the previous assumption that CCO-deficient 
patches are caused by mtDNA mutation and that all CCO-deficient cells contain the 
same mtDNA mutation, this finding would suggest that CCO-deficient patches can 
represent clonal populations of acinar cells and that trans-differentiation between acinar 
and β-cells is unlikely to occur. However, in the pancreas, our results show that CCO-
deficient patches were often to be found in the areas of pancreatic autolysis and 
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necrosis. The pancreas is full of potentially lytic enzymes, thus autolysis readily occurs 
after patient death and so detection of CCO deficiency in pancreatic tissue should 
always be viewed cautiously. 
    Furthermore, the mtDNA genotyping showed that both CCO-positive and -
deficient cells can have the same mtDNA mutation. Since these genetic alterations in 
mtDNA were also found in CCO-positive cells, often some distance from the negative 
patch, it could be that such changes rather than being mutations are in fact 
polymorphisms. The fact that these polymorphisms have not been described to date (see 
http://www.mitomap.org/MITOMAP), does not rule out this possibility. Nevertheless, 
patches of CCO deficiency were found in the pancreas, but the reason for these was not 
clear from the present analysis.  
    CCO deficiencies are amongst the most common defects of the respiratory chain 
found in mitochondrial diseases and mostly caused by mtDNA mutations. However, the 
mutations in nuclear genes encoding for subunits of CCO and/or in genes coding for 
proteins involved in the nuclear-mitochondrial communication can also cause mtDNA 
disorders (Diaz and Moraes, 2008; DiMauro and Schon, 2008). Furthermore, several 
factors can also affect CCO activity. The enzyme activity is regulated by a gamut of 
molecules including hormones, membrane lipids and second messengers. For example, 
oxidized cardiolipin and nitric oxide inhibit CCO activity (Brunori et al., 2004; Paradies 
et al., 1997). Moreover, CCO activity is also controlled by allosteric 
inhibition/activation by ATP/ADP and by phosphorylation of different subunits by 
kinases (Acin-Perez et al., 2009; Kadenbach et al., 2000; Miyazaki et al., 2003). 
Additionally, damage to mitochondria caused primarily by ROS generated by the 
mitochondria themselves can also lead to CCO deficiency (Duchen, 2004; Wei et al., 
1998). The free radicals direct damage to mitochondrial proteins, decrease their affinity 
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for substrates or coenzymes and, thereby, decrease their function (Liu et al., 2002). 
CCO deficiency has been observed during the aging process in normal human heart, 
muscle, parathyroid, as well as liver (Muller-Hocker, 1989, 1990; Muller-Hocker et al., 
1996; Muller-Hocker et al., 1997). However, the causative pathogenetic mechanisms 
remain to be established. In our study, both normal and diseased pancreas could have a 
CCO deficiency. The CCO deficiency found in the pancreas in this study tended to be 
located adjacent to autolytic regions, an observation which has not been reported in 
other organs.  We suggest this is a confounding factor, possibly unique to the pancreas 
because of the particularly high content of lytic enzymes.  
    Using mtDNA mutations as clonal markers has been widely applied to the study of 
stem cell biology in many human organs, including intestine, stomach, skin, liver and 
pancreas (Fellous et al., 2009a; Fellous et al., 2009b; Greaves et al., 2006; Gutierrez-
Gonzalez et al., 2009; McDonald et al., 2008). If wild-type mtDNA had been found in 
nearby CCO-positive cells, there would be every reason to believe that our observed 
CCO-deficient patches were formed by clonal expansion from a mtDNA mutated 
progenitor cell. However, this was not the case in the two patients that were analysed, 
leading us to conclude that these clear genetic changes were unreported genetic 
polymorphisms. However, my methodology highlights the crucial need to acquire both 
CCO-positive and –deficient cell mtDNA genomes before any claims that CCO-
deficient patches represent clonal proliferative units can be made.  
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Chapter 9: Conclusions and Future Studies 
Lineage analysis is a powerful tool for understanding adult stem cell behaviour, 
however, choosing the right marker is crucial. In this thesis, two different lineage 
analysis methods have been used in an animal model and human specimens 
respectively. The “Y chromosome” was used as a clonal marker for tracing BMDCs in 
an experimental pancreatitis mouse model, and “mtDNA mutation” was used as a 
marker for tracing stem/progenitor cell lineages in human liver and pancreas. Both 
methods are well established in our laboratory. I was very fortunate to learn these two 
different methods during my period of PhD study.  
 
9.1 Using the Y chromosome as a marker for tracing BMDCs in a 
mouse model of pancreatitis 
From three experiments related to BM sex-mismatch transplantation and experimental 
pancreatitis in mice, I have come to the conclusion that BMDCs directly contribute to 
pancreatic fibrosis. It has been demonstrated that BM cells can differentiate along the 
myofibroblast and fibroblast lineage, synthesising and secreting components of the 
ECM in many organs such as the liver, lung, kidney and intestine (Lin et al., 2008). In 
our experiments, the results showed that BM-derived myofibroblasts functionally 
contribute to pancreatic fibrosis, an observation similar to the previous findings in other 
organs. The BM-derived myofibroblasts accounted for about 8% of α-SMA 
(myofibroblasts) positive cells in the pancreata of mice in the mild pancreatitis model. 
In addition, an ex vivo study confirmed that some myofibroblasts isolated from the 
pancreas were BM-derived. Furthermore, using Col1α1r/r transgenic mice BM, I have 
demonstrated the functional role of BM-derived myofibroblasts. The severity of 
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pancreatic fibrosis, assessed by scoring of Sirius red staining and mRNA expression of 
pro-collagen 1, were both higher in mice that received Col1α1r/r transgenic mice BM 
cells compared to the mice that received WT BM cells. Thus the genotype of BM cells 
can alter pancreatic fibrosis. 
    In order to further investigate the roles of BMDCs in pancreatitis and fibrosis, BM-
derived fibrocytes were studied. Fibrocytes are circulating pro-fibrogenic cells that can 
produce ECM and ECM-modifying enzymes, and can further differentiate into active 
myofibroblasts both in vitro and in vivo (Bellini and Mattoli, 2007). It has been 
demonstrated that fibrocytes participate in many human fibrotic diseases such as 
hypertrophic scars (Yang et al., 2005), systemic sclerosis (Postlethwaite et al., 2004), 
nephrogenic fibrosing dermopathy (Cowper and Bucala, 2003), and pulmonary disease 
especially that characterized by repeated inflammation and repair, like asthma (Schmidt 
et al., 2003), and interstitial pulmonary fibrosis (Mehrad et al., 2007). However, the 
contribution of of these fibrocytes has not been clearly demonstrated in pancreatitis 
when I started this experiment. In my experiments, the results showed that collagen-
producing CD45+Col1+ fibrocytes are BM-derived cells, but comprise only a rare 
population in the BM and PB. A subpopulation of morphologically lymphocyte-like 
CD45+Col1+ fibrocytes may exist in the circulating blood. These fibrocytes can 
migrate into acute inflammatory and fibrotic pancreatic tissue, are generally located in 
the collagen-rich areas and further may contribute to pancreatic fibrosis by 
differentiation into myofibroblasts. My results demonstrated that BM-derived fibrocytes 
can participate in the process of acute and chronic pancreatitis and may further 
contribute to pancreatic fibrosis. 
    Cytokines are biologically active molecules that influence the survival, 
proliferation and migration of cells. Among the various cytokines, IL-10 is considered 
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as an anti-inflammatory cytokine and is mainly expressed and secreted by a variety of 
cell types derived from the BM (Moore et al., 2001). However, the roles of this cytokine 
and BMDCs in pancreatitis have not been well studied. The aim of the final experiment 
in the mouse model of pancreatitis was to see whether BM-secreted IL-10 can affect 
pancreatic inflammation as well as the degree of fibrosis. My results showed that the 
degree of fibrosis, the inflammatory cell response as well as the number of BM-derived 
myofibroblasts were all elevated in the IL-10 KO BM transplanted mice, but only in the 
recovery phase of pancreatic fibrosis after cessation of cerulein injections, suggesting a 
potential anti-fibrotic role of IL-10 in pancreas. 
    In conclusion, the results in this thesis suggest that BM-derived myofibroblasts and 
fibrocytes contribute to pancreatitis and fibrosis. Furthermore, the genotype of the BM-
cells can alter these reactions as seen after transplantation of either BM cells deficient in 
IL-10 or BM cells from Col1α1r/r transgenic mice; both resulted in increased fibrosis.  
 
9.2 Using mtDNA mutations as a marker for tracing stem/progenitor 
cell lineages in human liver and pancreas 
In this thesis, “mtDNA mutations” were used as clonal markers in several human tissues 
including normal liver, cirrhotic liver, normal pancreas and chronic pancreatitis. Patches 
of CCO-deficient cells could be observed by IHC and enzymatic methods. Further 
sequencing of the mtDNA revealed that cells within an individual patch contained a 
common mutation(s), indicating such cell patches are clonal proliferative units. As stem 
cells are thought to be the only cell type that survive for a long enough period of time to 
allow mitochondria with mutated mtDNA to become dominant (~80% mutated 
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mtDNA), it is reasonable to suppose these clonal proliferative units have their origin in 
stem cells.  
    The clonality and cells of origin of hepatcyte RNs in human liver cirrhosis were 
investigated by this method. RNs were classified as either CCO-deficient or CCO-
positive, and among 526 nodules from 10 cases, 18% were homogeneously CCO-
deficient, whereas only 3% had a mixed phenotype. Further sequencing of their entire 
mtDNA genomes showed that CCO-deficient nodules analyzed were monoclonal in 
nature, possessing up to four common mutations in all hepatocytes in a given nodule. 
Moreover, the identification of identical mutations in HPCs abutting CCO-deficient 
nodules proved that the nodules can have their origins from such cells. My results 
highlight a novel pathway for the monoclonal derivation of human cirrhotic RNs from 
HPCs. 
    It had been suggested that the periportal hepatocytes in normal liver contained the 
fewest mtDNA mutations (De Alwis et al., 2009). In that preliminary study, the entire 
mitochondrial genome in cells at three locations along the portal tract: hepatic vein axis 
were analyzed, and it was found that additional mtDNA mutations accumulated in the 
hepatocytes furthest from the portal tract. Based on this, they suggested that cells must 
be migrating in that direction. In this study, I attempted to build a phylogenetic tree in 
the normal liver by using the same approach. Although I failed to acquire the whole 
mtDNA genome from some groups of cells, my results confirmed their findings that 
mtDNA mutations in hepatocytes appear to accumulate as cells migrate away from the 
periportal region. Not surprisingly, this mtDNA mutation burden also seemed to 
accumulate gradually, i.e. we witnessed heteroplasmy in hepatocytes away from the 
portal rim. 
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    In the final experiment, this technique was applied to human normal pancreas and 
chronic pancreatitis. Although the primary goal was to test whether clonal expansion 
can encompass acinar cells and β-cells, some unexpected findings of CCO deficiency in 
normal and diseased pancreas were demonstrated. The results showed that CCO 
deficiency can occur because of autolysis, a process that the pancreas is particularly 
prone to. On the other hand, I never found a CCO deficiency in insulin-positive β-cells. 
Moreover, the same mtDNA alterations were found in the mtDNA genome from both 
CCO-negative and -positive cells in the pancreas, suggesting that perhaps these were 
previously unreported genetic polymorphisms.  
 
9.3 Future studies 
After finishing my studies, I have to go back my clinical post as a Consultant 
Gastroenterologist in Chang-Gung Memorial Hospital, Taipei, Taiwan. In addition to 
the routine clinical service, I have to continue my research work. In this regard, I am 
particularly interested in the translational research aspect of BM stem cell plasticity and 
mtDNA mutations in the diseased liver and pancreas. My hospital has a large collection 
of transplanted recipients, including both solid organ transplantation and BM 
transplantation. These transplant recepients, either sex-matched or sex-mismatched have 
developed many surgical and medical complications after transplantation. Therefore, if 
the pathological specimens are available, I can investigate BM-derived cells within 
these organs. By combining the techniques of IHC staining and ISH for Y chromosome 
detection (sex-mismatched transplantation- either male donor and female recipient in 
case of BM transplantation, or female donor and male recipient in case of solid organ 
transplantation), it is possible to examine the roles of BMDCs in certain pathological 
conditions. For example, if the liver specimens can be aquired from sex-mismatched 
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recipients with fulminant hepatitis, we can test whether BM cells give rise to 
hepatocytes after massive liver necrosis. It has been demonstrated that gastric epithelial 
cancers can originate from BM cells in an animal model (Houghton et al., 2004). It 
would be interesting to see whether BM cells can also give rise to hepatocellular 
carcinoma when suitable specimens become available. 
    Since a mouse model of BM-mismatched transplantation and cerulein-induced 
pancreatitis has been established in this study, I want to use this animal model to test the 
effect of other cytokines and drugs on BMDCs in pancreatitis. For example, 
Granulocyte colony-stimulating factor (G-CSF) is a haematopoietic stem cell mobilizer; 
a recent study showed that human HSCs mobilized by G-SCF can promote kidney 
repair afters ischaemia/reperfusion renal injury in a mouse by mainly paracrine 
mechanisms (Li et al., 2010). It would be intesting to see the effects of G-CSF on 
BMDCs, the inflammatory response and the degree of pancreatic fibrosis in my 
pancreatic model. 
    In terms of extending my research on mtDNA mutations, I want to further 
investigate the pathological meaning of the CCO-deficiencies and mtDNA mutations in 
the liver. It has been demonstrated that increased mtDNA mutations and CCO-deficient 
patches are found in cirrhotic liver compared with normal liver (Muller-Hocker et al., 
1997), however, the mechanisms resulting in this change are unknown. Our Department 
has a large collection of clinical data and specimens from patients with chronic viral 
hepatitis and liver cirrhosis. It would be interesting to see whether the mtDNA mutation 
load correlates with disease progression. Furthermore, it has been suggested that 
hepatocellular carcinomas are monoclonal and come from monoclonal dysplastic 
nodules based on the method for clonal analysis using restriction fragment length 
polymorphism of the X chromosome-linked phosphoglycerokinase gene and on random 
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inactivation of the gene by methylation (Aihara et al., 1996). I would like to see whether 
hepatocellular carcinoma tends to arise from CCO-negative hepatocytes by examining 
CCO activity and the mtDNA genome in liver tumours. My research showed that RNs 
in cirrhotic liver can be generated from the progenitor cells within the abutting DRs. 
However, DRs are scarce in the livers of patients with primary biliary cirrhosis, 
therefore I would like to explore the clonality of RNs and identify the possible stem cell 
niches in this particular disease. In the liver I would also like to continue my study into 
the direction of hepatocyte migration, ideally finding a CCO-deficient patch that could 
be sampled along the complete axis from portal rim to hepatic vein. If hepatocytes 
acquire subtle increases to the mutation burden as they migrate, then this would be most 
sensitively monitored by next-generation sequencing that could pick up minor changes 
in heteroplasmy. 
    It was an unexpected finding to me that CCO-positive cells and -negative cells 
could have the same mtDNA mutations in the human pancreas. The reason may be 
simply because the genetic change was an un-discovered polymorphism for the patient. 
Clearly more investigation is required of this ‘difficult’ organ, but it would be very 
significant if we could discover clonal patches that encompass islet cells and ducts, 
since this would substantiate the growing ‘rodent literature’ that suggests that pancreatic 
ductal cells can give rise to islet cells under an appropriate regenerative demand.  
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